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mSUMMARY
Literature review
A literature review of the stability of antibiotics in peritoneal dialysis fluids was
conducted. The information obtained was collated and presented in a format which
would serve as a useful working reference for hospital pharmacists. It was found that
the stability of antibiotics in peritoneal dialysis fluids had received little attention in the
literature. The review highlighted the lack of information on the stability and
compatibility of many of the antibiotics and antibiotic combinations commonly used for
the treatment of peritonitis. Despite increasing interest in intraperitoneal antifungal
chemotherapy, there was no information on the stability of antifungal agents in
peritoneal dialysis fluids.
Stability studies
A study of the stability of the antifungal agent, miconazole, in peritonealdialysis fluid
was conducted. Greater than 10% loss of the initial miconazole concentration occurred
within 4 hours when this drug was added to peritoneal dialysis fluid and stored in
polyvinyl chloride (PVC) bags at 20°C. Similar admixtures were stable for at least
3 days when stored in glass ampoules under the same conditions. These findings
indicated that the loss of miconazole observed in PVC bags was due primarily to an
interaction with the container, rather than chemical decomposition in solution.
Approximately 28% of the miconazole lost from the solution was recovered from the
plastic by methanolic extraction, representing sorption of miconazole by the PVC
container. In the clinical situation, the rapid loss of miconazole from peritoneal dialysis
fluid stored in PVC bags, would demand that such admixtures be prepared immediately
prior to administration.
IV
A study of the stability of both components of the antibacterial combination,
co-trimoxazole, in peritoneal dialysis fluid was conducted. Greater than 10% loss of
the initial trimethoprim concentration occurred within 3 days when admixtures of
co-trimoxazole in peritoneal dialysis fluid were stored in PVC bags at 20°C. The
concentration of trimethoprim in similar admixtures stored in glass ampoules under the
same conditions, remained virtually unchanged for 9 days. This suggested that the loss
of trimethoprim observed in admixtures stored in PVC bags, may have been due to an
interaction with the container.
Greater than 10% loss of the initial sulphamethoxazole concentration occurred within
2 days in admixtures stored in PVC bags. Similar losses occurred in admixtures stored
in glass ampoules, suggesting that the mechanism of this loss was primarily chemical
decomposition in solution. Further evidence for this proposition, was the time
dependent increase in concentration of an unknown decomposition product in
admixtures stored in both plastic and glass containers. It was suspected that this
compound was a derivative of sulphamethoxazole, however it was demonstrated that it
was not sulphanilic acid or 5-methyl-3-isoxazolamine, which have previously been
identified as decomposition products of sulphamethoxazole under acidconditions.
This study found that the shelf-life of admixtures of co-trimoxazole in peritoneal
dialysis fluid stored in PVC bags at 20°C, was limited by the stability of the
sulphamethoxazole component. The data conservatively indicated a shelf-life of
approximately 12 hours, since greater than 10% loss of the initial sulphamethoxazole
concentration had occurred in this time in one of the admixtures examined.
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CHAPTER 1
STABELTTY OF ANTIBIOTICS IN PERITONEAL DIALYSIS FLUIDS
1.1 Introduction
1.1.1 An overview of peritoneal dialysis
In 1923, Ganter reported an improvement in the condition of a uremic guinea pig after
the intermittent infusion and removal of saline solution from the peritoneal cavity. He
noted that after an intraperitoneal (i.p.) dwell time of one hour, the urea-nitrogen
concentration in the fluid approximated that in the blood. Ganter also reported an
improvement in the condition of a uremic woman after the instillation of 1.5 L of saline
solution into the peritoneal cavity, and that the i.p. infusion of 3 L of saline solution in a
patient with diabetic coma produceda reversalof the unconscious state. Following these
observations, Ganter proposed that the peritoneal membrane allowed the passage of toxic
substances from the blood into the peritoneal cavity (1).
During the period from 1923 to 1948, 101 patients were reported as having received
some form of peritoneal dialysis. Of the 63 patients who suffered reversible renal
disease, 32 were treated successfully with this dialysis technique. During this
pioneering period of peritoneal dialysis, three complications accounted for the majority
of deaths; (i) pulmonary oedema, (ii) uremia, and (iii) peritonitis. At this time peritoneal
dialysis was largely confined to animal experimentation and the treatment of acute renal
failure in humans. It was also used successfully for the treatment of hypercalcaemia and
various poisonings. The high incidence of peritonitis, and the failure to develop a
successful peritoneal access device, lead to the abandonment of attempts to establish long
term peritoneal dialysis (1,2).
2In 1963, Boen commenced treatment of a patient using peritoneal dialysis in which the
dialysis fluid was introduced into the peritoneal cavity using a repeated puncture
technique. Effective control of the uremic state was obtained using an intermittent
dialysis regime consisting of three or four dialysis sessions per week, each session
lasting approximately 10 hours and using approximately 40 L of fluid. This regime
became known as intermittent peritoneal dialysis. Using the repeated puncture
technique, Boen's patient was maintained on intermittent peritoneal dialysis for three
years prior to a successful kidney transplant, and the feasibility of long term peritoneal
dialysis for the management of end-stage renal disease was therefore established.
Tenckhoff, Boen's co-worker, confirmed the success of this procedure by maintaining a
patient on intermittentperitonealdialysis for three and a half years in a home setting. In
1966, Lasker et al also reported success with the repeated puncture technique in
5 patients (1, 3).
Peritoneal access devices
Although the repeated puncture technique was associatedwith a low risk of infection and
enabled the feasibility of long term peritoneal dialysis to be established, the procedure
was both unpleasant for the patient and demanding on staff, who would have to carry
out the procedure at least three times weekly for each patient. Attention was once again
turned to the development of a long term peritoneal access device. In 1968, Tenckhoff
designed a silicone rubber catheter with two dacron cuffs which were intended to anchor
the catheter to the abdominal wall, and to close the sinus tract around the catheter,
thereby preventing bacterial intrusion. This catheter gained widespread acceptance and
was the most important factor in promoting long term peritoneal dialysis in other
centres (1). Many other catheter designs have evolved. A modified version of
Tenckhoffs double cuff catheter, with a catheter adapter made of titanium and a luer lock
configuration between the adapter and the plastic extension tubing, is in widespread use
today (4).
3Peritoneal dialysisfluid and automated dialysis
During the first years of peritonealdialysis, either normal saline or 5% glucose solutions
were used as dialysis fluids. Problems associated with pulmonary oedema and acidosis
lead to the developmentof more appropriate dialysis fluid formulations and stricterfluid
balance control. Water was found to be absorbed when bypotonic solutions were
instilled into the peritoneal cavity, whereas bypertonic solutions produced ultrafiltration
(water excretion). The osmolarity of dialysis fluids was varied by altering the glucose
concentration and in this way the patient's fluid balancecould be controlled. Magnesium
and calcium were included in dialysis fluid formulations to maintain adequate serum
levels. Bicarbonate was added to correct acidosis, however problems associated with
sterilisation and storage (caramelisationof glucose and calcium carbonate precipitation),
meant that the fluid bad to be mixed immediately prior to administration. This ultimately
lead to the replacement of bicarbonate with either acetate or lactate. Potassium was
added when necessary to correct bypokalaemia (1,5).
The development of a safe and practical source of dialysis fluid was a necessary step in
ensuring a future for long term peritoneal dialysis. Prior to 1959, clinicians prepared the
dialysis fluid by adding concentrated solutions of electrolytes and glucose to bottles of
sterile distilled water. In 1959, commercial dialysis fluid became available. When Boen
first attempted long term peritoneal dialysis in 1962, be decided to eliminate the bottle
change as a source of infection. One intermittent peritoneal dialysis session using 40 L
of dialysis fluid ordinarily involved 40 bottle exchanges. Boen developed a closed
sterile system in which dialysis fluid was manufactured and sterilised in 40 L carboys.
Timers and clamps were incorporated to control fluid inflow, dwell time and fluid
outflow, and so the first automated peritoneal dialysis machine was created. Because of
the special equipment required for Boen's "fluid factory", installation was only really
suited to hospitals, however in this setting it proved to be extremely successful, with
most hospitals in the United States of America still using this system during the early
1980's (1, 3).
The difficulty of transporting large volumes of fluid prevented the widespread
application of peritoneal dialysis to the home setting. Tenckhoffs first attempt to
manufacture sterile dialysis fluid in the home employed a miniature autoclave in which
water was sterilised before being combined with a concentrated dialysis fluid using an
automated proportioning device. More widespread application in the home was achieved
in 1972, when reverse osmosis replaced the autoclave as a means of water sterilisation.
The reverse osmosis dialysis machine established automated peritoneal dialysis in the
home setting and increased the number of patients treated in this situation with peritoneal
dialysis (1-3).
Continuous ambulatory peritoneal dialysis
In 1976, Popovich, Moncrief and co-workers described a novel portable peritoneal
dialysis technique which they called "equilibrium dialysis" (6). A 2 L volume of dialysis
fluid was gravity infused into the peritoneal cavity and allowed to equilibrate for
approximately 5 hours. An empty container was then connected to the catheter, and the
dialysis fluid effluent was drained out of the peritoneal cavity by placing the container
below the level of the abdomen. A 2 L volume of fresh fluid was immediately infused
again and the cycle repeated. Five exchanges were performed every day. Equilibrium
dialysis meant that the peritoneal membrane was continually in contact with dialysis fluid
and, apart from the exchange procedure, the patient was able to conduct normal
activities. Additional experience with this technique was reported by Moncrief et al and
Popovich et al in 1978, and it was given the name "continuous ambulatory peritoneal
dialysis (CAPD)" (7, 8).
Recurrent infection was a major problem in these first CAPD patients, with an incidence
of peritonitis of approximately one episode every ten patient weeks. In the same year.
5Robson and Oreopoulos were able to halve the number of connections associated with
this technique by using peritoneal dialysis fluid supplied in flexible plastic containers.
After infusion, the empty bag remained connected to the catheter, was carried on the
body, and was used subsequently to receive the peritoneal dialysis effluent. In this way
the incidence of peritonitis was reduced to approximately one episode every 7.1 patient
months (9).
Otherperitoneal dialysis regimes
Several variations of the original concept of equilibrium dialysis have evolved.
Continuous cyclic peritoneal dialysis (CCPD) was introduced in 1980 with the aim of
providing automated dialysis at night and ambulatory dialysis during the day (10). An
automated cycler machine delivers multiple overnight exchanges and an additional
exchange in the morning. The dialysis fluid then remains in the peritoneal cavity for a
prolonged dwell during the day. The advantages of this regime include the freedom
from exchanges during the day, the restriction of the exchange venue to the home, and
the reduction in the number of connections and disconnections. During CCPD, the
direction of flow of dialysis fluid immediately after connection is always out of the
peritoneal cavity, and this is considered to be an advantage in reducing the risk of touch
contamination entering the peritoneal cavity. This feature can also be incorporated into
CAPD following the development of various connection tubing designs (11). A
reduction in the incidence of peritonitis was one of the major objectives of the
development of CCPD, and although this has heen demonstrated in some centres, the
peritoneal dialysis regime with the least risk of complications remains
controversial (12, 13).
Peritoneal dialysis population
The use of peritoneal dialysis increased slowly despite significant advances in the
development of long term peritoneal dialysis in the 1970's, for example the introduction
6of automated at home dialysis. Following the introduction of CAPD, however, an
enormous increase in the peritoneal dialysis population occurred. The European Dialysis
and Transplant Association reported a four-fold increase in the number of peritoneal
dialysis patients between 1977 and 1979, with 38% of peritoneal dialysis patients in
1979 using CAPD (2). In the United States of America, the National Dialysis Registry
data in 1974 showed only 72 patients being treated with peritoneal dialysis, which
represented 1.4% of the total dialysis population. The number of peritoneal dialysis
patients increased to approximately 4 000 in 1980,10 200 in 1983, and 15 300 in 1987,
which represented 7.7%, 14.2% and 15.6% of the total dialysis population respectively.
In 1980, 61% of peritoneal dialysis patients were using CAPD and by 1987 this had
increased to 85% (2,14).
In October 1988 there were 2 598 dialysis dependent patients in Australia of whom 68%
were receiving haemodialysis and 32% were receiving peritoneal dialysis. In 1980,
peritoneal dialysis patients represented 15% of the total dialysis population. This
increased steadily to 30% in 1984, but has not shown any appreciable change since. In
1988,peritonealdialysis was the most common form of dialysis in young patients; 85%
of children (<10 years), and 50% of the teenage group (10-19 years), were receiving
peritoneal dialysis. Peritoneal dialysis was also used frequently in the elderly (70-89
years), (49%). CAPD accounted for 95% of all peritoneal dialysispatients in Australia,
with the remainder receiving intermittent peritoneal dialysis. 32% of all dialysis
dependent patients were using hospital based facilities for dialysis, 16% were using
satellite basedfacilities, and 52% were dialysing at home. A majority of homedialysis
patients (56%) were on CAPD (15).
1.1.2 Continuous ambulatory peritoneal dialysis (CAPDl
1.1.2.1 Advantages of CAPD
CAPD is an alternative to haemodialysis for the treatment of patients with end-stage renal
disease. The main advantages offered by this dialysis method are greater patient mobility
and independence (because there is no reliance on a machine), elimination of the need for
a routine vascular access, and the availability of at home dialysis. A recent survey of
renal units in Australia showed that the most common reason for selecting CAPD over
other dialysis methods was the desirability of at home dialysis (16).
CAPD does not compromise the dialytic efficiency possible with haemodialysis, and in
fact offers several advantages over intermittent dialysis methods.
Steady state blood chemistries
The blood chemistries of patients on CAPD achieve steady state after a few weeks of
treatment because there is constant removal of water and waste products from the body.
In contrast, intermittent dialysis techniques such as haemodialysis and intermittent
peritoneal dialysis are associated with large fluctuations in blood concentrations of waste
products. These fluctuations can produce clinical symptoms. A disequilibrium
syndrome, characterised by headache, nausea, CNS disturbances and rapid decline in
blood pressure, results from the rapid removal of water and solutes during
haemodialysis (17).
Haemodynamic control
CAPD avoids the large fluctuations in fluid volume and blood pressure which are often
associated with intermittent dialysis techniques. Because there is continuous removal of
water, excellent control of blood pressure and fluid balance can be achieved, enabling a
8more liberal fluid intake than is tolerated with haemodialysis. The removal of excess salt
and water, and therefore the control of hypertension and oedema, can be achieved by
using dialysis fluid of high osmolarity or by increasing the frequency of exchanges.
Conversely, intravascular volume can be increased by using dialysis fluid of low
osmolarity or by prolonging the i.p. dwell time (18). It is often possible to withdraw
antihypertensive medication in CAPD patients (19). In addition, CAPD patients
generally show a rise in haematocrit, not normally seen with other dialysis
methods (20, 21).
Dietary restrictions
Although moderate dietary restrictions are imposed on the CAPD patient, these are less
rigid than those associatedwith intermittent dialysis techniques, especiallywith respect
to salt and water intake. A restricted carbohydrate diet is necessary due to the
appreciable glucose absorption from the dialysis fluid, whereas a high protein diet is
necessary to compensate for protein losses to the dialysis fluid. Restriction of dietary
potassium is seldom necessary (18).
Children
CAPD is an attractive alternative to haemodialysis in the paediatric population. The
features which favour the use of CAPD in the younger age group include: (i) freedom
from repeated needle punctures and other difficulties associated with maintaining a
vascular access, (ii) reduced dietary restrictions, and (iii) ambulatory home based
dialysis (22). Data on the age distribution of dialysis dependent patients in Australia
suggests that CAPD has become the treatment of choicefor children with end-stagerenal
disease (15). This has also been the experience in the United States of America (23).
9Diabetics
Diabetic nephropathy is a significant cause of renal disease in dialysis dependent patients
and CAPD has become the preferred method of dialysis in diabetics (15). Firstly,
peripheral vascular disease and the difficulties associated with maintaining a vascular
access limit the application of haemodialysis in diabetic patients. Secondly, CAPD
achieves better blood glucose control than other dialysis methods. Insulin is routinely
administered intraperitoneally via the dialysis fluid, and this has been shown to produce
better glucose control than subcutaneous administration. The diabetic patient is taught to
add insulin to the dialysis fluid bag, or to inject the insulin into the connecting tubing
immediately before infusion of the dialysis fluid (24,25).
1.1.2.2 Problems associated with CAPD
CAPD imposes an appreciable technical burden on the patient. The technique involves
multiple connections and disconnections which are time consuming and are associated
with a risk of infection. Intensive patient training in aseptic technique, care of the
chronic indwelling catheter and control of fluid balance is required. CAPD patients must
possess the capability and motivation to accept the responsibility of self dialysis. Many
authors have emphasised the importance of patient selection and psycho-social factors in
influencing the success of CAPD (18, 26, 27). Although CAPD makes home dialysis
possible for many patients, a successful CAPD program requires a large commitment by
specialised staff for both training and support services. It also requires adequate hospital
back-up facilities, including haemodialysis, in the event of complications (28).
Protein loss
Protein loss in the dialysis fluid is considerable and can be compensated for by
adherence to a high protein diet. Dietary education is important to promote the ingestion
of high quality protein with least reliance on milk and nulk products which, in large
10
amounts, can produce hyperphosphataemia. Malnutrition and wasting are common
problems in patients with end-stage renal disease but are perhaps more prevalent in
peritoneal dialysis patients. Malnutrition can develop through increased protein loss
during dialysis and/or decreased appetite, both of which occur during episodes of
peritonitis (18, 29).
Glucose absorption
The quantity of glucose absorbed from the dialysis fluid contributes significantly to the
carbohydrate and energy intake of the CAPD patient. It is suggested that this glucose
absorption is responsible for the frequency of obesity and hypertriglyceridaemia in
CAPD patients (29, 30). Cardiovascular disease is the main cause of death in dialysis
dependent patients, but it is unclear how obesity and hypertriglyceridaemia affect the
long term prognosis of CAPD patients (15, 29). Much attention has been directed
towards the development of an alternative osmotic agent. Many agents have been
investigated, including fructose, sorbitol, xylitol, amino acids, gelatin, glycerol,
dextrans and glucose polymers, but none have proven to be as effective as glucose in
producing ultrafiltration, and at the same time devoid of side-effects (30).
Intra-abdominalpressure
Increasedintra-abdominal pressure due to the continuous presenceof dialysis fluid in the
abdominal cavity, can give rise to several complications. The most common of these is
the development of abdominal hernias. Raised intra-abdominal pressure can also
aggravate or lead to the development of haemorrhoids and lower back pain. Internal and
external dialysis fluid leaks can occur and, less commonly, cardiopulmonary function
may be compromised (29).
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Long term membrane viability
Unlike haemodialysis, CAPD is dependent on a living membrane which has
characteristics that vary between individuals and circumstances. Some patients have
been treated for more than five years on CAPD without any apparent deterioration in
dialysing capacity, while others have shown progressive loss of ultrafiltration and gross
impairment after less than two years. Patients in whomimpairment of dialysing capacity
has occurred may have developed extensive i.p. adhesions and/or fibrosis or, in rare
instances, go on to develop sclerosing peritonitis, a severe complication associated with
a high morbidity (31).
The long term viability of the peritoneal membrane, and the factors which influence this,
are uncertain. Possible causes of decreased dialysingcapacity include low dialysis fluid
pH, excessive use of hypertonic dialysis fluids, chemical irritation (for example dialysis
fluids containing acetate, i.p. administered drugs or antiseptics), irritation due to
particulate matter in the dialysis fluid, administration of beta blockers, irritation caused
by the catheter, and peritonitis (31-34).
Peritonitis
Recurrent peritonitis continues to be the primarycomplication of CAPD and is the major
impediment to prolonged success with this dialysis technique. This has been illustrated
by a recent survey of CAPD patients in Australia which found that 64% of patients
transferring from CAPD to another form of dialysis, did so because of peritonitis (16).
Other reasons for transfer included infections along the catheter tract (tunnel infections),
and skin exit-site infections, giving a total of 73% of transfers due to infectious
complications. It is also possible that infection played a role in some other reasons given
for transferring to an alternative form of dialysis, for example "unable to manage
self-care" and "inadequate dialysis".
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An analysis of CAPD technique survival in Australia shows that the probability of
uninterrupted peritoneal dialysis in patients commencing CAPD during the period from
1985 to 1988 inclusive, was 65% one year after commencement, and 47% at two years.
In this analysis, transfer to an alternative form of dialysis (for a period greater than one
month), and death were regarded as technique failures. Increasing age was associated
with a significant reduction in technique survival, whereas diabetes did not confer any
adverse effect. Of interest is the relationship between technique survival and the year in
which CAPD was commenced, which shows that there has been very little change in one
year technique survival between 1981 (61%) and 1987 (64%). The incidence of
peritonitis in CAPD patients in Australia is unknown, however during the twelve month
period to October 1988, peritonitis was directly responsible for thirteen deaths in dialysis
dependent patients (15,16).
A greater appreciation of the extent of the peritonitis problem can be gained from the
Report of the National CAPD Registry of the United States of America (13). Patients
commencing CAPD during the period from 1981 to 1988, and receiving end-stage renal
disease therapy for the first time, experienced an overall peritonitis rate of 1.3 episodes
per patient year. Despite the introduction of newer connection devices, improvement in
patient training and reports of decreased rates of peritonitis by individual centres, the
incidence of peritonitis, when related to the year in which CAPD was commenced, has
not changed since 1981 (1.3 episodes per patient year). For patients new to CAPD, the
probability of experiencing at least one episode of peritonitis is 40% at the end of
6 months of therapy, 60% at one year, and 80% at two years. Long term single centre
studies in other countries have reported similar figures (35).
Peritonitis is usually characterised by a cloudy dialysis fluid effluent (with an elevated
white blood cell count); low grade fever, mild abdominal pain and changes in peritoneal
membrane permeability. Approximately two-thirds of peritonitis episodes are caused by
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gram-positive organisms originating from the skin (13, 36-38). Staphylococcus
epidermidis, previously recognised as an important pathogen in infections associated
with vascular catheters (39), is the most common infecting organism. Approximately
20% of peritonitis episodes are caused by gram-negative organisms, including E.coli and
Pseudomonas spp, and a small number are caused by non-bacteiial pathogens including
fungi and algae (40-42). The bio-type and phage-type of organisms cultured from the
skin, nose and hands of CAPD patients, when compared to the bacteria isolated from the
peritoneal effluent of these patients during peritonitis episodes, shows that CAPD
patients are at a much greater risk from their own flora than from their external
environment (38).
Many centres have reported that a majority of peritonitis episodes have occurred in a
minorityof theirpatientpopulation (18, 38,43). The factors whichpredispose a patient
to recurrent episodes of peritonitis are unknown. Non-adherence to aseptic technique is
often implicated as the cause of a peritonitis episode, and the number of
connect/disconnect procedures is considered to be related to the risk of infection.
However, the failure of changes which have occurred in patient selection, patient
training, connection devices (for example UV sterilisation chambers, sterile welding
devices), anddelivery systems (forexample in-line filters), to produce a significant and
consistent improvement in the incidence of peritonitis, indicates that there aremultiple
risk factors involved (13, 15, 43, 44). Changes which occur in the peritoneal defence
mechanisms of the CAPD patient are poorly understood but may be of great
importance (45-47). Bacterial and fungal colonisation of the catheter have been
frequently observed (48, 49), and adherent bacteria have been shown to have greater
resistance to the action of antibiotics (50, 51). Ash has suggested that the type of
catheter employed and the method of catheter placement are related to the incidence of
peritonitis (52). Some authors have commented that the role of material defects, for
example cracks in the connection equipment leading to dialysate leaks, may have been
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understated in recurrent peritonitis (18, 53). Two other factors which indicate that the
cause of peritonitis is far more complex than can be singularly attributed to contamination
during the exchange procedure, are the well recognised but obscure phenomena of sterile
peritonitis and eosinophiUc peritonitis in which no causative organisms can be isolated.
These episodes have been reported to occur in approximately 15% of cases (13), and
they are often assumed to be associated with chemical irritants, for example components
of the dialysis fluid, plasticisers leached from the dialysis fluid container, or i.p.
administered drugs (54-56). Others have claimed that this anomaly is due to inadequate
microbiological culture techniques (37).
1.1.2.3 Treatment of peritonitis
The treatment of peritonitis must be initiated on empiric grounds before culture and
sensitivity results are known. Initial antibiotic therapy should cover a broad spectrum of
organisms, both gram-positive and gram-negative, and should be dependent on the
sensitivity pattern of Staphylococcus epidermidis in each centre (57, 58). When a
microbiological diagnosis is available the antibiotic therapy can then be rationalised.
Antibiotics are most frequently administered by direct addition to the dialysis fluid. This
i.p. route of administration has several advantages over other parenteral routes of
administration:
(i) It is a convenient route of administration because it employs a pre-existing access
and eliminates the need to obtain a vascular access.
(ii) Intraperitoneal administration achieves high local drug concentrations and has a
greater potential to eradicate organisms which may persist in stagnant residual pools of
dialysate within the peritoneal cavity.
(iii) Therapeutic blood levels of most antibiotics are achievable by i.p. adnninistration
alone. Penetration of antibiotics from the peritoneal cavity to semm is usually rapid and
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extensive, eliminating the need for intravenous (i.v.) loading doses. Seldom, however,
is penetration from serum to the peritoneal cavity as effective (59, 60).
(iv) The i.p. administration of antibiotics enablesuncomplicatedepisodes of peritonitis
to be managed at home or on an out-patient basis. Individual centres have demonstrated
their preference for out-patient management (61, 62), and the majority of renal units in
Australia do not routinely admit patients for the treatment of peritonitis (16).
1.1.3 Stabihty of antibiotics in peritoneal dialysis fluids
Questions are often directed to hospital pharmacists concerning the stability and
compatibility of drugs for i.p. administration. An overwhelming majority of patients
undergoing peritoneal dialysis in Australia are on CAPD and use proprietary "ready to
use" dialysis fluids which contain between 0.5% and 4.5% glucose. Antibiotics for i.p.
administration are added directly to the dialysis fluid prior to its instillation into the
peritoneal cavity. Peritonitis episodes in CAPD patients are routinely managed on an at
home or out-patient basis and, in these settings, it is important to know the viability of
the drug in pre-loaded bags. For example, is it possible to dispense a weekend supply
of pre-loaded bags to a patient? Is it appropriate for a patient to pre-load a day's supply
of dialysis fluid at one sitting? Of considerable interest to pharmacists is the use of drug
combinations for the treatment of CAPD peritonitis. Initial empiric therapy is directed to
broad-spectrum cover and frequently involves a combination of a penicillin or
cephalosporin with an aminoglycoside. In many centres, heparin is routinely added to
the dialysis fluid during episodes of peritonitis; it prevents the formation of fibrin
filaments and is believed to be important in preventing the development of i.p.
adhesions (5). The insulin requirement of diabetics generally increases during episodes
of peritonitis and this group of patients will continue adding insulin to their dialysis
fluid. The fluid is usually warmed to approximately 37°C prior to use in order to prevent
discomfort when instiUed into the peritoneal cavity. These practices have the potential to
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create a number of pharmaceutical problems.
Knowledge of drug stability in concentrated dialysis fluids is also important for a
minority of patients undergoing intermittent peritoneal dialysis. Concentrateddialysis
fluids contain 30% or 50% glucose and are intended for use with dialysis machines
containing automatedproportioning systems. The machine which lead to the widespread
application of intermittent peritoneal dialysis to the home setting during the 1970's, uses
reverse osmosis to convert a tap water supply into sterile, apyrogenic water, and an
automated proportioning systemfor using the water so produced to accurately dilute the
concentrated dialysis fluid. The dialysis fluid delivered to the peritoneal cavity generally
contains between 0.5% and 4.5% glucose, however drugs intended for
i.p. administration are added to the concentrated fluid prior to its passage through the
automated proportioning system. Drugs added at the beginning of the dialysis session
will be in contact with the concentrate for up to 10 hours, and will be heated to 37°C
during this time.
Greatinterest has beengenerated in thepharmacokinetics of drugs in peritoneal dialysis
patients. Knowledge of the stability of a drugin dialysis fluid is also necessary in this
context in order to accurately quantitate the processes of drug absorption and clearance
after i.p. administration (59).
Pharmacists seeking information on the stability andcompatibility of drugs in peritoneal
dialysis fluids encounter a number of problems:
(i) Few studies have investigated the stability of drugs in peritoneal dialysis fluids
(ii) Ready retrieval of the published data is seldom possible due to the scatter of
information over a wide range of sources
(iii) The application of the information is limited when differences exist between the
study parameters and the clinical setting (for example composition of the dialysis fluid).
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or when study parameters (for example storagetemperature) have not been stated
(iv) Two or more studies may provide conflicting information
Because of these problems, pharmacists advising on i.p. drug administration frequently
refer to the readily accessible information on drug stability and compatibility in i.v.
infusion fluids. The application of this information to i.p. drug administration is
questionable, primarilybecauseof thedifferences in composition betweenthe commonly
used i.v. infusion fluids and peritoneal dialysis fluids. Infusion fluids used for i.v. drug
administration are isotonic and are generally either solutions of glucose, sodium
chloride, glucose and sodium chloride combined, or electrolyte solutions containing
sodium, potassium, calcium, chloride and lactate ions (for example Hartmann's
solution). Peritoneal dialysis fluids usually contain glucose and sodium chloride in
combination with other electrolytes (calcium, magnesium and lactate), and are
hypertonic. Differences also exist between the drug concentrations normally
administered intravenously and those concentrations administered intraperitoneally to the
renally impaired patient. Another important factor which questions the usefulness of i.v.
admixture guidelines, is whether this information is in fact relevant to
i.p. administration. Drug combinations which are known to produce a precipitate, for
example gentamicin sulphate and heparin sodium, would be contraindicated for i.v.
administration (63), but does this physico-chemical incompatibility also contraindicate
i.p. administration?
Three reviews of the therapeutic management of peritonitis have been published which
have collated a limited amount of data on drug stability in peritoneal dialysis
fluids (64-66). None represents a complete review of the literature in this area, and the
application of the information presented is limited by the lack of detail, for example
storageconditions not specified, drug concentration not stated or peritonealdialysis fluid
formulation not stated. In some instances the authors have drawn conclusions which the
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cited studies do not support, including instances where stability has been inferred from
pharmacokinetic studies rather than having been demonstratedusing controlled stability
studies (64, 65). This over-simplified presentation of a portion of the literature is of little
value to hospital pharmacists needing to make decisions concerning the viability of drugs
administered to the peritoneal cavity.
1.2 Aims
The aims of this study were: (i) to conduct a literature review of the stability of
antibiotics in peritoneal dialysis fluids, and (ii) to collate the published information and
present it in a format which would serve as a usefulreference for hospital pharmacists.
1.3 Methods
1.3.1 Literature review
Access to stability studies was obtained through Index Medicus, Medline database,
correspondence with drug companies, and references contained in related journal
articles.
1.3.2 Collation and presentation of the data
The stability studies were analysed and the data was collated and presented in a format
which would facilitate its use as a reference for hospital pharmacists. The features
chosen for this presentation were:
Drug monographs
All the data relevant to a particular drug was collated under the name of the drag. When
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a study examined a combination of two or more drugs, the data was presented under the
name of each dmg. Drug monographs were arranged in alphabetical order.
Tabulated data
The data collated for each drug was presented in tabulated format. The tables contained a
reference to each study, details of the study parameters, the method used to determine
drug stability and a brief description of the results of each study.
CAPDfluid versus concentratedperitoneal dialysisfluids
To facilitate analysis of the data, the stability studies were divided into two categories:
(i) Those studies conducted in peritoneal dialysis fluids containing between 0.5% and
4.5% glucose. These fluids were collectively referred to as "CAPD fluids". Although
these fluids are used most commonly in CAPD, the bags can also be connected in series
and used with automatic cycler machines for CCPD and intermittent peritoneal dialysis.
(ii) Those studies conducted in concentrated peritoneal dialysis fluids containing 30%
or 50% glucose. These fluids were collectively referred to as "peritoneal dialysis fluid
concentrates". Since no patients were reported to be using reverse osmosis dialysis
machines in Australia in October 1986 (16), few, if any, would be expected to be
currently using peritoneal dialysis fluid concentrates. However, stability studies
conducted in peritoneal dialysis fluid concentrates were presented because the review
was designed to be relevant to practices in other countries as well as in Australia.
Another issue which favoured the collation of this information, is the predicted increase
in popularity of some form of semi-automated, semi-ambulatory peritoneal dialysis (such
as CCPD and variations of this technique), resulting from efforts to increase dialytic
efficiency and to reduce the incidence of peritonitis which has proved to be so much of a
problem with CAPD (2, 4, 14, 67). If this were to happen, a renewed interest in
automated proportioning systems could be expected because such systems would
eliminate the risk of contamination associated with multiple serial connections of 2 L
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peritoneal dialysis fluid containers.
Stability studies versus efficacy studies
Three methods have been used to investigate the stability of antibiotics in peritoneal
dialysis fluids:
(i) Visual analysis for evidence of physical incompatibility
(ii) Stability determined by assaying for unchanged drug
(iii) Stability determined by measuring change in drug activity over time
Also included in this review were studies which examined the susceptibility of a test
organism to peritoneal dialysis fluid or peritoneal dialysis effluent containing an
antibiotic. These were collectively referred to as "efficacy studies", and were not true
indicators of antibiotic stability in these fluids. Efficacy studies aim to mimic the
conditions during a peritonitis episode, in which an antibiotic is added to the dialysis
fluid in order to eradicate an organism residing within the peritoneal cavity. The activity
of the antibiotic under these conditions is therefore of clinical relevance and may be an
important factor in predicting treatment outcome (51). The feature which distinguishes
efficacy studies from stability studies, is that the peritoneal dialysis fluid or effluent is
not only the test solution to which the antibiotic is added, but also the growth medium
for the test organism. The fate of a population of test organisms under these conditions
reflects in part the effect of the dialysis fluid or effluent on this population. In the
absence of controls designed to quantify this activity, the effect of the dialysis fluid or
effluent on the activity of the antibiotic cannot be differentiated. None of the efficacy
studies included in this review used controls to quantify the activity of peritoneal dialysis
fluid or effluent on the test population, however this activity has been reported elsewhere
in the literature. Several studies have demonstrated that CAPD fluids inhibit the growth
of staphylococci (68-72). Some investigators concluded that CAPD fluid was
bactericidal. Others found that while CAPD fluid inhibited the growth of staphylococci.
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the organisms remained viable. The effect of CAPD fluids on other bacteria is less clear
(68-71). Some studies found that E. coU and P. aeruginosa did not grow in CAPD
fluids, whUe others found that these bacteria grew well. All studies demonstrated that
peritoneal dialysis effluent was a more favourable growth medium than unused CAPD
fluid for all the organisms tested.
Three methods have been used to investigate the efficacy of antibiotics in peritoneal
dialysis fluids and peritoneal dialysis effluent:
(i) Measurement of the minimum inhibitory concentration of the antibiotic
(ii) Measurement of the minimum bactericidal concentration of the antibiotic
(iii) Analysis of the bacterial population as a function of time (time/kill curves)
The method and results of efficacy studies were tabulated in italics to distinguish them
from stability studies.
Summary
To conclude each monograph, a summary of the tabulated data was presented for studies
conducted in CAPD fluids and studies conducted in peritoneal dialysis fluid
concentrates. Information on the stability and/or efficacy of the drug alone in peritoneal
dialysis fluid was presented first, followed by information on its stability and/or efficacy
when combined with other drugs. When applicable, the summary included comments
on conflicting data, and comments on factors which may limit the application of the data
to the clinical setting.
Guide to interpreting the data
A detailed guide to interpreting the tabulated data was provided in the introductory pages
of the review. This included information on CAPD fluids and peritoneal dialysis fluid
concentrates, stabihty and efficacy studies, study methods, drag nomenclature, order of
presentation, standardisation of expression and units of measurement, abbreviations and
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content of the appendices. Recommendations for the appropriate use of the document
were provided, and limitations associated with the application of the information were
highlighted.
1.4 Results
A document containing monographs for 33 antibiotics was produced and is presented in
Appendix 1.
1.5 Discussion
Despite the routine use of i.p. antibiotics for the treatment of peritonitis, there are few
studies which have investigated the stability of antibiotics in peritoneal dialysis fluids.
Antibiotic combinations and antibiotics in combination with heparin and/or insulin are
used frequently, yet the stability and compatibility of these combinations in dialysis
fluids has received little attention. Some of the drugs for which stability information is
available, are rarely used in today's clinical setting, for example carbenicillin. On the
other hand, there is little or no stability information available for many of the drugs
commonly used in renal units in Austraha, for example flucloxacillin and co-trimoxazole.
Despite the increasing incidence of fungal peritonitis and the increased interest in the use
of i.p. antifungal agents, there is no information on the stability of antifungal agents in
peritoneal dialysis fluids.
Of particular concem is the lack of well designed stability studies. Many of the studies
reviewed failed to define many of the important variables which can affect drug stability
in solution, for example drug concentration, storage temperature, peritoneal dialysis fluid
container and peritoneal dialysis fluid composition. In addition, none of the studies
reviewed provided evidence of the stability-indicating capability of the assay, in other
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words the ability of the assay to unequivocally distinguish and quantitate unchanged
drug in the presence of decomposition products.
The stability and compatibility of drugs in peritoneal dialysis fluids has not received the
same attention that has been given to intravenously administered drugs. Intraperitoneal
drug combinations are used, and i.p. admixtures are stored in the absence of stability
data and, in many cases, in contravention of accepted i.v. admixture guidehnes. In some
centres, visual evidence of a physico-chemical incompatibility, for example haze or
precipitate formation, is not regarded as contraindicating i.p. administration.
Precipitation is expected to occur with some admixtures and occasionally attracts the
additional instruction to "shake the bag" prior to instillation into the peritoneal cavity.
This liberal approach to i.p. drug administration arises from the knowledge that a
physico-chemical incompatibility resulting in precipitation will not produce a
life-threatening situation. One disadvantage of this approach must be the risk of
compromising the therapeutic efficacy of drugs administered to the peritoneal cavity,
thereby compromising a rapid and successful treatment outcome.
An as yet unknown factor, which may prove to be an even greater disadvantage of this
approach, is the effectof precipitates, decomposition products andreaction products on
the peritoneal membrane. Sterile peritonitis and eosinophilic peritonitis have a high
incidence in the peritoneal dialysis population (13). The cause of these phenomena is
unknown, but chemical irritation of the peritoneal membrane by intraperitoneally
administered compounds has been demonstrated (55, 56). Uncertainty also surrounds
those factors which reduce the long term viabihty of the peritoneal membrane. Chemical
irritation and irritation due to particulate matter have been suggested as possible
contributing factors (33, 34, 73, 74).
Greater knowledge of the stabilityof drugs in peritoneal dialysis fluids, and the effects
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of precipitates on the peritoneal membrane, is clearly required. Peritoneal dialysis
patients are dependent on efficacious drug treatment to reduce the morbidity of
peritonitis, and they are dependent on maintaining the function and integrity of the
peritoneal membrane for their survival.
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CHAPTER 2
STABILITY OF MICONAZOLE IN PERITONEAL DIALYSIS FLUID
2.1 Introduction
2.1.1 Fungal peritonitis: characterisation and incidence
Fungal peritonitis is a rare infectious complication usually occurring in one of two
settings: (i) abdominal surgery or perforation, and (ii) peritoneal dialysis. It has been
reported with increasing frequency since the advent of CAPD in 1976, and the
subsequent increased use of peritoneal dialysis for the treatment of patients with
end-stage renal disease (40, 75-78). Yeasts, particularly Candida spp., are the most
common organisms causing fungal peritonitis. Infections due to filamentous fungi have
rarely been reported (38). Fungal peritonitis is associated with a high morbidity and
mortality, and poses a difficult management problem (79-81).
The incidence of fungal peritonitis in the CAPD population in Australia is unknown,
however peritonitis was directly responsible for thirty five deaths in peritoneal dialysis
patients during the three year period to October 1988, and ten of these were due to fungal
infection (15, 16, 82).
A special report of the National CAPD Registry of the United States of America has
examined the characteristics of successive peritonitis episodes in a population who were
commenced on CAPD during the period from January 1984 to June 1986
(n=6 335), (83). Fungal infection was present in only 2.7% of first peritonitis
episodes, however following an initial fungal infection, 50% of recurrent infections also
cultured fungi. Although each peritonitis episode was reported as a new and distinct
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event, the high probability for a recurrent infection to also culture fungi, may be due in
part to relapse. It can be difficult to distinguish between relapse and reinfection,
especially as the time interval between peritonitis episodes shortens. This study reported
a median time interval of two months between the first and second fungal infection.
The incidence of fungal peritonitis has been reported by several individual renal units
during the period from 1983 to 1987 (76,78-80, 84-86). These have ranged from 3.5%
of all peritonitis episodes during a three and a half year period, to 15% during a two year
period (78, 84).
2.1.2 Risk factors for fungal peritonitis
Impairment of host defence mechanisms during chronic renal failure, and the presence of
a permanent indwelling catheter, are considered to contribute to the emergence of
Candida as an important pathogen. Candida peritonitis in peritoneal dialysis patients can
occasionally be attributed to obvious predisposing factors, such as bowel perforation or
gross contamination of the dialysis system. In most cases, however, it is probable that
multiple interacting factors are involved. Several risk factors have been proposed in the
literature, foremost of which is the recent administration of antibiotics (within one month
prior to the onset of fungal peritonitis). This is usually associated with an episode of
bacterial peritonitis (40, 75, 77, 87-90). Other risk factors which have been proposed
include recurrent episodes of bacterial peritonitis and frequent antibiotic administration
(76, 78, 88, 91), hospitalisation (40), immunosuppressive therapy (40, 76), and
diabetes (77, 90).
A study of seventeen cases of fungal peritonitis in CARD patients failed to identify any
epidemiologic, demographic or clinical factors which characterise patients developing
this type of infection (80). In view of the relatively low incidence of fungal peritonitis.
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large prospective studies would be required to test the validity of proposed risk factors.
2.1.3 Treatment of fungal peritonitis
The treatment of fungal peritonitis is based on the need to eradicate the infection as
rapidly and safely as possible, while considering the need to preserve the peritoneum as
a dialysingmembrane. Many different treatmentrecommendations have been published
since the early reports of this complication in patients with chronic indwelling catheters.
The three main approaches to treatment are; (i) systemic and/or i.p. antifungal
chemotherapy with catheter in situ, (ii) removal of the catheter plus supplementary
antifungal chemotherapy, and (iii) removal of the catheter.
(i) Antifungal chemotherapy with catheter in situ
The successful treatment of fungal peritonitis using an i.p. antifungal agent with a
chronic indwelling catheter in situ, was described as early as 1975, prior to the
introduction of CAPD (92). Several more recent studies have also reported the
successful treatment of fungal peritonitis using systemic and/or i.p. antifungal
chemotherapy in patients with chronic indwelling catheters in situ (77, 84, 88, 89,
93-95). Advantages of this treatment optioninclude uninterruptedperitonealdialysis,
preservationof the peritoneum for dialysis (by preventing the formation of adhesions),
reduction in the demandfor haemodialysis, andelimination of the needfor surgery.
The best route of administration for antifungal chemotherapy has attractedconsiderable
discussion in the literature. Some authors havecommented on the therapeutic advantage
of i.p. administration, reporting treatment successes with i.p. administration (88), or
treatment failures with i.v. administration (91). Others have drawn attention to treatment
failures when i.p. administration was used alone, and suggest that combinationtherapy
with systemic antifungals or catheter removal is necessary to achieve cure (93).
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Successful treatment has also been reported using oral chemotherapy in patients without
interrupting CAPD (85).
Some antifungal agents can cause local irritation when instilled into the peritoneal cavity.
Intraperitoneal amphotericin is frequently reported as causing pain (76, 84, 89-91, 96,
97), and it has been suggested that its use is associated with peritoneal fibrosis (40).
There are isolated reports of local irritation due to flucytosine and miconazole (80, 92,
98).
(a) Antifungal chemotherapy plus catheter removal
Early catheter removal has been identified by many authors as the most important step in
a combined approach with antifungal chemotherapy, for the successful treatment of
fungal peritonitis (75, 78, 86, 90, 97, 99). This is emphasised by reports of persistent
fungal colonisation of the catheter after seemingly adequate chemotherapy had produced
sterile peritoneal effluent (78,97).
Intraperitoneal adhesions and abscess formation are problems associated with catheter
removal and interruption of peritoneal dialysis. Often the dialysing capacity of the
peritoneum is impaired and it is frequently not possible to resume peritoneal dialysis after
resolution of the infection (79, 81, 95). Early or immediate replacement of the catheter
enables early resumption of peritoneal dialysis, and has been recommended as a solution
to these problems (100).
(Hi) Catheter removal
It has been reported that removal of the peritoneal catheter alone will achieve cure in
some cases (75, 93). Peritonitis episodes in which antifungal chemotherapy was
unsuccessful, have been cured by removal of the catheter concurrent with cessation of
chemotherapy (101). Maintenance of a better nutritional status has been identified as
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another factor in favour of ceasing peritoneal dialysis (99).
There is no general consensus regarding the treatment of choice for fungal peritonitis in
peritoneal dialysis patients. The approach to treatment depends on a number of
variables, including organism identification, feasibility of haemodialysis, need to
continue peritoneal dialysis, history of peritonitis, and concurrent illness. Accordingly,
some authors have advocated a more flexible approach to the management of fungal
peritonitis, and have recommended that an initial trial period with antifungal agents may
be warranted prior to catheter removal (40,76,102). Two other controversial issues of
treatment are the choice of antifungal agent and the use of peritoneal lavage. Probably
the most serious problems in the management of fungal peritonitis are delayed diagnosis,
and failure to initiate therapy quickly (40).
2.1.4 Stability of antifungal agents in peritoneal dialysis fluids
Despite the interest in i.p. antifungal chemotherapy, there is little information on the
stability or compatibility of antifungal agents in peritoneal dialysis fluids (103).
Amphotericin is known to precipitate in electrolyte and/or acidic solutions (63), and
precipitation in peritoneal dialysis fluid has occasionally been reported (93). The effect
of amphotericin precipitation on the peritoneal membrane, or on antifungal activity in
vivo, is unknown.
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2.1.5 Miconazole in the treatment of fungal peritonitis
Miconazole is an imidazole derivative possessing broad spectrum antifungal activity and
some gram positive antibacterial activity (Figure 2.1). Clinical efficacy has been
demonstrated against Candida, Coccidioides, Cryptococcus and Paracoccidioides spp. It
acts by inhibiting the biosynthesis of membrane lipids, causing disruption to the
permeability and integrity of fungal cell membranes (104). Miconazole has been
administered intraperitoneally for the treatment of fungal peritonitis in concentrations
ranging from 2 to 50 mg per litre of dialysate (84, 90, 93, 95, 99). Although dilutions
of miconazole in 0.9% sodium chloride and 5% glucose injections are reported to be
stable for 24 hours at room temperature, no information is available concerning the
stability of miconazole in plastic containers (105), or in peritoneal dialysis fluids (103).
2.2 Aims
The aim of this study was to investigate the stability of miconazole in peritoneal dialysis
fluid (PDF). The following aspects were examined:
(i) The stability-indicating capability of the assay
(ii) The stability of miconazole in PDF when stored in 2 L polyvinyl chloride (PVC) bags
(iii) The stability of miconazole in PDF when stored in glass ampoules
(iv) The sorption of miconazole by a 2 L PVC container
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Figure 2.1 Miconazole
l-(2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl)-lH-
imidazole
CH2—CH—O—CH2 / Vc.
w
Cl
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2.3 Methods
2.3.1 Materials
1. Miconazole injection 10 mg/mL (Daktarin®, Janssen, Belgium) Batch 85F11/031
2. PDF containing glucose 4.25%, sodium 132 mmol/L, calcium 1.75 mmol/L,
magnesium 0.25 mmol/L, chloride 96 mmol/L and lactate 40 mmol/L. Osmolarity
485 milliosmoles/L (Dianeal® PD-2, Travenol, Australia) Batch A39H1
3. Miconazole nitrate (Janssen, Belgium) Batch ZR14889H 1001, donated by
Janssen, Australia.
4. Methanol, HPLC grade (Waters Associates, MA, USA)
5. Ammonium dihydrogen phosphate, laboratory reagent grade (L.R.)
6. p-Dichlorobenzene, L.R.
7. Sulphuric acid, L.R.
8. Sodium hydroxide, L.R.
2.3.2 Analysis of miconazole
A high performance liquid chromatographic (HPLC) assay modified from that described
by McGookin et al (106), was used to determine miconazole concentrations, using
p-dichlorobenzene as an intemal standard. Figure 2.2 shows a typical chromatogram of
miconazole in PDF. The retention time for miconazole was approximately 8 minutes.
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Figure2.2 Chromatogram of miconazole in PDF(~20 mg/L) withinternal standard (IS)
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2.3.2.1 Instrumentation
Column; jaBondapak C18 stainless steel 3.9 mm i.d. x 30 cm (Waters
Associates)
Guard column: Bondapak C18/Corasil 37-50 jim (Waters Associates)
Solvent delivery system: Waters Associates Model M45
Absorbance detector: Waters Associates Model 441
2.3.2.2 Operating parameters
Mobile phase: 15% v/v 0.05M ammonium dihydrogen phosphate (pH4.6)
in methanol, filtered through a 0.45 |J.m membrane filter and
degassed under vacuum before use.
Flow rate: 1.0 mL/min
Absorbance wavelength: 229 nm
Temperature: 20 ± 2°C
2.3.2.3 Calibration curve
A stock solution containing miconazole nitrate 2 g/L in methanol was prepared on the
first day of the study. Aliquots of 50, 100, 150, 200 and 250 jaL were pipetted into
25 mL volumetric flasks and adjusted to volume with PDF. This produced standard
solutions containing 4, 8,12, 16 and 20 mg/L of miconazole nitrate respectively. Each
standard solution was assayed immediately after preparation.
A calibration curve was constructed by plotting the peak height ratio of miconazole
nitrate to internal standard, against miconazole nitrate concentration (Figure 2.3). Each
point on the calibrationcurve was determinedat leastonce on each day of the study.
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Figure 2.3 Calibration curve for miconazole nitrate
(The number of data points for each concentration is indicated in brackets)
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The intra-day coefficient of variation was 3.6% at 20 mg/L (n=6), and 5.8% at 4 mg/L
(n=6). The inter-day coefficient of variation was 3.9% at 20 mg/L (n=6), and 11.8% at
4 mg/L (n=6).
2.3.2.4 Sample preparation
A 200 |iL sample of a solution of miconazole in PDF was combined with 200 |iL of
internal standard (p-dichlorobenzene 4 mg/L in methanol). A 20 |iL aliquot of the
resulting mixture was injected onto the column. Assays were performed immediately
after sample preparation.
2.3.3 Stability-indicatingcapabilitvof the assay
Two hundred microlitres of miconazole injection werepipetted into a 100 mL volumetric
flask and adjusted to volume with PDF to produce a concentration of approximately
20 mg/L of miconazole. The resulting solution had a pH of approximately 6.0.
Duplicate samples of the solution were assayed immediately to determine the initial
miconazole concentration. Of the remaining solution:
(i) 2 mL was transferred into each of two glass ampoules and sealed
(ii) A portion was acidified to pH~2 with IM H2SO4; 2 mL of the acidified solution
was transferred into each of two glass ampoules and sealed
(iii) A portion was rendered alkaline to pH~l 1 with IM NaOH; 2 mL of the alkaline
solution was transferred into each of two glass ampoules and sealed
PDF without added miconazole was treated in a similar manner. The ampoules were
then autoclaved for 1 hour at 118°C. Duplicate samples from each ampoule were
assayed to determine the miconazole concentration. Numerous samples from each
ampoule were also chromatographed without internal standard. The chromatograms of
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all injections were compared and examined for changes suggesting the presence of
decomposition products of miconazole.
2.3.4 Stability of miconazole in PDF stored in PVC bags
The method of preparation of admixtures used in this stability study was designed to
simulate actual use conditions. Four millilitres of miconazole injection were measured in
a 5 mL capacity plastic syringe and injected via the additive port into a commercially
available PVC bag containing approximately 2080 mL of PDF. This produced a
concentration of approximately 20 mg/L of miconazole. The bag was shaken vigorously
by hand for one minute and a sample of the solution was assayed immediately, in
duplicate, to determine the initial miconazole concentration. At 2, 4, 6, 12, 24, 48, 72,
120 and 216 hours after admixture, the bag was shaken gently by hand for one minute
and a sample of the solution was assayed immediately, in duplicate, to determine the
miconazole concentration. On each occasion approximately 1 mL samples were drawn
from the bag via the additive port using a glass syringe. The additive port was swabbed
with 70% alcohol before and after puncture, and sterile syringes and needles were used
to maintain the sterility of the admixture. The bag was stored at 20 ± 2°C, exposed to
ambient light, and was undisturbed between sampling times. The experiment was
performed in duplicate.
2.3.5 Stability of miconazole in PDF stored in glass ampoules
Two hundred microlitres of miconazole injection were pipetted into a 100 mL volumetric
flask and adjusted to volume with PDF to produce a concentration of approximately
20 mg/L of miconazole. Four samples of the resulting solution were assayed
immediately to determine the initial miconazole concentration. One rmllilitre aliquots of
the remaining solution were transferred into 1 mL glass ampoules and sealed. At 24, 48,
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72, 168 and 216 hours after admixture, two ampoules were opened and the solution in
each was assayed immediately, in duplicate, to determine the miconazole concentration.
The ampoules were stored at 20 ± 2°C and exposed to ambient light. Care was taken not
to shake or disturb the ampoules during storage to prevent contamination of the solution
by decomposition products which may have been generated at the ampoule tip during the
heat sealing process.
2.3.6 Sorption of miconazole by a PVC container
A solution of miconazole in PDF stored in a 2 L PVC bag was retained from the
previously described study (2.3.4). The bag had been stored on a bench top at 20 ± 2°C
and exposed to ambient light. Twenty one days after admixture, the bag was drained
and duplicate samples of the solution were assayed to determine the miconazole
concentration. The bag was cut along the seam into two halves. The inner surface of the
plastic was rinsed with running distilled water and dried. Two 1 cm^ sections and two
2 cm2 sections of plastic were cut from an unprinted area of the bag. Each section was
placed in a glass vial containing 4 mL of methanol and agitated. After 18 hours and
42 hours agitation, a sample of methanolic solution from each vial was assayed in
duplicate to determine the miconazole concentration. A 2 L PVC bag containing PDF
without added miconazole, was prepared in a similar manner and acted as a control. The
inner surface area of each bag was calculatedgeometrically to be 1 120 cm^.
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2.4 Results
2.4.1 Stability-indicating capability of the assay
Chromatograms of the following solutions are illustrated in Figure 2.4;
(a) Miconazole in PDF (pH~6) assayed immediately after preparation
(b) Miconazole in PDF (pH~6) autoclaved for 1 hour at 118°C
(c) Miconazole in PDF (pH adjusted to ~2) autoclaved for 1 hour at 118°C
(d) Miconazole in PDF (pH adjusted to ~11) autoclaved for 1 hour at 118°C
The concentration of miconazole in the autoclaved solutions at unadjusted, acid and
alkaline pH was 93%, 92% and 81%, respectively, of the initial concentration
(19.4 mg/L) measured in solution (a).
The appearance of the chromatograms in the region of the solvent front varied
significantly after autoclaving under different pH conditions. These changes were
identical to those observed in chromatograms of the corresponding control solutions,
shown in Figure 2.5 at reduced absorbance detector sensitivity, and may be associated
with decomposition products of components of the PDF, for example glucose (107).
These changes did not interfere with the peaks due to miconazole or internal standard.
No extra peaks or changes, suggesting the presence of decomposition products of
miconazole, were apparent in any of the chromatograms.
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Figure 2.4 Chromatograms of miconazole (Mic) in PDF in glass ampoules
Internal standard (IS)
(a) Miconazole in PDF (pH~6) assayed immediately afterpreparation
(b) Miconazole in PDF (pH~6) autoclaved for 1 hour at 118°C
(c) Miconazole in PDF(pHadjusted to~2) autoclaved for 1 hour at 118°C
(d) Miconazole inPDF (pH adjusted to -11) autoclaved for 1hour at 118°C
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2.4.2 Stability of miconazole in PDF stored in PVC bags
The percentages of miconazole remaining in PDF stored in PVC bags are illustrated in
Figure 2.6. A decline in miconazole concentration occurred in each bag during the study
period, the rate of loss being greatest during the first 24 hours. Less than 90% of the
initial concentration remained in each bag 4 hours after admixture. Less than 11% of the
initial concentration remained in the solutions 216 hours (9 days) after admixture. No
visible evidence of precipitation was observed in the solutions during the study period.
When the pooled data (replicate assays from duplicate bags) was plotted
semi-logarithmically (log [% initial concentration remaining] versus time), a curved plot
was obtained indicating that monoexponential or simple first-order kinetics did not
adequately model the loss of miconazole from solution. Feathering or resolving this
curve as residuals yielded two straight line segments. The first-order rate constants for
this biexponential rate profile of miconazole loss from PDF were 0.05 h'l and
0.006 h-1.
2.4.3 Stability of miconazole in PDF stored in glass ampoules
The percentages of miconazole remainingin PDF storedin glass ampoules are illustrated
in Figure2.6. A gradual decline in miconazole concentration occurred in each ampoule
during the study period. Greater than 90% of the initial concentration was maintained
for 3 days in each ampoule. Greater than 10% loss of initial concentration was observed
in both ampoules 168 hours (7 days) after admixture. No visible evidence of
precipitation was observed in the solutions during the study period.
Figure 2.6 Miconazole concentrations in admixtures stored in PVC bags and
glass ampoules *
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2.4.4 Sorption of miconazole by a PVC container
The concentration of miconazole remaining in solution 21 days after admixture was
1.5 mg/L, which represented 7.5% of the initial concentration. The results of the
methanolic extraction of miconazole from plastic are shown in Table 2.1. The quantity
of miconazole extracted was greaterper unit surface area from 1 cm^ sections compared
to 2 cm2 sections, and slightly more miconazole was extracted from the plastic after
42 hours of agitation than after 18 hours. The mean quantity of miconazole recovered
from the plastic by this method accounted for 28.3 ±3.1% (mean ± SD, n=8) of the
loss observed in the solution. Methanolic extracts of the corresponding controls showed
no detectable peaks when assayed.
2.5 Discussion
Miconazole was found to be remarkably stable under conditions of extreme heat and pH
which were intentionally applied in an attempt to promote its decomposition. Failure of
these conditions to cause any substantial degree of chemical decomposition, means that it
is not possible to unequivocally describe the abihty of the assay to detect decomposition
products of miconazole. However, it also indicates that substantial chemical
decomposition is highly unlikely to occur under the relatively mild storage conditions
employed in the stability studies conducted in both plastic and glass containers. The
application of higher temperatures and prolonged heating may have produced greater
decomposition of miconazole. To do so would have been of doubtful further benefit in
assessing the abihty of the assay to determine miconazole stability in solutions stored at
room temperature. Such extreme conditions could, for instance, lead to the formation of
decomposition products by mechanisms not relevant to storage at room temperature.
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Table 2.1 Recovery of miconazole fromplastic aftermethanolic extraction
Dimensions Extraction Total miconazole Total Percent miconazole loss
of plastic time recovered from miconazole recovered from plastic §
sample strip sample strip * in plastic *t
(cm) (hours) (lig) (mg) Mean Range
1 X 1 18 12.1 13.6 29.8 1.4
1 X 1 42 12.8 14.3 31.4 2.5
2x1 18 20.2 11.3 24.8 4.4
2x1 42 22.1 12.4 27.1 2.2
* Mean of duplicate determinations
t Based on calculated total area of plastic = 1120 cm
§ Mean and range of duplicate determinations
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This study demonstrates that a significant loss of miconazole (>10% of initial
concentration) occurs within 4 hours when the drug is added to PDF containing 4.25%
glucose and stored in PVC bags at 20 ± 2°C. A similar admixture was stable for at least
3 days when stored in glass ampoules under the same conditions. These findings alone
suggest that the loss of miconazole observed in PVC bags is due largely to an interaction
with the container, rather than chemical decomposition in solution. This proposition is
supported by the results of the experiment designed to assess the stability-indicating
capability of the assay (2.4.1). In the clinical situation, the rapid loss of miconazole
from PDF stored in PVC bags would demand that such admixtures be prepared
immediately prior to administration.
PVC is one of many polymers employed in the pharmaceutical industry for the
manufacture of drug containers and delivery systems. Polymers are generally combined
with one or more additives to improve the properties of the plastic, or to reduce its unit
cost. Some of the more common additives are antioxidants, antisag agents, antistatic
agents, colours, cross-linking agents, flame retardants, plasticisers, stabilisers and
reinforcing agents (108). Numerous studies have reported the interaction of drugs with
their containers and delivery systems. Autian and Brewer in 1958 were among the first
to give attention to drug-plastic interactions when they reported the effect of a large
number of parenteral products on disposable plastic-hubbed syringes (109). The
mechanism, quantification and prediction of such interactions have been the focus of
many subsequent studies (110 and references cited therein).
Four types of drug-plastic interactions have been identified: (i) permeation, (ii) leaching,
(iii) sorption, and (iv) chemical reaction. Each of these processes can cause significant
changes in the properties of the plastic. Conversely, subtle changes in the properties of
the plastic, for example by polymer degradation or variation in plasticiser content, can
have a significant effect on drug-container interactions (108, 111).
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(i) Permeation
No plastic currently used in the pharmaceutical industry presents such a complete barrier
to gases and other types of molecules as does an all-glass container. Oxygen and other
gases in the external environment may enter the drug solution by passing through the
plastic container wall. Conversely, a volatile constituent within the container may pass
through the container wall to the external environment. Other solutes may also permeate
the container, thereby reducing the concentration of that component in solution.
(ii) Leaching
Leaching refers to the migration of a component from the plastic into the solution in
contact with it. A component leached from the plastic may remain in solution, or form a
suspension of discrete particles.
(Hi) Sorption
Sorptionrefers to the movement of a solute from the solution into the polymeric stracture
of the drug container or delivery system. Sorption consists of the processes of
adsorption (interactionof a solute at the drug/plastic interface) and absorption (entrance
of the solute into the bodyof thepolymer). The forces of interaction are generally of the
physical type, although chemical interaction or "chemisorption" has occasionally been
reported. Sorption is a prerequisite to permeation.
(iv) Chemical reaction
A solute may react chemically with a constituent of the plastic. The solute most
frequently involvedin this type of interaction is a decomposition product generatedin the
solution after periods of storage, and the constituent of the plastic is usually an additive
rather than the polymer. This interactionoftenresultsin discolourationof the plastic.
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In this study, approximately 28% of the miconazole lost from solution could be
recovered from the plastic by methanolic extraction. This represents sorption of
miconazole by the PVC container. The loss of miconazole from the solution showed a
biexponential rate profile. Since extremely long times (weeks or months) are generally
required to attain or even approach an equihbrium situation during sorption of solutes by
plastic infusion systems (112, 113), this biexponential profile may represent a loss of
miconazole by the separate processes of partition and diffusion, as discussed by Polack
etal(114).
The miconazole lost from the solution and not recovered from the plastic, may be due to:
(i) incomplete extraction of miconazole from the plastic, (ii) chemical reaction of
miconazole with components of the plastic, (iii) loss of miconazole by permeation,
and/or (iv) chemical decomposition of miconazole.
McGookin et al have studied the sorption of miconazole dissolved in 0.9% sodium
chloride injection by an i.v. infusion bag and various administration sets (106). The
percentage sorption observed after transfer of the solution through the administration sets
ranged from 1 to 10% of the initial concentration, with a mean of 4.8%. Sorption of
miconazole after 24 hours storage in PVC infusion bags was of the order of 5%. The
loss of miconazole observed in this study was assumed to be due to sorption, however
McGookin et al did not investigate other mechanisms of loss, or prove sorptive loss
per se. They concluded that the interaction of miconazole with plastic containers and
administration sets is unlikely to be clinically significant. In contrast, this study
demonstrates that the interaction of miconazole with a PVC container may result in a
clinically significant loss from the solution.
In 1971, Autian proposed many factors which influence the permeation and sorption of
drugs by plastic containers and delivery systems (108). These included temperature.
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physico-chemical properties of the polymer (for example degree of crystallinity),
physico-chemical properties of the drug (for example solubility, polarity and molecular
weight), solution volume, solvent, pH, degree of drug ionisation, drug concentration,
and the presence of other constituents in the solution.
Numerous studies have subsequently investigated the importance of many of these
factors in controlling the rate and extent of drug-plastic interactions. For example, it has
been demonstrated that different polymers exhibit different potentials to interact with
drugs in solution. The loss of nitroglycerin and many of the benzodiazepines in PVC
infusion systems has been extensively reported (115-123). However, nitroglycerin and
diazepam have been shown to be stable in polyethylene (119, 121), and polypropylene
containers (120). Similar findings have been reported for other solutes (120,124), and
have identified PVC as the polymer most frequently associated with sorption of drugs by
containers and dehvery systems (110).
Increased temperature has been reported by many authors to cause an increase in the rate
and/or extent of uptake of various drugs by plastic infusion systems (121, 125-128).
Uptake of solutes has also been demonstrated to increase with an increase in the surface
area to volume ratio of the infusion bag (116, 120,127). Lipid solubility and degree of
ionisation have been identified as two important physico-chemical properties of the drug
which influence its ability to interact with plastic infusion systems, with uptake into
plastic generally limited to unionised, lipid soluble molecules (118, 129,130).
The effect of concentration on the uptake of solutes by plastic infusion systems is less
clear. Several studies have shown that the percentage loss of organic nitrates and
diazepam from PVC bags was independent of the initial concentration (116, 120, 121,
131). However, the percentage loss of warfarin sodium and chlormethiazole from PVC
bags was reported to be concentration dependent (111, 125). Factors which make
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concentration an important variable in the uptake of some drugs and not others, are
largely unknown, but appear to be associated with two different rate controlling
processes, one being the diffusion of drug in the plastic matrix, and the other being a
saturable binding or adsorptive process (132). It is possible that some drugs may
enhance their own sorption by interacting with the polymer, for example the
plasticisation of PVC by chlormethiazole (111). The investigation of the effect of
concentration on the sorptive loss of a solute is complicated by the effect which a change
in concentration can have on the pH of the solution (120,132)
Many questions also surround the importance of other constituents in the solution and
their influence on solute uptake by plastic infusion systems. Moorhatch and Chiou
demonstrated that the sorption of vitamin A acetate was enhanced in the presence of
0.9% sodium chloride compared to water, and that the sorption of both warfarin sodium
and vitamin A acetate was enhanced in the presence of 5% glucose (125). However,
comparisons of 0.9% sodium chloride and 5% glucose injections as diluents have shown
no influence on the rate of uptake of a variety of organic nitrates and benzodiazepines by
plastic infusion systems (116, 117, 123, 131, 133).
Variation in one or more of the many factors which influence the uptake of drugs by
plastic infusion systems may be responsible for the difference between the results of this
study and those of McGookin et al (106). Possible differences between the polymer
composition of the PVC bags used in this and McGookin et al's study may cause
variation in sorptive loss, and the polymer type of the administration sets used in the
latter study was not stated. The different characteristics of PDF and 0.9% sodium
chloride injection as diluents may also cause variation in sorptive loss. PDF is more
acidic than 0.9% sodium chloride injection, and a decrease in pH would be expected to
decrease the sorptive loss of miconazole (a weak base) to plastic infusion systems.
Therefore the difference in diluent pH alone cannot explain the different results of these
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studies. The concentration of miconazole, however, will also affect the pH of the
adnoixture, since miconazole i.v. solution has a pH in the range 3.7 to 5.7 (134). The
volume of the infusion solution, the concentration of miconazole, and the pH of the
admixture, are important variables which are not stated in McGookin et al's report, but
which are essential for making a critical comparison with the present study.
52
CHAPTERS
STABILITY OF CO-TRIMOXAZOLE IN PERITONEAL DIALYSIS FLUID
3.1 Introduction
A combination of the two antibacterial agents, sulphamethoxazole and trimethoprim, in a
fixed 5:1 ratio, is commonly known as co-trimoxazole (Figure 3.1). Co-trimoxazole is
active against a wide range of gram-negative and gram-positive organisms, including
E.coli and Staphylococcus spp. Sulphamethoxazole inhibits the bacterial synthesis of
dihydrofolic acid by competing with para-aminobenzoic acid. Trimethoprim blocks the
production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly
inhibiting the enzyme dihydrofolate reductase. Hence co-tiimoxazole exerts its effect by
blocking two consecutive steps in the pathway by which microorganisms synthesise
tetrahydrofolic acid. It is this reduced form of folic acid which is essential for cellular
metabolism, including the synthesis of puiines and DNA (135). Co-trimoxazole has
been administered intraperitoneally for the treatment of peritonitis in concentrations
ranging from 5 to 40 mg of trimethoprim, and 25 to 200 mg of sulphamethoxazole, per
litre of dialysate (53, 136-138). Despite the use of i.p. co-trimoxazole, both alone and in
combination with other drugs, there is no information on the stability or compatibility of
co-trimoxazole in PDF's (103).
Figure 3.1
Sulphamethoxazole
3-(4-aminobenzenesulphonamido)-5-methyli.soxazole
NH2 (\ /) SO2—NH
\ /
N
CH3
Trimethoprim
2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyramidine
NH2 OCH3
N=(NH, ^ y CH2 ^ ^ OCH;
bCH.
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3.2 Aims
The aim of this study was to investigate the stability of co-trimoxazole in PDF. The
following aspects were examined:
(i) The stability-indicating capability of the assay
(ii) The stability of co-trimoxazole in PDF when stored in 2 L PVC bags
(in) The stability of co-trimoxazole in PDF when stored in glass ampoules
(iv) Identification of a decomposition product present in co-trimoxazole/PDF admixtures
3.3 Methods
3.3.1 Materials
1. Co-trimoxazole injectioncontaining 400 mg of sulphamethoxazole and 80 mg of
trimethoprim in5 mL (Bactrim ®, Roche, Switzerland) Batch B1004
2. PDF containing glucose 4.25%, sodium 132 mmol/L, calcium 1.75 mmol/L,
magnesium 0.25 mmol/L, chloride 96 mmol/L, lactate 40 mmol/L. Osmolarity
485 irdlliosmoles/L (Dianeal ®PD-2, Travenol, Australia) Batch A39H1
3. Sulphamethoxazole (Sigma, MO, USA) Lot lOlF-0243
4. Trimethoprim (donated by Roche, Australia) Lot 771 840
5. Sulphadimidine B.P. (Central Medical Store, Hobart)
6. Acetonitrile, HPLC grade (Waters Associates, MA, USA)
7. Methanol, HPLC grade (Waters Associates, MA, USA)
8. Disodium hydrogen phosphate, analytical reagent grade (A.R.), (May and Baker,
Australia)
9. Potassium dihydrogen phosphate A.R. (May and Baker, Australia)
10. Sulphanihc acidL.R. (BDH Chemicals, England)
11. Glacial acetic acid L.R. (BDH Chemicals, England)
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12. Acetic anhydride L.R. (Ajax Chemicals, Australia)
13. Sulphuric acid A.R. (Ajax Chemicals, Australia)
14. Sodium hydroxide A.R. (May and Baker, Australia)
15. Diethyl ether A.R. (May and Baker, Australia)
16. Pentafluoropropionic anhydride (Pierce, U.S.A.)
17. Bis(trimethylsilyl)trifluoroacetamide (Pierce, U.S.A.)
18. Ethanol (C.S.R., Australia)
19. Dichloromethane A.R. (Ajax Chemicals, Australia)
20. Ammonia solution A.R. (BDH Chemicals, England)
21. Anhydrous sodium carbonate A.R. (Standard Laboratories, Australia)
22. Ethyl acetate A.R. (May and Baker, Australia)
23. Benzene, re-distiUed
24. 5-Methyl-3-isoxazolamine was synthesised using the method described by Manzo
et al (139). Sulphamethoxazole (500 mg) was dissolved in a mixture of glacial
acetic acid (20 mL) and acetic anhydride (5 mL) and boiled for 5 minutes. When
cool, the solution was combined with distilled water and ice. The precipitate
produced was collected and dried to yield a weight of approximately 390 mg. The
precipitate was dissolved in 2.5 mL of 40% w/v sulphuric acid and boiled for
3 minutes. The cooled solution was rendered alkaline with 10% w/v sodium
hydroxide solution and extracted with 3x4 mL volumes of diethyl ether. The
pooled extracts were evaporated to dryness. A sample of the resulting compound
was analysed by mass spectrometry (MS). A second sample was dissolved in
ethanol and analysed by UV spectrometry.
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3.3.2 Analysis of co-trimoxazole
An HPLC assay modified from that described by Rumble (140), was used to determine
sulphamethoxazole and trimethoprim concentrations, using sulphadimidine as an internal
standard. Figme 3.2 shows a typical chromatogram of co-trimoxazole in PDF. The
retention times for trimethoprim and sulphamethoxazole were approximately 16 and
18 minutes respectively.
3.3.2.1 Instrumentation
Column; |iBondapak CIS stainless steel 3.9 mm i.d. x 30 cm (Waters
Associates)
Guard column: Bondapak ClS/Corasil 37-50 jim (Waters Associates)
Solvent delivery system: Waters Associates Model M45
Absorbance detector: Waters Associates Model 441
3.3.2.2 Operating parameters
Mobile phase: 17% v/v acetonitrile in 0.067M phosphate buffer (pH 6.2),
filtered through a 0.45 |im membrane filter and degassed
under vacuum before use.
Flow rate: 1.0 mL/min
Absorbance wavelength: 229 nm
Temperature: 20 ± 2°C
Figure 3.2 Chromatogram ofco-trimoxazole in PDF with internal standard (IS)
(-100/20 mg/L sulphamethoxazole/trimethoprim)
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3.3.2.3 Calibration curves
A stock solution containing sulphamethoxazole 10 g/L and trimethoprim 2 g/L in
methanol was prepared on the first day of the study. Aliquots of 50, 100, 150, 200 and
250 |J,L were pipetted into 25 mL volumetric flasks and adjusted to volume with PDF.
This produced standard solutions containing 20/4,40/8, 60/12, 80/16, and 100/20 mg/L
of sulphamethoxazole / trimethoprim respectively. Each standard solution was assayed
immediately after preparation.
A calibration curve for sulphamethoxazole was constructed by plotting the peak height
ratio of sulphamethoxazole to internal standard, against sulphamethoxazole concentration
(Figure 3.3). The intra-day coefficient of variation was 2.0% at 100 mg/L (n=6), and
2.5% at 20 mg/L (n=6). The inter-day coefficient of variation was 0.8% at 100 mg/L
(n=4), and 1.1% at 20 mg/L (n=4).
A calibration curve for trimethoprim was constructed by plotting the peak height ratio of
trimethoprim to internal standard, against trimethoprimconcentration (Figure 3.4). The
intra-day coefficient of variation was 3.9% at 20 mg/L (n=7), and 3.1% at 4 mg/L
(n=6). The inter-day coefficient of variation was 3.0% at 20 mg/L (n=4), and 3.7% at
4 mg/L (n=4).
3.3.2.4 Sample preparation
A 200 |J,L sample of a solution of co-trimoxazole in PDF was combined with 200 |iL of
internal standard (sulphadimidine 52 mg/L in methanol). A 20 |iL aliquot of the
resulting mixture was injected onto the column. Assays were performed immediately
after sample preparation.
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Figure 3.3 Calibration curve for sulphamethoxazole
(The number of data points for each concentration is indicated in brackets)
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Figure 3.4 Calibration curve for trimethoprim
(The number of data points for each concentration is indicated in brackets)
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3.3.3 Stability-indicating capability of the assay
A 250 |IL aliquot of co-trimoxazole injection was pipetted into a 200 inL yolumetric flask
and adjusted to yolume with PDF to produce a concentration of approximately 100 mg/L
of sulphamethoxazole, and 20 mg/L of trimethoprim. The resulting solution had a pH of
approximately 6.0. Four samples of the solution were assayed immediately to determine
the initial sulphamethoxazole and trimethoprim concentrations. Of the remaining
solution:
(i) 2 mL was transferred into each of two glass ampoules and sealed
(ii) A portion was acidified to pH~2 with IM H2SO4; 2 mL of the acidified solution
was transferred into each of two glass ampoules and sealed
(iii) A portion was rendered alkaline to pH~ll with IM NaOH; 2 mL of the alkaline
solution was transferred into each of two glass ampoules and sealed
The ampoules were then autoclayed for 1 hour at 118°C. Duplicate samples from each
ampoule were assayed to determine the sulphamethoxazole and trimethoprim
concentrations. Numerous samples from each ampoule were also chromatographed
without internal standard. The chromatograms of all injections were compared and
examined for changes suggesting the presence of decomposition products of
co-trimoxazole.
3.3.4 Stability of co-trimoxazole in PDF stored in PVC bags
The method of preparation of admixtures used in this stability study was designed to
simulate actual use conditions. A 2.5 mL yolume of co-trimoxazole injection was
measured in a 2.5 mL capacity plastic syringe and injected yia the additiye port into a
commercially ayailable PVC bag containing approximately 2080 mL of PDF. This
produced concentrations of approximately 100 mg/L of sulphamethoxazole and 20 mg/L
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of trimethoprim. The bag was shaken vigorously by hand for one minute and a sample
of the solution was assayed immediately, in duplicate, to determine the initial
sulphamethoxazole and trimethoprim concentrations. At 2, 6, 12, 24, 48, 72 and 216
hours after admixture, the bag was shaken gently by hand for one minute and a sample
of the solution was assayed immediately, in duplicate, to determine the
sulphamethoxazole and trimethoprim concentrations. On each occasion approximately
1 mL samples were drawn from the bag via the additive port using a glass syringe. The
additive port was swabbed with 70% alcohol before and after puncture, and sterile
syringes and needles were used to maintain the sterility of the admixture. The bag was
stored at 20 ± 2°C, exposed to ambient light, and was undisturbed between sampling
times. The experiment was performed in duplicate.
3.3.5 Stability of co-trimoxazole in PDF stored in glass ampoules
A 250 |jL aliquot of co-trimoxazole injection was pipetted into a 200 mL volumetric flask
and adjusted to volume with PDF to produce a concentration of approximately 100 mg/L
of sulphamethoxazole, and 20 mg/L of trimethoprim. Four samples of the resulting
solution were assayed immediately to determine the initial sulphamethoxazole and
trimethoprim concentrations. One millilitre aliquots of the remaining solution were
transferred into 1 mL glass ampoules and sealed. At 2, 6, 12, 24, 48, 72, and 216
hours after admixture, two ampoules were opened and the solution in each was assayed
immediately, in duplicate, to determine the sulphamethoxazole and trimethoprim
concentrations. The ampoules were stored at 20 ± 2°C and exposed to ambient light.
Care was taken not to shake or disturb the ampoules during storage to prevent
contamination of the solution by decomposition products which may have been
generated at the ampoule tip during the heat sealing process.
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3.3.6 Identification of a decomposition product in co-trimoxazole/PDF admixtures
In an acid environment, sulphamethoxazole has been shown to hydrolyse yielding
sulphanilic acid and 5-methyl-3-isoxazolamine, and on extended heating additional
diazotisable products are formed (141). The initial approach to identifying an unknown
decomposition product present in co-trimoxazole/PDF admixtures after storage, was
directed towards the known decomposition products of sulphamethoxazole, namely
sulphanilic acid and 5-methyl-3-isoxazolamine (Figure 3.5). Subsequent experiments to
identify the decomposition product were based on its extraction and isolation from
co-trimoxazole/PDF admixtures. Each of the admixtures used in these experiments had
an initial concentration of approximately 100 mg/L of sulphamethoxazole and 20 mg/L
of tiimethoprim.
3.3.6.1 Comparison with known decomposition products
Solutions of sulphanilic acid (~10 mg/L in PDF) and 5-methyl-3-isoxazolamine
(-20 mg/L in PDF) were prepared and analysed by HPLC. Chromatograms of these
solutions were compared with chromatograms of co-trimoxazole/PDF admixtures after
various storage intervals in both PVC bags and glass ampoules.
Sulphanilic acid and 5-methyl-3-isoxazolamine were co-chromatographed with
(i) co-trimoxazole/PDF admixtures after various storage intervals in both PVC bags and
glass ampoules, and (ii) co-trimoxazole/PDF admixtures which had undergone
accelerated degradation under conditions of extreme heat and pH.
Figure 3.5 Hydrolysis of sulphamelhoxazole
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3.3.6.2 Direct probe MS analysis
A 5 mL sample of a solution of co-trimoxazole in PDF, stored for 10 days in a PVC bag,
was reduced by evaporation under vacuum and azeotrope formation with ethyl acetate
and benzene. Evaporation to dryness did not prove possible under these conditions
because of the high glucose content of the sample. The resulting residue was subjected
to direct probe MS analysis
3.3.6.3 Extraction of column effluent fractions: gas chromatography/mass
spectrometrv analvsis
Four samples of a solution of co-trimoxazole in PDF, stored for 10 days in a PVC bag,
were injected onto the HPLC column. Fractions of the column effluent, corresponding
to the elution of the unknown decomposition product, were collected between 5 and
7 minutes after injection of each sample. The pooled fractions (~8 mL) were rendered
alkaline with ammonia solution and extracted with 3 x 20 mL volumes of
dichloromethane. The pooled extracts were dried over anhydrous sodium carbonate,
filtered and evaporated to dryness. The extract was derivatised with
pentafluoropropionic anhydride (PFPA), and bis(trimethylsilyl)trifluoroacetamide
(BSTFA), and analysed by gas chromatography/mass spectrometry (GCMS). GCMS
was carried out using a Hewlett Packard 5890 GO coupled with an HP 5970 mass
selective detector and an HP 59970A data system. A 25 m x 0.32 mm internal diameter
fused silica capillary column (HP-5 Ultra) of film thickness 0.52 |im was used with
helium carrier gas at a linear velocity of 40 cm/sec at 60°C. The oven temperature was
programmed from 60°C to 290°C at 10°/min. The injector temperature was 250°C, and
the detector temperature was 290°C. The capillary injector was operated in the splitless
mode.
66
3.3.6.4 Extraction with dichloromethane: HPLC andGCMS analysis
Three 10 mL samples of a solution of co-trimoxazole in PDF, stored for 16 days in a
PVC bag, were obtained. One 10 mL sample was acidified to pH~2 with IM H2SO4.
A second sample was rendered alkaline to pH~ll with ammonia solution, and the
remaining sample was unadjusted (pH~6). Each sample was extracted with 2 x 20 mL
volumes of dicblorometbane. The aqueous phase of each sample remaining after
extraction was reserved and analysed by KffLC. The extracts were dried over
anhydrous sodium carbonate, filtered and evaporated to dryness. The extracts were
derivatised with PFPA and BSTFA and analysed by GCMS, as previously described
(3.3.6.3). Three 10 mL samples of PDF without added co-trimoxazole, were extracted
and analysed in a similar manner as reagent blanks.
3.4 Results
3.4.1 Stability-indicating capabilitv of the assay
Chromatograms of the following solutions are illustrated in Figure 3.6:
(a) Co-trimoxazole in PDF (pH~6) assayed immediatelyafter preparation
(b) Co-trimoxazole in PDF (pH~6) autoclaved for 1 hour at 118°C
(c) Co-trimoxazole in PDF (pH adjusted to ~2) autoclaved for 1 hour at 118°C
(d) Co-trimoxazole in PDF (pH adjusted to ~11) autoclaved for 1 hour at 118°C
Changes which are evident in the chromatograms of the autoclaved solutions include a
reduction in the peak heights of sulphamethoxazole and trimethoprim, and the
appearance of several additional peaks between 2 and 12 minutes after injection.
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Figure 3.6 Chromatograms of co-trimoxazole in PDF in glass ampoules
Internal standard (IS)
(a) Co-trimoxazole in PDF (pH~6) assayed immediately after preparation
(b) Co-trimoxazole in PDF (pH~6) autoclaved for Ih at 118°C
(c) Co-trimoxazole in PDF (pH adjusted to ~2) autoclaved for Ih at 118°C
(d) Co-trimoxazole in PDF (pH adjusted to ~11) autoclaved for Ih at 118°C
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The concentration of sulphamethoxazole in the autoclaved solutions at unadjusted, acid
and alkaline pH was 69%, 50% and 54%, respectively, of the initial concentration
(86.4 mg/L) measured in solution (a). The concentration of trimethoprim in the
autoclaved solutions at unadjusted, acid and alkaline pH was 93%, 92% and 72%,
respectively, of the initial concentration (17.5 mg/L) measured in solution (a). The assay
is therefore able to detect a decrease in the concentration of sulphamethoxazole and
trimethoprim resulting from their decomposition in conditions of extreme heat and pH.
At least some of the products formed under these conditions are detectable by this assay
and appear as additional peaks in the chromatograms.
3.4.2 Stability of co-trimoxazolein PDF stored in PVC bags
The percentages of sulphamethoxazole remaining in PDF stored in PVC bags are
illustrated in Figure 3.7. A decline in sulphamethoxazole concentration occurred in each
bag during the study period. Greater than 10% loss of initial concentration was
observed in one bag at 12 hours, and in both bags 48 hours after admixture. A 20% loss
of initial concentration was observed in each bag 72 hours after admixture.
Approximately 57% of the initial concentration remained in the solutions 216 hours
(9 days) after admixture. When the pooled data (replicate assays from duplicate bags)
was plotted semi-logarithmically (log [% initial concentration remaining] versus time),
visual inspection of the resulting straight line suggested a time to 90% initial
concentration of approximately 17 hours. Some deviation from linearity was observed
in the data prior to 12 hours.
The percentages of trimethoprim remaining in PDF stored in PVC bags are illustrated in
Figure 3.8. Greater than 10% loss of initial concentration was observed in each bag
72 hours after admixture. Approximately 84% of the initial concentration remained in
the solutions 216 hours (9 days) after admixture.
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Figure 3.7 Sulphamethoxazole concentrations in admixtures stored in PVC bags and
glass ampoules *
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Figure 3.8 Trimethoprim concentrations in admixtures stored in PVC bags and
glass ampoules *
c
a
c
4)
O
c
6
73
•J3
901
80
70-
60-
50-
40-
30-
20-
10-
0
0
—r-
24
I
48
I
72 96 120 144 168
Hours
Refer to Appendix 3 for data
Amp 1
Amp 2
Amp 3
Amp 4
Bag 1
Bag 2
—I 1
192 216
71
A new peak, attributed to a decomposition product, was present in the chromatograms of
all solutions 2 hours or more after admixture. This peak eluted approximately 6 minutes
after injection of the sample, and gradually increased in size at each sampling time during
the study period (Figure 3.9). Figure 3.10 shows this peak in a chromatogram of a
solution stored for 72 hours. No visible evidence of precipitation was observed in the
solutions during the study period.
3.4.3 Stability of co-trimoxazolein PDF stored in glass ampoules
A malfunction in the solvent delivery system prevented the assay of the 216 hour
samples during the initial stability experiment. A repeat experiment was performed in
which samples were assayed in duplicate at 0, 24, 48, 72, 168 and 216 hours after
admixture. The results of both experiments are presented.
The percentages of sulphamethoxazole remaining in PDF stored in glass ampoules are
illustrated in Figure 3.7. A decline in sulphamethoxazole concentration occurred m each
ampoule during the study period. Greater than 10% loss of initial concentration was
observed in two ampoules 48 hours after admixture, and in all ampoules 72 hours after
admixture. The repeat experiment showed that approximately 64% of the initial
concentrationremained in the solutions 216 hours (9 days) after admixture.
The percentages of trimethoprim remaining in PDF stored in glass ampoules are
illustrated in Figure 3.8. Greater than 90% of the initial concentration was measured in
each ampoule at all sampling times during the study period.
A decomposition product, previously detected in solutions stored in PVC bags, was also
detected in solutions stored in glass ampoules. This was represented by a new peak in
the chromatogramsof all solutions 2 hours or more after admixture. This peak eluted
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Figure 3.9 Peak height ratio of unknown decomposition product in admixtures stored
in PVC bags and glass ampoules. (Each point is the mean of duplicate
determinations, range < 0.04)
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Figure 3.10 Chromatograms of co-trimoxazole in PDF in PVC bags
(a) Immediately after admixture
(b) 72 hours after admixture
Internal standard (IS)
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approximately 6 minutes after injection of the sample, and gradually increased in size at
each sampling time during the study period (Figure 3.9). No visible evidence of
precipitation was observed in any of the solutions during the study period.
3.4.4 Identification of a decomposition product in co-trimoxazole/PDF admixtures
3.4.4.1 Comparison with known decomposition products
Sulphanilic acid
Chromatograms of the following solutions are illustrated in Figure 3.11.
(a) PDF
(b) Sulphanilic acid in PDF
(c) Co-trimoxazole in PDF after storage for 10 days in a glass ampoule
Sulphanilic acid present in solution (b) eluted with the solvent front, approximately
3 minutes after injection of the sample. The unknown decomposition product present in
solution (c) had a retention time of approximately 6 minutes. The unknown
decomposition product was therefore,not sulphanilic acid. It is possible that sulphanilic
acid may have been present in the stored admixtures, but was not visible in the
chromatograms because of the peaks due to PDF and the solvent front. Figure 3.12
shows the chromatograms of a co-trimoxazole/PDF admixture before and after the
addition of sulphanilic acid. Sulphanilic acid clearly produced a change in the
chromatogram approximately 3 minutes after injection of the sample, while the size and
shape of the unknown peak remained unchanged. This supports the conclusion that the
unknown decomposition product is not sulphanilic acid.
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Figure 3.11 Chromatograms which demonstrate that the unknown decomposition
product present in co-trimoxazole/PDF admixtures is not sulphanilic acid
(a) PDF
(b) Sulphanilic acid in PDF
(c) Co-trimoxazole in PDF after storage for 10 days
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Figure 3.12 Chromatograms which demonstrate that the unknown decomposition
product present in co-trimoxazoIe/PDF admixtures is not sulphanilic acid
(a) Co-trimoxazole in PDF after storage for 10 days
(b) Solution (a) plus sulphanilic acid
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Figure 3.13 Mass spectrum of synthetic5-methyl-3-isoxazolainine
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5 -Methyl-3-isoxazolamine
The mass spectram of the synthetic 5-methyl-3-isoxazolamine is shown in Figure 3.13.
The spectrum shows a molecular ion at m/z 98 and is identical to a reference spectmm of
5-methyl-3-isoxazolamine (142). The UV spectrum of 5-methyl-3-isoxazolamine is
illustrated in Figure 3.14. Maximum absorbance occurred at 208 nm. Significant
absorbance was evident at 230 nm, suggesting that this compound will be detected at the
HPLC wavelength employed in this study.
Chromatograms of the following solutions are illustrated in Figure 3.15.
(a) 5-Methyl-3-isoxazolamine in PDF
(b) Co-trimoxazole in PDF after storage for 16 days in a PVC bag
(c) Solution (a) and (b) combined
5-Methyl-3-isoxazolamine present in solutions (a) and (c) eluted approximately
4.8 minutes after injection. The unknown decomposition product present in solutions
(b) and (c) had a retention time of approximately 6 minutes. The unknown
decomposition product was therefore not 5-methyl-3-isoxazolamine.
5-Methyl-3-isoxazolamine was not detected in any of the stored admixtures, and this
provides indirect evidence that sulphandic acid was probably not present either.
Chromatograms of co-trimoxazole/PDF admixtures which had undergone accelerated
degradation under conditions of extreme heat and pH (Figure 3.6), showed a large
number of decomposition products eluting between 3 and 8 minutes after injection. It
was possible that the unknown decomposition product (detected in admixtures stored at
room temperature) was among these, however due to the complexity of the
chromatograms in this region, it was difficult to confirm its presence. It was also not
possible to confirm the presence of sulphanilic acid or 5-methyl-3-isoxazolamine, despite
co-chromatographing these compounds with the autoclaved solutions.
Figure 3.14 UV spectrum of synthetic 5-methyl-3-isoxazolamine
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Figure 3.15 Chromatograms which demonstrate that the unknown decomposition
product present in co-trimoxazole/PDF admixtures is not
5-methyl-3-isoxazolamine
(a) 5-Methyl-3-isoxazolamine in PDF
(b) Co-trimoxazole in PDF after storage for 16 days
(c) Solution (a) and (b) combined
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3.4.4.2 Direct probe MS analysis
Because of the large amounts of glucose present in the co-trimoxazole/PDF admixture,
the mass spectrum of the concentrated sample introduced directly on the probe showed
only the spectrum of glucose, and it was not possible to obtain any information
regarding the stracture of the unknown decomposition product.
3.4.4.3 Extraction of column effluent fractions: GCMS analysis
GCMS results of this experiment were inconclusive.
3.4.4.4 Extraction with dichloromethane: HPLC and GCMS analysis
Chromatograms (HPLC) of the following solutions are illustrated in Figure 3.16:
(a) Co-trimoxazole in PDF after storage for 16 days in a PVC bag (pH~6)
(b) Solution (a) extracted with dichloromethane
(c) Solution (a), (pH adjusted to ~2), extracted with dichloromethane
(d) Solution (a), (pH adjusted to ~11), extracted with dichloromethane
The unknown decompositionproduct was extracted most effectively from the acidified
solution, with a reduction in peak height of approximately 65%. Very little change in
peak height occurred after extraction under unadjusted and alkaline conditions. This
indicates that the unknown decomposition product is acidic in nature.
Figure 3.17 shows the mass spectrum of the major chromatographic peak resulting from
GCMS analysis of the extract of the acidified solution. High resolution mass
spectrometry confirmed a molecular formula of C10H15NO2S, consistent with
N-butylbenzenesulphonamide. The mass spectrum was found to be identical with a
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Figure 3.16 Chromatograms showing extraction of unknown decomposition product
at various pH's using dichloromethane
(a) Co-trimoxazole in PDF after storage for 16 days (pH~6)
(b) Solution (a) extracted with dichloromethane
(c) Solution (a), (pH adjusted to ~2), extracted with dichloromethane
(d) Solution (a), (pH adjusted to ~11), extracted with dichloromethane
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Figure 3.17 Mass spectrum of the major GC peak resulting from GCMS analysis of
an extract of a co-trimoxazole/PDF admixture. The admixture was stored
for 16 days in a PVC bag and extractedunder acidic conditions.
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reference spectrum of that compound (143). Although N-butylbenzenesulphonamide
bears some structural relationship to sulphamethoxazole, it was also identified in
approximately equal amounts in the reagent blanks (PDF without added co-trimoxazole).
It is possible that N-butylbenzenesulphonamide, which is used as a plasticiser (144),
may have leached from the PVC bags during storage. No further information regarding
the identity of the decomposition product was obtained from these experiments.
3.5 Discussion
The inherent advantage ofHPLC as an analytical technique for stability studies, lies in its
ability to separate and detect distinct chemical entities. However, HPLC analysis may
not be stability indicating when, for example, decomposition products elute with the
intact drug, or when other drugs or solution components elute with or interfere with the
intact drug (145). The HPLC assay used in these stability experiments was able to
quantitate the intact drug in the presence of decomposition products which were
produced when an admixture of co-trimoxazole in PDF was subjected to intense heat and
extreme pH to intentionally decompose it. This provides evidence of the
stability-indicating capability of the assay.
A significant loss of sulphamethoxazole (> 10% of initial concentration) occurred within
48 hours when an admixture of co-trimoxazole in PDF containing 4.25% glucose was
stored in PVC bags at 20 ± 2°C. Greater than 10% loss of initial concentration was
observed in one bag at 12 hours. A comparison of the stability experiments conducted in
PVC bags and glass ampoules provides some insight into the mechanism of loss of
sulphamethoxazole from co-trimoxazole/PDF admixtures. If the loss of
sulphamethoxazole was due to an interaction with the container, such as sorption or
permeation, then the stability of sulphamethoxazole in PVC bags and glass ampoules
would be expected to be dissimilar. However, in these experiments, sulphamethoxazole
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stability seemed to be unrelated to the container type, with similar losses occurring from
admixtures stored in PVC bags and glass ampoules. This suggests that the mechanism
of this loss is primarily chemical decomposition in solution. Further evidence for this
proposition was the time dependent increase in concentration of an unknown
decomposition product in admixtures stored in both plastic and glass, and this may have
been a decomposition product of sulphamethoxazole. The loss of sulphamethoxazole
from admixtures stored in PVC bags showed some deviation from first-order kinetics
prior to 12 hours, suggesting that an initial, more rapid loss of sulphamethoxazole may
have occurred by some other process.
The loss of trimethoprim from admixtures stored in PVC bags was greater than from
admixtures stored in glass ampoules throughout the study period. Greater than 10% loss
of the initial concentration occurred within 3 days in admixtures stored in PVC bags,
whereas trimethoprim was stable for at least 9 days when similar admixtures were stored
in glass ampoules under the same conditions. This suggests that the loss of trimethoprim
from admixtures stored in PVC bags may be due to an interaction with the container.
Kowaluk et al found that there was negligible loss due to sorption when trimethoprim
dissolved in 0.9% sodium chloride injection (25 mg/L) was stored in PVC bags for one
week at 15-20°C (118). Negligible loss due to sorption was also observed during
simulated infusion through a burette chamber and PVC tubing, and when solutions were
stored in polyolefin syringes for 24 hours (132).
This study demonstrates that the shelf-life of an admixture of co-trimoxazole in PDF is
limited by the stability of the sulphamethoxazole component, since the rate of loss of
sulphamethoxazole was greater than the rate of loss of trimethoprim during the study
period. A greater number of studies and sampling times would enable a more accurate
determination of the time for 10% decomposition, however the present study
conservatively indicates a shelf-life of only 12 hours, since greater than 10% loss of the
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initial sulphamethoxazole concentration had occurred in this time in one of the bags
examined.
Co-trimoxazole injection must be diluted prior to i.v. administration, and studies of the
stability of co-trimoxazole in various i.v. infusion fluids have produced highly divergent
results. Trissel has reviewed two studies which have examined the stability of
co-trimoxazole in 5% glucose injection (3.2 / 0.64 g/L sulphamethoxazole/trimethoprim)
at 22-25°C (63). One study concluded that the admixture was physically and chemically
stable for 24 hours, while the second study observed turbidity and precipitation at
4 hours, and 28% loss of trimethoprim in 24 hours. A more recent study reported that
similar admixtures were stable for 48 hours (146), while the manufacturer advises that
the administration of such admixtures must be completed within 2 hours (147). These
studies have also produced conflicting information regarding the stability of more
concentrated solutions of co-trimoxazole, and the compatibility of co-trimoxazole with
other diluents. Even the manufacturers information differs with respect to the suitability
of various infusion fluids as diluents. Information provided by the manufacturer in
Australia includes 0.9% sodium chloride injection as a suitable diluent (147), however
manufacturers information quoted in American sources advise that co-trimoxazole should
not be admixed with any infusion fluids apart from 5% glucose injection (63, 148).
Turbidity and precipitation in i.v. admixtures is well recognised and has been shown to
be dependent on the concentration of co-trimoxazole, the duration of storage and the
diluent employed (146). Most studies have identified trimethoprim as the stability
limiting component (63, 146). Few direct comparisons can be made between these
studies and the present stability study conducted in PDF. In addition to the different
characteristics of the dUuents, there are the large differences in the concentrations of
co-trimoxazole examined. The concentrations of co-trimoxazole employed in
admixtures for i.v. administration are much greater than those employed for i.p.
administration. These differences, plus the conflicting information which exists for
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co-trimoxazole stability in i.v. infusion fluids, emphasise the importance of conducting
stability studies in PDF for intraperitoneally administered drugs.
The unknown decomposition product present in co-trimoxazole /PDF admixtures stored
in both PVC bags and glass ampoules, was not present when PDF alone was stored in
PVC bags for prolonged periods at 20°C. It was therefore a decomposition or reaction
product of sulphamethoxazole, trimethoprim, or excipients in the co-trimoxazole
injection. Identification of this unknown decomposition product may have provided
information on the fate of sulphamethoxazole or trimethoprim in the stored admixtures.
It was suspected that the compound was a derivative of sulphamethoxazole, because an
increase in concentration of this compound was associated with a decrease in
concentration of sulphamethoxazole in admixtures stored in both plastic and glass. The
concentration of trimethoprim, on the other hand, decreased in plastic and remained
constant in glass, and was therefore seemingly unrelated to the emergence of the
unknown compound. Although it did not prove possible to identify this decomposition
product, it was demonstrated that it was not sulphanilic acid or
5-methyl-3-isoxazolamine, which have previously been identified as decomposition
products of sulphamethoxazole under acid conditions.
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INTRODUCTION
Thefrequent occurrence ofperitonitis continues tobe a major complication of peritoneal dialysis in thetreatment ofpatients with endstage renal disease. Peritonitis is themajor
impediment to the prolonged success of this dialysis technique. This has been illustrated bya recent survey of continuous ambulatory peritoneal dialysis (CAPD) patients inAustralia
which found that 64% of patients transferring from CAPD to another form of dialysis, did so becauseof peritonitis (40).
Effective antibiotic therapy must notonly provide adequate serum andtissue drug levels, butmust beable toeradicate organisms that may persist in stagnant residual pools ofdialysate
within theperitoneal cavity. The intraperitoneal (i.p.) administration of antibiotics is convenient and has the potential advantage ofproducing high local drug concentrations. Therapeutic
serum levels ofmany antibiotics can beachieved and maintained byi.p. administration alone (41). Although it has become routine practice toadminister antibiotics to the peritoneal cavity
viathedialysate, there arefew studies documenting thestability of antibiotics in these fluids. Peritoneal dialysis fluid contains electrolytes including sodium, chloride, calcium and
magnesium, either acetate or lactate as a source of bicarbonate, andanosmotically active agent, usually glucose. It has an acid pH, usually in therange 5.0-5.5. Stability and compatibility
guidelines available for IVadmixtures may notbeappropriate for peritoneal dialysis fluids norrelevant toi.p. administration. Several reviews have included a small amount ofstability data
(30, 31, 32,48). The application ofthis data is limited by a lack ofdetail and, in some cases, the authors have drawn conclusions which their cited studies do not support. Stability has
sometimes been inferred from pharmacokinetic studies. This review has collated the stability and efficacy studies which have been conducted inperitoneal dialysis fluids and presents them
in tablesunderthenameof eachantibiotic for whichdata exists. For each antibiotic a summary of the data is presented.
The majority ofpatients undergoing peritoneal dialysis use pre-mixed "ready to use" proprietary dialysis solutions which contain between 0.5% and 4.5% glucose. Antibiotics for i.p.
administration are added directly tothe peritoneal dialysis fluid prior toits instillation into the peritoneal cavity. Tofacilitate analysis of stability studies, peritoneal dialysis fluids containing
between 0.5% and 4.5% glucose have been grouped together and are collectively referred toas "CAPD fluids". Although these fluids are mainly used incontinuous ambulatory peritoneal
dialysis (CAPD), they can also beused with automated cycler equipment forcontinuous cyclic peritoneal dialysis (CCPD), andintermittent peritoneal dialysis (IPD).
Stability studies conducted inconcentrated peritoneal dialysis fluids have also been reviewed. These fluids contain 30% or50% glucose and are intended for use with automated proportioning
systems. One such system is the reverse osmosis dialysis machine which uses reverse osmosis toconvert a tap water supply into sterile, apyrogenic water, and an automated proportioning
system for using the water soproduced toaccurately dilute the concentrated dialysis fluid. The delivered dialysis fluid generally contains between 0.5% and 4.5% glucose. Antibiotics for i.p.
administration are generally added to theconcentrated dialysis fluid priorto itspassage through theautomated proportioning system. The useofreverse osmosis dialysis machines and
concentrated dialysis fluids obviates the need for the large volume of"ready touse" dialysis fluid normally required for one IPD session. Their use has declined due to the popularity ofCAPD
and there were no patients using reverse osmosis dialysis machines inAustralia as atOctober 1986 (40). An increase in the popularity ofCCPD, orvariations ofthis technique, may see a
renewed interest inautomated proportioning systems (41). Tofacilitate analysis of stability studies, peritoneal dialysis fluids containing 30% or50% glucose have been grouped together and
are collectively referred to as "peritoneal dialysis fluid concentrates".
The studies reviewed can be classified as either stability or efficacy studies, and these are described in detail below.
Stability of antibiotics In peritoneal dialysis fluids
Three methods have been used to investigate the stability of antibiotics in peritoneal dialysis fluids:
1. Physical compatibility
A drugis described asphysically compatible witha peritoneal dialysis fluid if thereis no visible evidence of an incompatibility. Visible evidence of an incompatibility includes the
formation of a precipitate, hazeor opalescence. Othervisible changes (forexample a colourchange) mayalsoconstitute a physical incompatibility. A drugdemonstrated to bephysically
compatible with a peritoneal dialysis fluid is not necessarily stable under the same test conditions.
2. Stabihty determined by direct analysis
Theextent of decomposition ofa drug canbemeasured using anassay which is specific for thechemical entity of theunchanged drug. Drugs which demonstrate <10% decomposition in
peritonealdialysisfluid are describedas stable over the test period.
The following analyticaltechniques have been referred to in this review:
enzyme multiplied immunoassay (EMIT)
fluorescence immunoassay (FIA)
high performance liquid chromatography(HPLC)
radioimmunoassay (RIA)
spectrophotometry (S)
3. Stability determined by measuring drug activity
Thestability ofa drug canbeinvestigated bymeasuring thechange in drug activity over time. This method isrestricted todrugs which have anactivity which is readily quantifiable.
An investigation of heparin stability, for example, can be made by measuring its effect on the clotting time of blood (CT).
Bioassay (B) is the term used for the measurement of antibiotic activity against a test organism. The activity of the antibiotic can be related to the concentration of antibioticin the test
solution in several ways, hut only two techniques have heen used by the studies included in this review.
(i) Agar well-diffusion technique
This involves adding samples of test solution to holes punched in an agarmedium which has beenspreadwitha cultureof test organisms. Following incubation, zones of inhibition
form around these agar wells, their diameter depending on theconcentration of antibiotic in thetestsolution. Theconcentration canbe determined byreference to a standard curve which
has been prepared by measuringthe zone diameter around solutions containing a known concentration of antibiotic.
(ii) Minimum inhibitory concentration
A sample of testsolution is serially diluted with a growth medium and innoculated with testorganisms. The minimum inhibitory dilution is the highest dilution of the testsolution
capable ofpreventing visible growth of the test organisms. Atthis dilution, the antibiotic is at its minimum inhibitory concentration (MIC). Atthis concentration the test organisms
remain viable, so that if transferred to a more favourable environment they would continue to grow.
Changes in antibiotic activity over time, as determined by bioassay, have been assessed in two ways:
(i) by comparing the activity of the antibiotic after a test period in peritoneal dialysis fluid to its initial activity in peritoneal dialysis fluid.
(ii) by comparing the activity of the antibiotic after a test period in peritoneal dialysis fluid to its activity after the same time in normal saline.
Antibiotics which retain ^0% of their initial activity in peritoneal dialysis fluid aredescribed as stable over thetestperiod. However, it is possible that these antibiotics have anactivity
in peritoneal dialysis fluid which is considerably less thantheiractivity in normal salineover thesametestperiod. Thisis demonstrated by one study which found thatall the antibiotics
testedmaintained theirinitial activity for4 hours in peritoneal dialysis fluidconcentrate, suggesting that theseantibiotics are stablein peritoneal dialysis fluid concentrate overthis test
period. However, thestudy also found that theinitial activity of several antibiotics in peritoneal dialysis fluid concentrate was significantly less than their initial activity innormal saline,
(9).
Efficacy of antibiotics in peritoneal dialysis fluids
Included in thisreview arestudies which investigate the fateof a testorganism in peritoneal dialysis fluidor peritoneal dialysis effluentcontaining an antibiotic. These studies aimto mimic
the conditions during a peritonitis episode, therefore the activity of the antibiotic under theseconditions maybe of clinical relevance. Theyarenot,however, tme indicators of antibiotic
stability in peritonealdialysis fluid or peritoneal dialysis effluent
Thedifference between these studies andthestability studies already described is thatperitoneal dialysis fluidor peritoneal dialysis effluentis not only the testsolution in which theantibiotic
is dissolved, but also the growth medium for the test organism. The results reflect inpart the effect of the dialysis fluid oreffluent on the test organism. In the absence ofcontrols designed
to quantify this activity, theeffect of thedialysis fluid or effluent on the activity of theantibiotic cannot bedifferentiated. This hasbeen thecasewith theefficacy studies included in this
review. The activity ofdialysis fluid and effluent alone against bacteria has been reported elsewhere in the literature. Several studies have demonstrated that CAPD fluids inhibit the growth
ofstaphylococci (8,21,42,43,44,45). Some investigators concluded that CAPD fluid was bactericidal. Others found that while CAPD fluid inhibited the growth ofstaphylococci, the
organisms remained viable. The effect ofCAPD fluids on other bacteria is notasclear (8,21,42,43). Some studies found thatE.coli andP.aeruginosa didnotgrow inCAPD fluids, whUe
others found these bacteria grew well. Allstudies demonstrated that peritoneal dialysis effluent was a more favourable growth medium than unused CAPD fluid for all testorganisms.
Threemethods, described below, have beenusedto determine thesusceptibility of a testorganism toperitoneal dialysis fluidor effluentcontaining an antibiotic. These havebeen
collectively termed bioactivitymethods, (b), whichappears in the tables in italics:
(i) Minimum inhibitory concentration (MIC)
Thelowest concentration of antibiotic capable of preventing the visible growth of an innoculum of testorganisms. At thisconcentration theorganisms remain viable, so thatif
transferredto a more favourable environmentthey wouldcontinue to grow.
(ii) Minimumbactericidal concentration (MBC)
Thelowest concentration of antibiotic capable of killing ^9.9% of the population of testorganisms.
(iii) Time/kill curves
A study of the bacterial population as a function of time.
INTERPRETATION OF THE TABLES
Drag Mfr Drag Mfr Solution Mfr Method Results Ref
[11 [21 [31 [4] [5] [6] [7] [8] [91
[10]
[1] Drug to which the table refers and the concentration tested.
[2] Manufacturer of the reference drug.
[3] Drug(s) used in combination with the reference drug and the concentration(s) tested.
[4] Manufacturer(s)of the drug(s) used in combinationwith the reference drug.
[5] Peritonealdialysis fluid (PDF) or peritonealdialysis (PD) effluent in which the drug or drag combinationwas tested.
[6] Manufacturer of the peritoneal dialysis fluid.
[7] Method used to assess the stability or efficacy of each drag or drag combination.
[8] A description of the results of the study.
[9] Reference to the original study.
[10] Sununary
Drug and concentration [1], [3]
When a study has specified the use of a salt of a drag or a drag base, this has been stated in the table e.g. Amikacin sulphate, Amikacin base. When this information is not available then
the drag name appears in the table as it appears in the original article e.g. Amikacin. Drags used in combinationwith the reference drag appear in column [3] in alphabetical order. Studies
of drag combinations have been reported under the name of each antibiotic used in the combination.
Theconcentration of each drag has been expressed in terms of mg org perlitre to facilitate comparison between thevarious studies. This does notnecessarily mean that thedrags were
testedin IL volumes of solution. Some tests wereperformed in test tubes using smallvolumes e.g. lOmL. Otherinvestigators addedthe drugs to volumes of solution normally instilled
intothe peritoneal cavity i.e. 2L. Tests performed inplastic bags have been identified in the results when this information is available from theoriginal article. There is noimplication that
the test concentration is appropriate for thetreatmentof peritonitis. A dash (-) indicates that the concentration of the drug was not stated.
Manufacturer abbreviations [2], [4], [6]
AB Abbott MSD Merck Sharp & Dohme
BE Beecham PD Parke-Davis
BR Bristol PF Pfizer
BS BiosedraLaboratory RI Riker
CSL Commonwealth Serum Laboratories RR Roerig
GL Glaxo SC Schering
HO Hoechst-Roussel SI Sigma
LE Ledffle TR Travenol
LI EU Lilly UP Upjohn
MG American McGaw WY Wyeth
MI Miles - Manufacturer not stated
ML Merrell Dow
Solution [5]
Test solutions containing between 0.5% and 4.5% glucose are grouped together ina table headed "CAPD fluids". Included in this table are tests conducted inperitoneal dialysis effluent
Test solutions containing 30% or50% glucose are grouped together in a table headed "Peritoneal dialysis fluid concentrates". The glucose concentration of the test solution is stated in the
table. Letters A-G refer to Appendix 1where full details of the composition ofthe solution are given. If the composition of the test solution is not specified in the study, this is stated in
the table.
Method [7]
The following abbreviations refer tothe method used toassess the stability orefficacy ofeach drug ordrug combination:
B bioassay
b bioactivity (measure ofthe efficacy ofperitoneal dialysisfluid orperitoneal dialysis effluent containing anantibiotic)
CT clotting time of fresh whole blood
EMIT enzyme multiplied immunoassay
FIA fluorescence immunoassay
HPLC high performance liquid chromatography
RIA radioimmunoassay
S spectrophotometry
V visual examination (macroscopic)
method not stated
When both drugs ofadrug combination have been tested, the first method appearing inthe column isapplicable tothe reference drug. Subsequent method(s) appearing inbrackets refer to
the drug(s) used incombination with the reference drug. When two methods have been used to assess the stability orefficacy ofone drag, these are both specified e.g.
Drag Mfr Drag Mfr Solution Mfr Method
Gentamicin
sulphate
5mg/L
and
8mg/L
SC PDF containing 2.5% glucose
(Dianeal), A.
TR RIA,*
EMIT*
Gentamicin
sulphate
8mg/L
Cefazolin
75mg/L
Heparin
lOOOunits/L
-
PDF containing 1.5% glucose
(composition not stated)
nA=
(HPLC)t
(-)§
* Gentamicin concentration determined by radioimmunoassay and
enzyme multiplied immunoassay.
~ Gentamicin concentration determined by fluorescence immunoassay.
t Cefazolin concentration determined byhigh performance liquid
chromatography.
§ Methodfor determining heparin stabilitynot stated.
Results [8]
The results of efficacy studies have beenprinted in italics to distinguish themfrom stability studies.
Tests performedin plasticbags have been identified when specified in the original article. Evidence or lack of evidence of a physical incompatibilityhas been reportedwhen specified in the
study; no commenton physical compatibility indicates that this was not examined. The time for 10% decomposition has been stated if this was determined. The temperatureat which the
test was conducted has been reported as specified in the study.
Summary [10]
A summaryof the tabulatedinformationis presented for each drag. The summary is intended as a brief overview of the available stability informationand as such would be a useful first
reference. In general, however, the summary shouldbe used in conjunction with the tables where greaterdetail is provided. The originalstudy shouldbe consulted whenmore information
is required. The summary includescommentson conflicting information where applicable,and mentionmay be made of those points which limit the application of the information.
Within the context of the summary, storage temperatures in the range 20°C-25°C inclusive have been referred to as "room temperature".
Abbreviations
A complete list of the abbreviationsused in this text appears in Appendix 2.
Limitations
As a consequence of the small number ofstability studies conducted in peritoneal dialysisfluids, several studies have been reviewedwhich would
otherwisehave been discarded due to lack ofdetailed information. Drug concentration, storage temperature and solution composition are three of
manyimportant variables which affect drug stability in solution. Studies which lack this informationare easily recognised in the tables and their
limitations maybe mentionedin the relevant summaries. Caution must be exercisedwhen usingstability informationfrom few studies,or from
studies which lack detailed information. This review is intended as an aid to professional judgement. Factors which have received little attention
in the literature include the stability and compatibility of drug combinations in peritoneal dialysisfluids, and the effectofprecipitation on the
peritoneal membrane. Until more information is available in this area, guidelinesavailablefor IV admixtureswill remain a valuable reference.
AMIKACIN
CAPD fluids
Drug Mfr Drug Mfr Solution Mfr Method Results Ref
Amikacin
(-)
PDF containing 1.5% glucose
(composition not stated)
B Initial activity retained for 24h at room temperature. 52
Amikacin
25mgfl:.
BR PDF containing 1.5% glucose
(Dianeal), A
PDF containing 1.5% glucose
(Dianeal) pH adjusted to 7.4
PD effluent collected after a 6h
i.p. dwell, G
TR
TR
b MBC against P.aeruginosa 16-32 times greater in PDF than in bufferedPDF
and Mueller-Hinton broth. MBC against P.aeruginosa 8 timesgreater in PD
effluent than in Mueller-Hinton broth.
Timefor >99.9% kill (amikacin 25mglL) was Ih in Mueller-Hinton broth,
2h in PD effluent, 6h in biffered PDF and 24h in PDF at 37°C.
3
Amikacin
20mg/L
Azlocillin
500mg/L
PDF containing 1.5% glucose
(Dianeal), A, pH adjusted to 7.2
TR EMIT
(HPLC)
Amikacin lost 10% of initial concentration in 30min and 30% in 8h in IL plastic
bags containing dialysate and azlocillin at 37°C.
Initial concentration of azlocillin retained for 8h.
47
Amikacin
sulphate
25mg/L
BR Cefamandole
nafate
125mg/L
LI PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD ^uent at 37 °Cmore rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
Amikacin
sulphate
25mg/L
BR Cefazolin
sodium
125mg/L
LI PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluent at 37°C more rapidly lethal than either
drug alone against E.coli,P.aeruginosa and S.aureus.
6
Amikacin
sulphate
25mg/L
BR Cefoxitin
sodium
125mg/L
MSD PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluent at 37"Cmorerapidlylethal than either
drugaloneagainstE.coli, P.aeruginosaand S.aureus.
6
Amikacin
Only onestudy has investigated anrikacin stability in CAPD fluid andfew details areprovided. Amikacin was stable in CAPD fluid containing 1.5% glucose for24hat room temperature,
however theconcentration tested is unknown (52). Onestudy investigating theefficacy of intraperitoneal amikacin found thattheactivity of amikacin against P.aeruginosa was significantly
inhibited in CAPD fluid andperitoneal dialysis effluent Thiswasdemonstrated in peritoneal dialysis fluidandeffluentof relatively lowglucose concentration (<1.5%), (3).
Amikacin in combination
Significant decomposition ofamikacin occurred within 30min when combined with azlocillin inpHadjusted CAPD fluid at37°C. Azlocillin was stable for 8h. Physical compatibility was
not commented on (47). [...continued next page]
SynergisticactivityagainstE.coli, P.aeraginosa and S.aureus was demonstrated when amikacin was combined with cefamandole, cefazolin or cefoxitin in peritonealdialysis effluent.
This does not imply synergismagainst other bacterial species or exclude the possibility of significant inactivation of one antibiotic by the other (6).
Peritoneal dialysis fluid concentrates
Drug Mir Dmg Mfr Solution Mfr Method Results Ref
Amikacin
sulphate
0.6g/L
BR PDF concentrate containing
30% glucose, H
TR B Activity after 4h in PDF concentrate similar to initial activity in normal saline.
Temperature not stated.
9
Amikacin
base
lOmg/L
and
50mg/L
BR PDF concentrate containing
50% glucose, D
MG B 25-30% loss of initial activity in 7h and 50-62% loss of initial activity in 24h
at room temperature. Loss of activity was greater at the lower amikacin
concentration.
1
Amikacin
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH acljusted to 6.8
-
B 42% loss of initial activity in 24h in PDF concentrate containing 50% glucose,
pH 6.8. 25% loss of initial activity in 24h in all other solutions.
Temperature not stated.
27
Amikacin
sulphate
0.6gfl.
BR Heparin
sodium
2500 units/L
RI PDF concentrate containing
30% glucose, H
TR B
(-)
Activityof amikacin maintainedfor 4h in PDF concentrate containing heparin.
Heparin not studied.
Temperature not stated.
9
Amikacin
Three studies have investigated amikacin stability in PDFconcentrates. Amikacin 6g/L was stable for4h in PDFconcentrate containing 30% glucose (9). Significant loss of activity
occurred within 24h at lower amikacin concentrations (1), and higher glucose concentration (1,27).
Amikacin in combination
Amikacin 6g/Lwas stable for4h when combined withheparin in PDF concentrate containing 30% glucose. The effectof the combination on heparin activity is unknown.
Physical compatibility was not commentedon (9).
AMPICILLIN
CAPD fluids
Drug Mfr Drag Mff Solution Mfr Method Results Ref
Ampicillin
50mg/L
BR PDF containing 4.25% glucose
(Dianeal 137, PD2), B, C
TR B Initial activity retained for 48h in IL or 2L plastic bags containing dialysate
at25'='C.
5
Ampicillin
50mg/L
BR Heparin
500 units/L
PDF containing 4.25% glucose
pianeal 137, PD2), B, C
TR B
(-)
Initial activity of ampicillin retained for 48h in IL or 2L plastic bags containing
dialysate and heparin at 25°C.
Heparin not studied.
5
Ampicillin
One studyhas demonstrated that ampicillin 50mg/Lis stable in CAPDfluids containing 4.25% glucosefor 48h at roomtemperature (5).
Ampicillin in combination
Ampicillin wasstable for48hat roomtemperature when combined with heparin in CAPD fluids containing 4.25% glucose. The effectof the combination on heparin activity is unknown.
Physical compatibility was not commented on (5).
Peritoneal dialvsis fluid concentrates
Drug Mfr Drag Mfir Solution Mfr Method Results Ref
Ampicillin
sodium
2.5gfl.
BR PDF concentrate containing
30% glucose, H
TR B Significant loss of activity occurred within lOmin in PDF concentrate compared
to normal saline (128 fold increase in MIC against E.coli). No further loss of
activity was evident at 4h.
Temperature not stated.
9
Ampicillin
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH adjusted to 6.8
-
B Up to 75% loss of initial activity in 24h in all solutions. This loss was greater
and faster in solutions of high glucose concentration and high pH.
Temperature not stated.
27
Ampicillin
sodium
2.5g/L
BR Gentamicin
sulphate
lOOmg/L
SC PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against E.coli after 4h in PDF
concentrate was the same as its activity after lOmin. The combined activity was
significantly greater than the activity of either antibiotic alone.
Temperature not stated.
9
10
Ampicillin BR Gentamicin SC PDF concentrate containing TR B The activityof the antibiotic combination againstE.coliwas significantly 9
sodium sulphate 30% glucose, H (B) inhibited after lOmin in PDF concentrate containing heparin. No further loss of
2.5g/L lOOmg/L activity was evident at 4h.
Heparin not studied.
Heparin RI (-) Temperature not stated.
sodium
2500 units/L
Ampicillin BR Heparin RI PDF concentrate containing TR B Ampicillin alone in PDF concentrate compared to normal saline showed 9
sodium sodium 30% glucose, H (-) significant loss of activity within lOmin (128 fold increase in MICagainst
2.5g/L 2500 units/L E.coli). No further loss of activity was evident at lOmin or 4h when combined
with heparin.
Heparin not studied.
Temperature not stated.
Ampicillin
Two studies have investigated ampicillin stability in PDF concentrates. One study demonstrated that ampicillin was not stable for 24h inPDF concentrates containing 30% or50% glucose,
however the concentration tested and the storage temperature are unknown (27). Asecond study demonstrated that a significant loss of ampicillin activity occurs within lOmin inPDF
concentrate when compared to its activity in normal saline (9).
Ampicillin in combination
Only one study has attempted toinvestigate ampicillin incombination with other drugs inPDF concentrate (9). The initial activity of the ampicillin plus gentamicin combination was
maintained for 4h in PDF concentrate containing 30% glucose. Synergistic activity against E.coli was demonstrated when ampicillin was combined with gentamicin. This does not imply
synergism against other bacterial species orexclude the possibility ofsignificant inactivation ofone orboth antibiotics. Physical compatibility was not commented on.
Heparin had no effect on the activity ofampicillin, but inhibited the combined activity ofampicillin plus gentamicin after only lOmin inPDF concentrate containing 30% glucose.
Theeffectof thecombinations on heparin activity is unknown. Physical compatibility wasnot commented on.
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AZLOCILLIN
CAPD fluids
Dmg Mfr Dmg Mfr Solution Mfr Method Results Ref
Azlocillin
200mg/L
MI PDF containing 4.25% glucose
(Dianeal 137, PD2), B, C
TR B Initial activity retained for 48h in IL or 2L plastic bags containing dialysate
at25°C.
5
Azlocillin
200mg/L
MI PDF containing 1.5% glucose
(Dianeal), A
PDF containing 1.5% glucose
(Dianeal) pH adjusted to 7.4
PD effluent collected after a 6h
i.p. dwell, G
TR
TR
b MBC against P.aeruginosa more than 16 times greater in PDF and PD effluent
than in Mueller-Hinton broth. MBC against P.aeruginosa 2-4 times greater in
biffered PDF than in Mueller-Hinton broth.
Timefor >99.9% kill (azlocillin lOOmgIL) was 6h in Mueller-Hinton broth
at 37°C. Bactericidal activity was not demonstrated in 24h in PDF, buffered
PDF or PD effluent.
3
Azlocillin
500mg/L
Amikacin
20mg/L
PDF containing 1.5% glucose
(Dianeal), A, pH adjusted to 7.2
TR HPLC
(EMIT)
Azlocillin stable for 8h in XL plastic bags containing dialysate and amikacin
at37°C.
Amikacin lost 10% of its initial concentration in 30min and 30% in 8h.
47
Azlocillin
SOOmg/L
Gentamicin
8mg/L
PDF containing 1.5% glucose
(Dianeal), A, pH adjusted to 7.2
TR HPLC
(EMIT)
Azlocillin stable for 8h in IL plastic bags containing dialysate and gentamicin
at ZTC.
Initial concentration of gentamicin maintained for 6h. >10% loss of initial
concentration occurred within 8h.
47
Azlocillin
200mg/L
MI Heparin
500 units/L
PDF containing 4.25% glucose
(Dianeal 137, PD2), B, C
TR B
(-)
Initial activity of azlocillin retained for 48h in IL or 2L plastic bags containing
dialysate and heparin at 25°C.
Heparin not studied.
5
Azlocillin
500mg/L
Netilmicin
7.5mg/L
PDF containing 1.5% glucose
(Dianeal), A, pH adjusted to 7.2
TR HPLC
(EMIT)
Azlocillin stable for 8h in IL plastic bags containing dialysate and netilmicin
at 37°C.
Initial concentration of netilmicin maintained for 6h. >10% loss of initial
concentration occurred within 8h.
47
Azloclllin
One study has demonstratedthat azlocillin 200mg/L is stable in CAPD fluids containing 4.25% glucose for 48h at room temperature (5). Another study investigating the efficacy of
intraperitoneal azlocillin found that the activity of azlocillin against P.aeruginosa was significantly inhibited in CAPD fluid and peritoneal dialysis effluent. This was demonstrated in
peritoneal dialysis fluid and effluent of relatively low glucose concentration (<1.5%), (3).
[...continued next page]
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Aziocillin in combination
Azlocillin wasstable for8h at 37°C when combined with amikacin in pH adjusted CAPD fluid, however significant decomposition of amikacin occurred within 30min. Physical
compatibility was not commented on (47).
Azlocillin was stable for8hat 37^0when combined with gentamicin inpHadjusted CAPD fluid, however significant decomposition of gentamicin occurred after 6h. Physical compatibility
was not commented on (47).
Azlocillin was stable for8hat 37°C when combined with netilmicin in pHadjusted CAPD fluid, however significant decomposition ofnetilmicin occurred after 6h. Physical compatibility
was not coimnented on (47).
Azlocillin was stable for48h at room temperature when combined with heparin in CAPD fluids containing 4.25% glucose. Theeffect of thecombination onheparin activity is unknown.
Physical compatibility was not commented on (5).
CARBENICILLIN
Peritoneal dialysis fluid concentrates
Drag Mff Drag Mff Solution Mff Method Results Ref
Carbenicillin
disodium
2g/L
RR PDF concentrate containing
30% glucose, H
TR B Significant loss of activityoccurredwithin lOmin in PDF concentrate compared
to normal saline (four-fold increase in MIC against E.coli). No further loss of
activity was evident at 4h.
Temperature not stated.
9
Carbenicillin
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH adjusted to 6.8
-
B Up to 75% loss of initial activity in 24h in all solutions. This loss was greater
and faster in solutionsof high glucose concentrationand high pH.
Temperature not stated.
27
Carbenicillin
disodium
2g/L
RR Gentamicin
sulphate
lOOmg/L
SC PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against E.coli after 4h in PDF
concentrate was the same as its activityafter lOmin. The combinedactivity was
similar to, but no greater than, the activity of either antibiotic alone.
Temperature not stated.
9
13
Carbenicillin
disodium
2g/L
i
RR Gentamicin
sulphate
lOOmg/L
Heparin
sodium
2500 units/L
SC
RI
PDF concentrate containing
30% glucose, H
TR B
(B)
(-)
The activity of the antibiotic combination against E.coli was unaffected by the
presence of heparin after lOmin and 4h in PDF concentrate. The combined
activity was similar to, but no greater than, the activity of either antibiotic alone.
Heparin not studied.
Temperature not stated.
9
Carbenicillin
disodium
2g/L
RR Heparin
sodium
2500 units/L
RI PDF concentrate containing
30% glucose, H
TR B
(-)
Carbenicillinalone in PDF concentrate compared to normal saline showed
significant loss of activity within lOmin (four-fold increase in MIC against
E.coli). No further loss of activity was evident at lOmin or 4h when combined
with heparin.
Heparin not studied.
Temperature not stated.
9
Carbenicillin
Two studies have investigated carbenicillin stability inPDF concentrates. One study demonstrated that carbenicillin was notstable for24h inPDF concentrates containing 30% or50%
glucose, however the concentration tested and the storage temperature areunknown (27). Asecond study demonstrated that a significant loss ofcarbenicillin activity occurs within lOmin
in PDF concentrate when compared to its activity in normal saline (9).
Carbenicillin in combination
Onlyonestudy has attempted to investigate carbenicillin in combination with otherdrugs in PDFconcentrate (9). Theinitial activity of thecarbenicillin plus gentamicin combination
was maintained for4h inPDFconcentrate containing 30% glucose. Synergistic activity against E.coli was notdemonstrated when carbenicillin was combined with gentamicin, however
this combination may besynergistic against otherbacterial species or provide broader activity against a variety of bacterial species. Physical compatibility was notcommented on.
Heparin had noeffect onthe activity ofcarbenicillin, oron the combined activity ofcarbenicillin plus gentamicin inPDF concentrate containing 30% glucose. The effect of the
combinations on heparin activity is unknovm. Physical compatibility was not commented on.
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CEFAMANDOLE
CAPD fluids
Dmg Mlir Dmg Mfr Solution Mfr Method Results Ref
Cefamandole
8mg/L
PDF containing 1.5% glucose
(Dianeal 137), B
TR B Initial activity retained for 24h at room temperature. 12
Cefamandole
2g/L
PDF containing 2.5% glucose, E MG V No visible precipitation in 3h at room temperature. 8
Cefamandole
nafate
125mg/L
LI Amikacin
sulphate
25mg/L
BR PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluentat 37°Cmore rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
Cefamandole
nafate
125mg/L
LI Gentamicin
sulphate
(-)
SC PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluent at 37 °Cmore rapidly lethal than either
drug alone against E.coli, P.aeruginosa and Sxtureus.
6
Cefamandole
nafate
125mg/L
LI Tobramycin
sulphate
(-)
LI PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluentat 37 °Cmore rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
Cefamandole
One study has demonstrated that cefamandole 8mg/L is stable in CAPD fluid containing 1.5% glucose for 24h at room temperature (12). Cefamandole 2g/L was physically compatible with
peritonealdialysisfluid containing2.5% glucosefor 3h at room temperature (8).
Cefamandole in combination
Synergistic activity against E.coli,P.aeruginosa andS.aureuswas demonstrated whencefamandole wascombinedwith amikacin, gentamicin or tobramycin in peritoneal dialysis effluent.
This does not imply synergismagainstother bacterial species or exclude the possibility of significantinactivationof one antibiotic by the other (6).
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CEFAMANDOLE (continued)
Peritoneal dialysis fluid concentrates
Drug Mfir Drug Mfi- Solution Mfr Method Results Ref
Cefamandole
nafate
2g/L
LI PDF concentrate containing
30% or 50% glucose, D
MG B,V Initial activity retained for 48h at 25°C and 96h at 5°C.
No visible precipitation in 24h at 25°C; haze observed within 24h in solutions
stored at 5°C.
13
Cefamandole
nafate
5g/L
LI PDF concentrate containing
30% or 50% glucose, D
MG B,V Initial activity retained for 48h at 25°C and 96h at 5°C.
Haze observed within 24h in solutions stored at 5°C and 25°C.
13
Cefamandole
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH adjusted to 6.8
-
B Initial activity retained for 24h in all solutions.
Temperature not stated.
27
Cefamandole
nafate
2g/L
PDF concentrate containing
30% glucose, H
TR B Significant loss ofactivity occurred within lOmin inPDF concentrate compared
to normal saline (256 fold increase in MIC against E.coli). Nofurther loss of
activity was evident at 4h.
Temperature not stated.
9
Cefamandole
nafate
2g/L
Heparin
sodium
2500 units/L
RI PDF concentrate containing
30% glucose, H
TR B
(-)
Cefamandole alone in PDFconcentrate compared to normal saline showed
significant loss of activity within lOmin (256 fold increase inMIC against
E.coli). No furtherloss of activitywas evidentat lOmin or 4h whencombined
with heparin.
Heparin not studied. Temperature not stated.
9
Cefamandole
Three studies have investigated cefamandole stability in PDF concentrates containing 30% or 50% glucose. Cefamandole 2g/L was stable for 48h at room temperature, however physical
incompatibihty was observed at ahigher cefamandole concentration (5g/L) or alower storage temperature (5°C), (13). Asecond study, in which the test concentration md storage temperature
are not specified, concluded that cefamandole was stable for 24h (27). Asignificant loss of cefamandole activity occurred within lOmin in PDF concentrate when compared to its activity in
normal saline (9).
Cefamandole in combination
Heparin had no effect on the activity of cefamandole in PDF concentrate containing 30% glucose. The effect of the combination on heparin activity is unknown. Physical compatibility
was not commented on (9).
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CEFAPIRIN
CAPD fluids
Drug Mfr Dmg Mfr Solution Mfr Method Results Ref
Cefapirin
125mg/L
BR PDF containing 1.5% or 4.25%
glucose (Dianeal 137), B
TR B At least 95% of initial activity retained for 24h in IL plastic bags containing
dialysate at 25°C.
10
Cefapirin
125mg/L
BR PDF containing 4.25% glucose
(Dianeal 137, PD2), B, C
TR B Initial activity retained for 48h in IL or 2L plastic bags containing dialysate
at25°C.
5
Cefapirin
500mg/L
BR PDF containing 4.25% glucose
(Dianeal 137), B
TR B 16% loss of initial activity in 24h in IL or 2L plastic bags containing dialysate
at35°C.
5
Cefapirin
2g/L
PDF containing 2.5% glucose, E MG V No visible precipitation in 3h at room temperature. 8
Cefapirin
125mg/L
BR Heparin
500 units/L
PDF containing 4.25% glucose
(Dianeal 137, PD2), B, C
TR B
(-)
Initial activity of cefapirin retained for 48h in IL or 2L plastic bags containing
dialysate and heparin at 25°C.
Heparin not studied.
5
Cefapirin
5(X)mg/L
BR Tobramycin
65nig/L
LI PDF containing 4.25% glucose
(Dianeal 137), B
TR B
(B)
Initial activity of each antibiotic retained for 24h in IL or 2L plastic bags
containing dialysate at 25®C.
5
Cefapirin
500mg/L
BR Tobramycin
65mg/L
LI PDF containing 4.25% glucose
(Dianeal 137), B
TR B
(B)
Cefapirin lost 16%of initial activityand tobramycin lost 12% of initial activity
within 24h when combined in IL or 2L plastic bags containingdialysate at 35°C.
5
Cefapirin
Two studies havedemonstrated thatcefapirin 125mg/Lis stable in CAPD fluids of various glucoseconcentrations for 24h at room temperature(5,10). At increasedtemperature, cefapirin
500mg/Lwas not stable for 24h (5). Cefapirin2g/L was physically compatible with peritoneal dialysis fluid containing 2.5% glucose for 3h at room temperature (8).
Cefapirin in combination
Cefapirin was stable for 48hat room temperature when combined withheparin in CAPDfluids containing 4.25% glucose. The effectof the combination on heparin activity is unknown.
Physical compatibility was not commented (5).
Cefapirin and tobramycin were stable for24hatroom temperature when combined in CAPD fluid containing 4.25% glucose. Atincreased temperature, a significant loss of activity of
each drug occurred within 24h (5).
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CEFAZOLIN
11U1U9
Drug Mfr Drag Mfr Solution Mfr Method Results Ref
Cefazolin
2g/L
-
PDF containing 2.5% glucose, E MG V No visible precipitation in 3h at room temperature. 8
Cefazolin
0.25-16mg/L
SI Mueller-Hinton agar reconstituted
with PD effluent collected after an
overnight dwell of PDF containing
2.5% glucose
(composition not stated)
b The MIC ofcefazolin inMueller-Hinton agar wasnotadversely affected by the
addition ofPD effluent when measured againstcoagulase-positive or coagulase-
negative staphylococci. *
49
Cefazolin
sodium
125mg/L
LI Amikacin
sulphate
25mg/L
BR PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal),F
b
(b)
Antibiotic combinationin PD effluent at 37°C more rapidly lethal than either
drugaloneagainstE.coli, P.aeruginosa andS.aureus.
6
Cefazolin
sodium
125mg/L
LI Gentamicin
sulphate
(-)
SC PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combinationin PD effluent at 37°C more rapidly lethal than either
drugalone againstE.coli, P.aeruginosa andS.aureus.
6
Cefazolin
75mg/L
and
150mg/L
Gentamicin
sulphate
Smg/L
Heparin
1000 units/L
-
PDF containing 1.5% glucose
(compositicHi not stated)
V,
HPLC
(FIA)
(-)
Cefazolin and gentamicin stable for 48h at 4°C, 26°C and 37°C in IL plastic
bags containingdialysate and heparin.
No visible precipitation.
Heparin not studied.
34
Cefazolin
75mg/L
and
150mg/L
Heparin
1000 units/L
PDF containing 1.5% glucose
(composition not stated)
V,
HPLC
(-)
Cefazolin stable for 48h at 4°C, 26°C and 37°C in IL plastic bags containing
dialysate and heparin.
No visible precipitation.
Heparin not studied.
34
Cefazolin
50mg/L
Moxalactam
disodium
30mg/L
LI PDF containing 1.5% glucose
(Dianeal), A
TR
(HPLC)
Moxalactam stable in solutions stored for 6h at 25°C then heated to 37°C for
30min.
Cefazolin not studied.
50
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Cefazolin
50mg/L
Moxalactam
discxlium
30mg/L
Vancomycin
25mg/L
LI PDF containing 1.5% glucose
(Dianeal), A
TR
(HPLC)
(-)
Moxalactam stable in solutions stored for 6h at 25°C then heated to 37°C for
30min.
Cefazolin and vancomycin not studied.
50
Cefazolin
sodium
125mg/L
LI Tobramycin
sulphate
(-)
LI PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD ^uent at 37°C more rapidly lethal than either
drug alone againstE.coli,P.aeruginosa and S.aureus.
6
Cefazolin
No studies have investigated the stability of cefazolin alone in CAPD fluids. Cefazolin 2g/L was physically compatible with peritoneal dialysis fluid containing 2.5% glucose for 3h at
room temperature(8). One study investigating the efficacy of intraperitonealcefazolin found that the activity of cefazolin against staphylococci was not inhibited by peritonealdialysis
effluent (49).
* Coagulase-positive staphylococciincludes S.aureus. Coagulase-negativestaphylococciincludes S.epidermidis.
Cefazolin in combination
Cefazolin, gentamicin and heparin werephysically compatible whencombinedin CAPDfluidcontaining 1.5% glucose. Both antibiotics were stablefor 48h at temperatures up to 37°C.
The effect of the combination on heparin activity is unknown (34).
Moxalactam was stable after storage for 6h at room temperature followed by heating to 37"'C for 30min when combined with cefazolin, and cefazolin plus vancomycin,in CAPD fluid
containing 1.5% glucose. The effect of the combinations on cefazolin and vancomycin stability is unknown. Physical compatibility was not commented on (50).
SynergisticactivityagainstE.coli,P.aeruginosaand S.aureuswas demonstratedwhen cefazolinwas combinedwith amikacin,gentamicin or tobramycinin peritonealdialysiseffluent.
This does not imply synergism against other bacterial species or exclude the possibility of significant inactivation of one antibiotic by the other (6).
Cefazolinand heparin werephysically compatible whencombinedin CAPDfluidcontaining 1.5%glucose. Cefazolinwas stable for 48h at temperatures up to 37°C. The effectof the
combination on heparin activity is unknown (34).
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CEFAZOLIN (continued)
Dmg Mfr Drug Mfr Solution Mfr Method Results Ref
Cefazolin
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH adjusted to 6.8
-
B Initial activity retained for 24h in all solutions.
Temperature not stated.
27
Cefazolin
Only one study has investigatedcefazolin stability in PDF concentrates and few details are provided. Cefazolin was stable for 24h in PDF concentrates containing 30% or 50% glucose,
however the concentration tested and the storage temperature are unknown (27).
CEFMENOXIME
CAPD fluids
Drug Mfr Drug Mfr Solution Mfr Method Results Ref
Cefmenoxime
4mg/L
PDF containing 1.5% glucose
(Dianeal 137), B
TR B Initial activity retained for 24h at room temperature. 12
Cefmenoxime
One studyhas demonstrated that cefmenoxime 4mg/Lis stable in CAPDfluid containing 1.5%glucosefor 24h at room temperature (12).
20
CEFOPERAZONE
CAPD fluids
Drug Mfr Dmg Mfr Solution Mfir Method Results Ref
Cefoperazone
4mg/L
PDF containing 1.5% glucose
(Dianeal 137), B
TR B Initial activity retained for 24b at room temperature. 12
Cefoperazone
Ig/L
PDF containing 1.5% glucose
(composition not stated)
B Initial activity retained for 10b at 37°C. 10% loss of initial activity m 24b
at 37°C.
51
Cefoperazone
(-)
PDF (composition not stated)
and PD effluent (composition not
stated)
b MIC's against a variety of test organisms in PDF and PD effluentsimilar to
MIC's determined in Mueller-Hinton broth.
26
Cefoperazone
Two studieshave investigated cefoperazone stability in CAPD fluids containing 1.5%glucose. Cefoperazone 4mg/L was stable for 24b at room temperature (12). A more concentrated
solutionof cefoperazone was stable for 10b at 37°C, but was not stable for 24b (51). One study investigating the efficacyof intraperitonealcefoperazonefound that the activityof
cefoperazoneagainst a varietyof bacterial species was not inhibited in CAPD fluid or peritoneal dialysis effluent (26).
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CEFOTAXIME
Drug Mlir Dmg Mfr Solution Mfr Method Results Ref
Cefotaxime
125mg/L
HO PDF containing 4.25% glucose
(Dianeal 137, PD2), B, C
TR B Initial activity retained for 24b in IL or 2L plastic bags containing dialysate
at 25°C. 20% loss of initial activity in 48b at 25°C.
5
Cefotaxime
4mg/L
PDF containing 1.5% glucose
(Dianeal 137), B
TR B Initial activity retained for 24b at room temperature. 12
Cefotaxime
2g/L
PDF containing 2.5% glucose, E MG V No visible precipitation in 3b at room temperature. 8
Cefotaxime
125mg/L
HO Heparin
500 units/L
PDF containing 4.25% glucose
(Dianeal 137, PD 2), B, C
TR B
(-)
Initial activity of cefotaxime retained for 24b in IL or 2L plastic bags
containing dialysate and beparin at 25°C. 20% loss of initial activity in 48h
at25°C.
Heparin not studied.
5
Cefotaxime
Two studies have investigatedcefotaxime stability in CAPD fluids of various glucose concentrations. Cefotaxime was stable for 24b at room temperature (5, 12), but was not stable
for 48b (5). Cefotaxime 2g/L was physicallycompatible with peritoneal dialysis fluid containing2.5% glucose for 3b at room temperature(8).
Cefotaxime in combination
Cefotaxime was stable for 24b at room temperature when combined with beparin in CAPD fluids containing 4.25% glucose, but was not stable for 48b. The effect of the combination
on beparin activity is unknown. Physicalcompatibility was not commentedon (5).
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CEFOXITIN
Dmg Mfr Drag Mfr Solution Mfr Method Results Ref
Cefoxitin
8mg/L
PDF containing 1.5% glucose
(Dianeal 137), B
TR B Initial activity retained for 24h at room temperature. 12
Cefoxitin
sodium
lOOmg/L
PDF (Dianeal), A,
glucose composition not stated
TR HPLC Stable for 24h at 37°C. 39
Cefoxitin
2g/L
" PDF containing 2.5% glucose, E MG V No visible precipitation in 3h at room temperature. 8
Cefoxitin
sodium
125mg/L
MSD Amikacin
sulphate
25mg/L
BR PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluent at 37°C more rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
Cefoxitin
sodium
125mg/L
MSD Gentamicin
sulphate
(-)
SC PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluent at 37°C more rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
Cefoxitin
sodium
125mg/L
MSD Tobramycin
sulphate
(-)
LI PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD fffluent at 37°C more rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
Cefoxitin
Two studies have investigated cefoxitin stability in CAPD fluids. Cefoxitin 8mg/L was stable in CAPD fluid containing 1.5% glucose for24hat room temperature (12). A more
concentrated solution of cefoxitin in CAPD fluidof unknown glucoseconcentration was stable for 24h at 37°C(39). Cefoxitin2g/L was physically compatible withperitoneal dialysis
fluid containing 2.5% glucose for 3h at room temperature (8).
Cefoxitin in combination
Synergistic activity against E.coli, P.aeruginosa andS.aureus wasdemonstrated when cefoxitin was combined withamikacin, gentamicin or tobramycin in peritoneal dialysis effluent.
This does notimply synergism against other bacterial species or exclude thepossibility of significant inactivation of oneantibiotic bytheother (6).
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CEFOXITIN (continued)
Drag Mfr Drag Mfr Solution Mfr Method Results Ref
Cefoxitin
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH adjusted to 6.8
-
B Initial activity retained for 24h in all solutions.
Temperature not stated.
27
Cefoxitin
Only one study has investigated cefoxitinstabilityin PDF concentrates and few details are provided. Cefoxitin was stable for 24h in PDF concentrates containing30% or 50% glucose,
however the concentration tested and the storage temperature are unknown (27).
CEFSULODIN
CAPD fluids
Drag Mfr Drag Mir Solution Mfr Method Results Ref
Cefsulodin
lOOmg/L
AB PDF containing 1.5% glucose
(Dianeal), A
PDF containing 1.5% glucose
(Dianeal) pH adjusted to 7.4
PD effluent collected after a 6h
i.p. dwell, G
TR
TR
b MBC against P.aeruginosa 4-8 times greater in PDF than in bi^ered PDF and
Mueller-Hinton broth. MBC against P.aeruginosa 16-32 times greater in PD
effluent than in Mueller-Hinton broth.
Timefor >99.9% kill (cefsulodin lOOmgIL) was 24h in Mueller-Hinton broth
at 37X1. Bactericidal activity was not demonstrated in 24h in PDF, buffered
PDF or PD ^uent.
3
Cefsulodin
No studieshave investigated the stabilityof cefsulodinin CAPD fluids. One study investigating the efficacy of intraperitonealcefsulodin found that the activityof cefsulodinagainst
P.aeraginosa wassignificantly inhibited in CAPDfluid andperitonealdialysis effluent This wasdemonstrated in peritonealdialysisfluid andeffluentof relatively low glucose concentration,
(<1.5%), (3).
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CEFTAZIDIME
CAPD fluids
Drag Mfr Drag Mfr Solution Mfr Method Results Ref
Ceftazidime
8mg/L
PDF containing 1.5% glucose
(Dianeal 137), B
TR B Initial activity retained for 24h at room temperature. 12
Ceftazidime
lOOmg/L
GL PDF containing 1.5% glucose
(Dianeal), A
PDF containing 1.5% glucose
(Dianeal) pH adjusted to 7.4
PD effluent collected after a 6h
i.p. dwell, G
TR
TR
b MBC against P.aeruginosa 8-16 times greater in PDF than in tigered PDF and
Mueller-Hinton broth. MBC against P.aeruginosa 32 times greater in PD
effluent than in Mueller-Hinton broth.
Timefor >99.9% kill (ceftazidime lOOmg/L) was 6h in Mueller-Hinton broth
at 37X1. Bactericidal activity was not demonstrated in 24h in PDF, buffered
PDF orPD effluent.
3
Ceftazidime
One study has demonstrated that ceftazidime 8mg/L is stable in CAPD fluid containing 1.5% glucose for 24h at room temperature (12). Another study investigating the efficacy of
intraperitoneal ceftazidime found that the activity of ceftazidime against P.aeraginosa was significantly inhibited in CAPD fluid and peritoneal dialysis effluent This was demonstrated in
peritoneal dialysis fluid and effluent of relatively low glucose concentration (<1.5%), (3).
CEFTRIAXONE
CAPD fluids
Drag Mff Drag Mfr Solution Mfr Method Results Ref
Ceftriaxone
4mg/L
PDF containing 1.5% glucose
(Dianeal 137), B
TR B Initial activity retained for 24h at room temperature. 12
Ceftriaxone
(-)
PDF (composition not stated) HPLC 16% loss of initial concentration in 5.5h and 25% loss of initial concentration in
6.75h at 37°C.
38
Ceftriaxone
Twostudies have investigated ceftriaxone stability in CAPD fluids. Ceftriaxone 4mg/L was stable in CAPD fluidcontaining 1.5% glucose for 24hat room temperature (12). At increased
temperature significant decomposition occurredwithin6h in CAPDfluid of unknown composition (38).
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CEFUROXIME
CAPD fluids
Dmg Mlir Dmg Mlir Solution Mfr Method Results Ref
Cefuroxime
13mg/L
PDF containing 1.5% glucose
(Dianeal 137), B
PD effluent
(composition not stated) pH 6.5
TR Initial activity retained for 24h in all solutions stored at 20°C.
13.7-16.6% loss of initial activity in 6h in solutions stored at 37°C. No further
loss evident at 24h.
17
Cefuroxime
50mg/L,
lOOmg/L,
150mg/L,
200mg/L
PDF containing 1.5% glucose
(Dianeal), A
TR B,
HPLC
Cefuroxime was added to dialysate in plastic bags and instilled immediately
into the peritoneal cavity. Concentrations measured in solutions left behind in
the plastic bags varied from 44.3% to 1351% of the calculated initial
concentration.
Binding of cefuroxime to the dialysate container was not assessed.
Temperature not stated.
2
Cefuroxime
One study has demonstrated that cefuroxime 13mg/L is stable in CAPD fluid containing 1.5% glucose for 24h at room temperature. At increased temperature a significant loss of activity
occurred within 6h (17). A second study concludes that a uniform mixture of cefuroxime in CAPD fluid may be difficult to achieve. Binding of cefuroxime to the plastic dialysate container
was proposed as a possible cause, but this was not investigated (2).
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CEPHALOTHIN
CAPD fluids
Dmg Mff Dmg Mff Solution Mff Method Results Ref
Cephalothin
2g/L
PDF containing 2.5% glucose, E MG V No visible precipitation in 3h at room temperature. 8
Cephalothin
(-)
PDF (composition not stated)
and PD effluent (composition
not stated)
b MIC's against a variety of test organisms in PDF and PD effluent similar to
MIC's determined in Mueller-Hinton broth.
26
Cephalothin
sodium
250mg/L
LI PDF containing 1.5% or 4.25%
glucose pianeal 137), B
TR HPLC A 2L plastic bag of PDF containing cephalothin was emptied over ISmin
through a CAPD administration set containing a 0.22pm filter (Peridex CAPD
Filter Set).
Binding of cephalothin to the administration set was not significant.
Binding of cephalothin to the dialysate container was not assessed.
Temperature not stated.
25
Cephalothin
No studies have investigated the stability of cephalothin in CAPD fluids. Cephalothin 2g/L was physically compatible with peritoneal dialysis fluid containing 2.5% glucose for 3h at
room temperature (8). Binding of cephalothin to an administration set containing an in-line 0.22)am filter was not significant (25). One study investigating the efficacy of intraperitoneal
cephalothinfound that the activityof cephalothinagainst a variety of bacterial species was not inhibitedin CAPD fluid or peritoneal dialysis effluent (26).
Dmg Mff Dmg Mff Solution Mff Method Results Ref
Cephalothin
lOOmg/L
PDF concentrate containing
50% glucose, D
MG B 60% loss of initial activity in 24h.
Temperature not stated.
20
Cephalothin
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH adjusted to 6.8
-
B Initial activity retained for 24h in all solutions.
Temperature not stated.
27
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Peritoneal dialysis fluid concentrates (continued)
Cephalothin
sodium
2g/L
PDF concentrate containing
30% glucose, H
TR B Significantloss of activityoccurred within lOminin PDF concentrate compared
to normal saline (8 fold increase in MIC against E.coli). No further loss of
activity was evident at 4h
Temperature not stated.
9
Cephalothin
sodium
2g/L
Gentamicin
sulphate
lOOmg/L
SC PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against E.coli after 4h in PDF
concentrate was the same as its activity after lOmin.The combined activity
was similar to, but no greater than, the activity of either antibiotic alone.
Temperature not stated.
9
Cephalothin
sodium
2g/L
Heparin
sodium
2500 units/L
R1 PDF concentrate containing
30% glucose, H
TR B
(-)
Cephalothin alone in PDF concentratecompared to normalsalineshowed
significant loss of activity within lOmin (8 fold increase in MIC against E.coli).
No further loss of activity was evident at lOmin or 4h when combined with
heparin.
Heparin not studied.
Temperature not stated.
9
Cephalothin
sodium
2g/L
Tobramycin
sulphate
lOOmg/L
LI PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against E.coli after 4h in PDF
concentratewas the same as its activity after lOmin. The combinedactivity
was significantly greater than the activity of tobramycin alone, butnogreater
than the activity of cephalothin alone.
Temperature not stated.
9
Cephalothin
sodium
2g/L
Tobramycin
sulphate
lOOmg/L
Heparin
sodium
2500 units/L
LI
R1
PDF concentrate containing
30% glucose, H
TR B
(B)
(-)
The activity of the antibiotic combination againstE.coli was unaffected by the
presence of heparin after lOmin and 4h in PDF concentrate. The combined
activity was significantly greater than the activity of tobramycin alone, but no
greater than the activity of cephalothin alone.
Heparin not studied.
Temperature not stated.
9
Cephalothin
Information concerning the stability ofcephalothin in PDF concentrates is conflicting. One study found that cephalothin lOOmg/L was not stable for 24h in PDF concentrate containing
50% glucose, however the storage temperature is unknown (20). Asecond study concluded that cephalothin was stable for 24h in PDF concentrates containing 30% or 50% glucose,
however the concentration tested and the storage temperature are unknown (27). Athird study demonstrated that a significant loss ofcephalothin activity occurs within lOmin in PDF
concentratecontaining 30% glucosewhen compared to its activity in normal saline (9).
Cephalothin in combination
Only one study has attempted to investigate cephalothin in combination with other drugs in PDF concentrate (9). The initial activity ofthe cephalothin plus gentamicin combination and
the cephalothin plus tobramycin combination was maintained for 4h in PDF concentrate containing 30% glucose. Physical compatibility was not commented on. [...continued next page]
Synergistic activityagainstE.coli was not demonstrated when cephalothin was combined with gentamicinor tobramycin, however these combinations may be synergistic againstother
bacterial species or provide broader activity against a variety of bacterial species.
Heparinhad no effecton the activity of cephalothin, or on the combinedactivityof cephalothin plus tobramycin in PDF concentrate containing 30%glucose. The effectof thecombinations
on heparin activity is unknown. Physical compatibility was not commented on.
CIPROFLOXACIN
CAPD fluids
28
Drug Mfr Drag Mff Solution Mff Method Results Ref
Ciprofloxacin
2mg/L
MI PDF containing 1.5% glucose
(Dianeal), A
PDF containing 1.5% glucose
(Dianeal) pH adjusted to 7.4
PD effluent collected after a 6h
i.p. dwell, G
TR
TR
b MBC againstP.aeruginosa32-64times greater inPDF than in bi^ered PDF and
Mueller-Hinton broth. MBCagainstP.aeruginosa8 times greater in PD
effluent than in Mueller-Hinton broth.
Timefor >99.9% kill (ciprofloxacin 2mglL) was Ih in PD effluent, 2h in
Mueller-Hinton brothand 24h in biffleredPDF at 37°C. Bactericidal activity
was not demonstrated in 24h in PDF.
3
Ciprofloxacin
0.25-16mg/L
Ml Mueller-Hinton agar reconstituted
with PD effluent collected after an
overnight dwell of PDF containing
2.5% glucose
(composition not stated)
b The MICofciprofloxacin inMueller-Hinton agar waj notadversely affected by
theaddition ofPD effluent when measured againstcoagulase-positive
staphylococci. The addition ofPD effluent raised theMICofciprofloxacin
against coagulase-negativestaphylococciin 66% of the isolates tested(n=50). *
49
Ciprofloxacin
Nostudies have investigated thestability of ciprofloxacin inCAPD fluids. Two studies have investigated theefficacy of intrapeiitoneal ciprofloxacin. CAPD fluid and peritoneal dialysis
effluent significantly inhibited the activity of ciprofloxacin against P.aeruginosa (3). Peritoneal dialysis effluent inhibited the activity ofciprofloxacin against the majority ofcoagulase-
negative staphylococci tested, however the MIC values obtained were within clinically achievable levels. Peritoneal dialysis effluent generdly had noadverse effect onthe activity of
ciprofloxacin againstcoagulase-positive staphylococci(49).
* Coagulase-positive staphylococci includes S.aureus. Coagulase-negative staphylococci includes S.epidermidis.
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CLINDAMYCIN
CAPD fluids
Drag Mff Drag Mff Solution Mff Method Results Ref
Clindamycin
lOmg/L
UP PDF containing 4.25% glucose
(Dianeal 137, PD 2), B, C
TR B Initial activityretained for 48h in IL or 2L plastic bagscontaining dialysate
at25°C.
5
Clindamycin
lOmg/L
UP Heparin
500 units/L
PDF containing 4.25% glucose
(Dianeal 137, PD 2), B, C
TR B
(-)
Initial activityof clindamycin retained for 48h in IL or 2L plastic bags
containing dialysate and heparin at 25°C.
Heparin not studied.
5
Clindamycin
Onestudy has demonstrated thatclindamycin lOmg/L is stable in CAPD fluids containing 4.25% glucose for48h at room temperature (5). A laterstudy bythesame investigators,
(not tabulated), has examined thetherapeutic implications of incomplete hydrolysis of clindamycin phosphate to its bioactive formin peritoneal dialysis fluids (11).
Clindamycin in combination
Clindamycin was stable for48hatroom temperature when combined with heparin in CAPD fluids containing 4.25% glucose. The effect of thecombination onheparin activity is unknown.
Physical compatibility was not commented on (5).
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GENTAMICIN
CAPD fluids
Drug Mfr Dmg Mfr Solution Mfr Method Results Ref
Gentamicin
lOmg/L
SC PDF containing 1.5% or 4.25%
glucose (Dianeal 137), B
TR B At least 95% of initial activity retained for 24h in IL plastic bags containing
dialysate at 25°C.
10
Gentamicin
sulphate
5mg/L
and
8mg/L
sc PDF containing 2.5% glucose
(Dianeal), E
TR RIA,
EMIT
Stable for 24h at23°C. 4
Gentamicin
(-)
PDF (composition not stated)
and PD effluent (composition
not stated)
b MIC against P.aeruginosafour times greater in PD effluentthan in PDF and
Mueller-Hinton broth.
26
Gentamicin
sulphate
30mg/L
SC PDF containing 1.5% glucose
(Dianeal 137), B
TR HPLC A 2L plastic bag of PDF containing gentamicin was emptied over 18min
through a CAPD administration set containing a 0.22|im filter (Peridex CAPD
Filter Set).
7.5% of the gentamicin was bound to the administration set.
Binding of gentamicin to the dialysate container was not assessed.
Temperature not stated.
25
Gentamicin
sulphate
30mg/L
sc PDF containing 4.25% glucose
(Dianeal 137), B
TR HPLC A 2L plastic bag of PDF containing gentamicin was emptied over 18min
through a CAPD administration set containing a 0.22p,m filter (Peridex CAPD
Filter Set).
25% of the gentamicin was bound to the administration set.
Binding of gentamicin to the dialysate container was not assessed.
Temperature not stated.
25
Gentamicin
8mg/L
Azlocillin
500mg/L
PDF containing 1.5% glucose
(Dianeal), A, pH adjusted to 7.2
TR EMIT
(HPLC)
Gentamicin stable for 6h in IL plastic bags containing dialysate and azlocillin
at 37°C. >10% loss of initial concentration occurred within 8h.
Initial concentration of azlocillin maintained for 8h.
47
Gentamicin
sulphate
(-)
sc Cefamandole
nafate
125mg/L
LI PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluent at 37"C more rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
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Gentamicin
sulphate
(-)
SC Cefazolin
sodium
125mg/L
LI PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD ^uent at 37°C more rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
Gentamicin
sulphate
8mg/L
Cefazolin
75mg/L
Heparin
lOOOunits/L
-
PDF containing 1.5% glucose
(composition not stated)
V,FIA
(HPLC)
(-)
Gentamicin and cefazolin stable for 48h at 4°C, 26°C and 37°C in IL plastic
bags containing dialysate and heparin.
No visible precipitation.
Heparin not studied.
34
Gentamicin
sulphate
8mg/L
Cefazolin
150mg/L
Heparin
lOOOunits/L
-
PDF containing 1.5% glucose
(composition not stated)
V, FIA
(HPLC)
(-)
Gentamicin and cefazolin stable for 48h at 4°C, 26°C and 37®C in IL plastic
bags containing dialysate and heparin.
No visible precipitation.
Heparin not studied.
34
Gentamicin
sulphate
(-)
SC Cefoxitin
sodium
125mg/L
MSD PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluent at 37°Cmore rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
Gentamicin
sulphate
8mg/L
Heparin
1000 units/L
PDF containing 1.5% glucose
(composition not stated)
V,FIA
(-)
Gentamicin stablefor 48h at 4°C, 26°C and 37°Cin IL plasticbagscontaining
dialysate and heparin.
No visible precipitation.
Heparin not studied.
34
Gentamicin
lOmg/L
Heparin
lOOOunits/L
PDF containing 1.5% glucose
(Dianeal), A
TR V,B
(S, CT)
Solutions were prepared in two ways:
(i) one drug added to a dilute solution of the other in PDF
(ii) two drugs combinedin concentratedsolution to produce a precipitation
reaction, then added to PDF
The activity of gentamicin after4-6h in both solutions was unaffected by the
presenceof heparin. The UV absorbanceof heparin after 4-6h in both solutions
was unaffected by the presence of gentamicin.
In the absence of a precipitate the anticoagulant activityof heparin after4-6h
was unaffected by the presence of gentamicin.Theanticoagulant activity of
heparin was significantly reduced in solutions which hadformed a precipitate,
even though the precipitate redissolved.
Temperature not stated.
18
19
32
Gentamicin
Two studies have demonstrated that gentamicin5-lOmg/L is stable in CAPD fluids of various glucoseconcentrations for 24h at room temperature (4, 10). Administration of CAPDfluid
containing gentamicin through an administration set containing an in-line 0.22|jm filter may result in significant binding to the administration set (25). One study investigating the efficacy
of intraperitonealgentamicinfound that the activity of gentamicin against P.aeruginosa was significantly inhibited in peritoneal dialysis effluent (26).
Gentamicin in combination
Gentamicin, cefazolin and heparinwere physicallycompatible when combined in CAPD fluid containing 1.5%glucose. Both antibioticswere stable for 48h at temperatures up to 37°C.
The effect of the combination on heparin activity is unknown (34).
Gentamicin and azlocillin werestablefor 6h at 37°Cwhencombinedin pH adjusted CAPDfluid. Significant decomposition of gentamicin occurred within 8h. Physical compatibility
was not commented on (47).
Synergistic activityagainstE.coli,P.aeruginosaand S.aureus was demonstratedwhen gentamicinwas combinedwith cefamandole, cefazolin or cefoxitin in peritonealdialysiseffluent
This does not imply synergism against other bacterial species or exclude the possibilityof significantinactivationof one antibiotic by the other (6).
Gentamicin andheparin arepotentially physically incompatible. A precipitatemay be avoidedby combining the twodrugs in dilute solution. Gentamicin was stablefor 48h at temperatures
up to 37°C whencombinedwith heparin in CAPD fluid containing 1.5% glucose. Heparin activity was maintainedfor 4-6h provided a precipitatedid not form (34,18, 19).
Drug Mff Dmg Mff Solution Mff Method Results Ref
Gentamicin
sulphate
lOOmg/L
SC PDF concentrate containing
30% glucose, H
TR B Significant loss of activity occurred within lOmin in PDF concentratecompared
to normal saline (four-fold increase in MIC against E.coli). No further loss of
activity was evident at 4h.
Temperature not stated.
9
Gentamicin
sulphate
160mg/L
sc PDF concentrate containing
30% glucose, H
TR EMIT Time for 10% decomposition calculated as 11 days at 23''C. 4
Gentamicin
sulphate
160mg/L
SC PDF concentrate containing
30% glucose, H
TR RIA Time for 10%decompositioncalculated as 2.7 days at 23°C. 4
Gentamicin
sulphate
3mg/L
and
lOmg/L
sc PDF concentrate containing
50% glucose, D
MG B 11-19% loss of initial activity in 7h and 24-49% loss of initial activity in 24h
at room temperature. Loss of activity was greater at the lower gentamicin
concentration.
1
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Gentamicin
sulphate
160mg/L
SC |PDF concentrate containing
50% glucose, H
TR EMIT 10% decomposition in 41.4h at 23°C. 4
Gentanucin
sulphate
160mg/L
SC PDF concentrate containing
50% glucose, H
TR RIA 10% decomposition in 37.6h at 23°C. 4
Gentamicin
200mg/L
PDF concentrate containing
50% glucose, D
MG B 20% loss of initial activity in 24h.
Temperature not stated.
20
Gentamicin
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH adjusted to 6.8
-
B 25% loss of initial activity in 6h and 30% loss of initial activity in 24h in all
solutions.
Temperature not stated.
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Gentamicin
sulphate
lOOmg/L
SC Ampicillin
sodium
2.5g/L
BR PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against E.coli after 4h in PDF
concentrate was the same as its activity after lOmin. The combined activity
was significantlygreater than the activity of either antibioticalone.
Temperature not stated.
9
Gentamicin
sulphate
lOOmg/L
SC Ampicillin
sodium
2.5g/L
Heparin
sodium
2500 units/L
BR
RI
PDF concentrate containing
30% glucose, H
TR B
(B)
(-)
The activityof the antibiotic combination againstE.coli was significantly
inhibitedafter lOmin in PDF concentrate containing heparin. No furtherloss of
activity was evident at 4h.
Heparin not studied.
Temperature not stated.
9
Gentamicin
sulphate
lOOmg/L
SC Cephalothin
sodium
2g/L
PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against E.coli after 4h in PDF
concentrate was the same as its activity after lOmin. The combined activity
was similar to, but no greater than, the activityof either antibiotic alone.
Temperature not stated.
9
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Peritoneal dialysis fluid concentrates (continued)
Gentamicin
sulphate
lOOmg/L
SC Carbenicillin
disodium
2g/L
RR PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against E.coli after 4h in PDF
concentratewas the same as its activity after lOmin. The combined activity
was similar to, but no greater than, the activity of either antibiotic alone.
Temperature not stated.
9
Gentamicin
sulphate
lOOmg/L
SC Carbenicillin
disodium
2g/L
Heparin
sodium
25(X) units/L
RR
RI
PDF concentrate containing
30% glucose, H
TR B
(B)
(-)
The activity of the antibiotic combination against E.coli was unaffectedby the
presence of heparin after lOmin and 4h in PDF concentrate. The combined
activity was similar to, but no greater than, the activity of either antibiotic
alone.
Heparin not studied.
Temperature not stated.
9
Gentamicin
sulphate
lOOmg/L
SC Heparin
sodium
2500 units/L
RI PDF concentrate containing
30% glucose, H
TR B
(-)
Gentamicin alonein PDF concentrate compared to normal saline showed
significant loss of activitywithin lOmin (four-fold increase in MIC against
E.coli). No further loss of activity was evident at lOmin or 4h when combined
with heparin.
Heparin not studied.
Temperature not stated.
9
Gentamicin
sulphate
lOOmg/L
SC Penicillin G
potassium
500 000
units/L
PD PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against S.aureus after 4h in PDF
concentratewas the same as its activity after lOmin. The combinedactivity
was significantlygreater than the activityof penicillinG alone.
Temperature not stated.
9
Gentamicin
sulphate
lOOmg/L
SC Penicillin G
potassium
500 000
units/L
Heparin
sodium
2500 units/L
PD
RI
PDF concentrate containing
30% glucose, H
TR B
(B)
(-)
The activityof the antibiotic combination againstS.aureus wasunaffected by
the presence of heparin after lOmin and 4h in PDF concentrate. The combined
activitywas significantly greater than the activityof penicillin G alone.
Heparin not studied.
Temperature not stated
9
Gentamicin
sulphate
lOOmg/L
SC Vancomycin
hydrochloride
750mg/L
LI PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against S.aureus after4h in PDF
concentrate was the same as its activityafter lOmin. The combined activity
wassimilarto, but no greaterthan, the activity of vancomycin alone.
Temperature not stated.
9
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Peritoneal dialysis fluid concentrates (continued)
Gentamicin SC Vancomycin LI PDF concentrate containing TR B The activity of the antibiotic combination against S.aureus was unaffected by 9
sulphate hydrochloride 30% glucose, H (B) the presence of heparin after lOmin and 4h in PDF concentrate. The combined
lOOmg/L 750mg/L activity was similar to, but no greater than, the activity of vancomycin alone.
Heparin not studied.
Heparin R1 (-) Temperature not stated.
sodium
2500 units/L
Gentamicin
Information concerningthe stabilityof gentamicin in PDF concentrates is conflicting. One study, using two direct analytical techniques, demonstrated that gentamicinwas stable for 24h
at room temperature in PDF concentrates containing 30% or 50% glucose (4). Three studies using bioassay as a measure of stability have demonstrated that a significant loss of activity
occurs within 24h (1,20,27), and probably occurs within 7h (1,27). One study demonstrated that a significant loss of gentamicin activity occurs within lOmin in PDF concentrate when
compared to its activity in normal saline (9).
Gentamicin in combination
Only one study has attempted to investigate gentamicin in combination with other drugs in PDF concentrate (9). This study measures the activity of antibiotics and antibiotic combinations
against one of two test organisms, E.coli and S.aureus. The synergism or lack of synergism of antibiotic combinations compared to either drug alone is demonstrated. However, because
both test organisms are sensitive, to some extent, to all of the antibiotics tested, any synergism demonstrated by an antibiotic combination does not exclude the possibility of significant
inactivation of one or both antibiotics. The inactivation of aminoglycosides by beta-lactam antibiotics in parenteral admixtures is well documented (46).
Therefore, interpretation of the results of this study should take into consideration three factors:
(i) synergism of an antibiotic combination does not exclude the possibility of significant inactivation of one or both antibiotics,
(ii) synergism of an antibiotic combination against the stated test organism does not imply synergism against other bacterial species,
(iii) an antibiotic combinationwhich is not synergistic against the stated test organism may be synergistic against other bacterial species or provide broader activity against a variety
of bacterial species.
The initial activity of each antibiotic combination tested was maintained for 4h in PDF concentrate containing 30% glucose. Synergistic activity against E.coli was demonstrated when
gentamicin was combined with ampicillin, but not when combined with cephalothin or carbenicillin. Synergistic activity against S.aureus was demonstrated when gentamicin was combined
with penicillin G, but not when combined with vancomycin. Physical compatibility was not commented on.
Heparin inhibited the combinedactivityof gentamicinplus ampicillin after only lOminin PDF concentratecontaining 30% glucose. Heparin had no effect on the activityof gentamicin
alone,or on the combined activity of gentamicin plus carbenicillin, gentamicin plus penicillinG, or gentamicin plus vancomycin. The effect of the combinations on heparin activity is
unknown. Physical compatibility was not commented on.
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IMIPENEM
Drug Mfr Dmg Mfr Solution Mfr Method Results Ref
Imipenem
O.Olmgfi.
and
O.lmg/L
MSD PD effluent
(composition not stated)
b MIC and MBC against S.aureus at 37°C was the same in PD effluentas in
Mueller-Hinton broth.
21
Imipenem
No studies have investigated thestability of imipenem in CAPD fluids. Onestudy investigating theefficacy of intraperitoneal imipenem found thattheactivity of imipenem against
S.aureus was not inhibited in peritoneal dialysis effluent (21).
KANAMYCIN
Dmg Mfr Dmg Mfr Solution Mfr Method Results Ref
Kanamycin
(-)
PDF containing 1.5% glucose
(Formular 1)
(composition not stated)
BS B 13% loss of activity in 6h and 29% loss of activity in 24h at 18°C. 29
Kanamycin
One studyhasinvestigated thestability of kanamycin in peritoneal dialysis fluidcontaining 1.5% glucose andit wasconducted prior to the introduction of CAPD. The testconcentration
and details of the solutioncomposition are unknown. A significant loss of kanamycin activityoccurred within 6h at 18°C (29).
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MEZLOCILLIN
CAPD fluids
Dmg Mfr Dmg Mfr Solution Mfr Method Results Ref
Mezlocillin
200mg/L
MI PDF containing 4.25% glucose
(Dianeal 137, PD2), B, C
TR B Initialactivityretainedfor 48h in IL or 2L plastic bagscontaining dialysate
at25°C.
5
Mezlocillin
2(X)mg/L
MI Heparin
500 units/L
PDF containing 4.25% glucose
(Dianeal 137, PD2), B, C
TR B
(-)
Initial activity of mezlocillin retainedfor 48h in IL or 2L plastic bags containing
dialysate and heparin at 25°C.
Heparin not studied.
5
Mezlocillin
One study has demonstrated that mezlocillin 200mg/L isstable in CAPD fluids containing 4.25% glucose for 48h atroom temperature (5).
Mezlocillin in combination
Mezlocillin was stable for 48h atroom temperature when combined with heparin inCAPD fluids containing 4.25% glucose. The effect ofthe combination on heparin activity is unknown.
Physical compatibility was not commented on (5).
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MOXALACTAM
CAPD fluids
Dmg Mlf Drag Mfr Solution Mfr Method Results Ref
Moxalactam
8mg/L
PDF containing 1.5% glucose
(Dianeal 137), B
TR B Initial activity retained for 24h at room temperature. 12
Moxalactam
disodium
30mg/L
LI PDF containing 1.5% glucose
(Dianeal), A
TR HPLC Stable in solutions stored for 6h at 25°C then heated to 37°C for 30min. 50
Moxalactam
2g/L
PDF containing 2.5% glucose, E MG V No visible precipitation in 3h at room temperature. 8
Moxalactam
disodium
30mg/L
LI Cefazolin
50mg/L
PDF containing 1.5% glucose
(Dianeal), A
TR HPLC
(-)
Moxalactam stable in solutions stored for 6h at 25°C then heated to 37°C for
30min.
Cefazolin not studied.
50
Moxalactam
disodium
30mg/L
LI Cefazolin
50mg/L
Vancomycin
25mg/L
-
PDF containing 1.5% glucose
(Dianeal), A
TR HPLC
(-)
(-)
Moxalactam stable in solutions stored for 6h at 25°C then heated to 37°C for
30min.
Cefazolin and vancomycin not studied.
50
Moxalactam
Two studies have investigated moxalactam stability in CAPD fluids containing 1.5% glucose. Moxalactam 8mg/L was stable for24hat room temperature (12), and moxalactam 30mg/L
was stable after storage for6hatroom temperature followed byheating to 37°C for30niin (50). Moxalactam 2g/L was physically compatible with peritoneal dialysis fluid containing
2.5% glucose for 3h at room temperature (8).
Moxalactam in combination
Moxalactam was stable after storage for6h atroomtemperature followed by heating to 37°C for30min when combined withcefazolin, andcefazolin plusvancomycin, in CAPD fluid
containing 1.5% glucose. Theeffect of thecombinations on cefazolin andvancomycin stability is imknown. Physical compatibility was not conunented on (50).
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MOXALACTAM (continued)
Drug Mfi- Drug Mff Solution Mff Method Results Ref
Moxalactam
disodium
2g/L
PDF concentrate containing
30% glucose, H
TR B Significant loss of activity occurred within lOmin in PDF concentratecompared
to normal saline (32 fold increase in MIC against E.coli). No further loss of
activity was evident at 4h.
Temperature not stated.
9
Moxalactam
disodium
2g/L
Heparin
sodium
2500 units/L
RI PDF concentrate containing
30% glucose, H
TR B
(-)
Moxalactam alone in PDF concentrate compared to normal saline showed
significant loss of activity within lOmin (32 fold increase in MIC against E.coli)
No further loss of activity was evident at lOmin or 4h when combined with
heparin.
Heparin not studied.
Temperature not stated.
9
Moxalactam
Onestudy hasdemonstrated thata significant lossof moxalactam activity occurs within lOmin in PDF concentrate containing 30% glucose when compared to its activity innormal saline,
(9).
Moxalactam in combination
Heparinhad no effecton the activity of moxalactam in PDF concentrate containing 30%glucose. The effectof the combination on heparin activityis unknown. Physical compatibility
was not commented on (9).
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NAFCILLIN
CAPD fluids
Drug Mfr Drug Mfr Solution Mff Method Results Ref
Nafcillin
lOOmg/L
WY PDF containing 4.25% glucose
Pianeal 137, PD2), B, C
TR B Initial activity retained for 24h in IL or 2L plastic bags containing dialysate
at 25°C. 15% loss of initial activity in 48h at 25°C.
5
Nafcillin
lOOmg/L
WY PDF containing 1.5% or 4.25%
glucose pianeal 137), B
TR B At least 95% of initial activity retained for 24h in IL plastic bags containing
dialysate at 25''C.
10
Nafcillin
lOOmg/L
WY Heparin
500 units/L
PDF containing 4.25% glucose
(Dianeal 137, PD2), B, C
TR B
(-)
Initial activity of nafcillin retained for 24h in IL or 2L plastic bags containing
dialysate and heparin at 25°C. 15% loss of initial activity in 48h at 25°C.
Heparin not studied.
5
Nafcillin
Two studies have demonstratedthat nafcillin lOOmg/L is stable in CAPD fluids of various glucose concentrations for 24h at room temperature (5,10). A significant loss of activity occurred
within 48h at room temperature (5).
Nafcillin in combination
Nafcillin was stable for 24h at room temperature when combined with heparin in CAPD fluids containing 4.25% glucose, but was not stable for 48h. The effect of the combination on
heparin activity is unknown. Physical compatibility was not commented on (5).
Dmg Mff Drug Mff Solution Mff Method Results Ref
Nafcillin
200mg/L
PDF concentrate containing
50% glucose, D
MG B Approximately 40% loss of initial activity in 24h.
Temperature not stated.
20
Nafcillin
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH adjusted to 6.8
-
B,V Precipitation observed within 6h in solutions at pH 5.7
Up to 75% loss of initial activity in 24h in all solutions. This loss was greater
and faster in solutionsof high glucose concentrationand high pH.
Temperature not stated.
27
Nafcillin
Two studies have investigated nafcillin stability inPDF concentrates. Nafcillin was notstable for24hinPDF concentrates containing 30% or 50% glucose (20,27), and physical
incompatibility was observedwithin 6h (27). The storage temperature was not specified in either study.
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NETILMICIN
CAPD fluids
Drug Mfr Dmg Mfr Solution Mfr Method Results Ref
Netilmicin
lOmg/L
SC PDF containing 1.5% glucose
(Dianeal), A
PDF containing 1.5% glucose
(Dianeal) pH adjusted to 7.4
PD effluent collected after a 6h
i.p. dwell, G
I'R
TR
b MBC against P.aeruginosa 2-4times greater inPDFthan inbuffered PDFand
Mueller-Hinton broth. MBC against P.aeruginosa 4-8times greater inPD
effluent than in Mueller-Hinton broth.
Timefor >99.9% kill (netilmicin lOmgIL) was Ih in Mueller-Hinton broth,
2h in PD effluent, 6h in buffered PDF and 24h in PDF at 37°C.
3
Netilmicin
7.5mg/L
Azlocillin
500mg/L
PDF containing 1.5% glucose
(Dianeal), A, pH adjusted to 7.2
TR EMIT
(HPLC)
Netilmicin stable for 6hin IL plastic bags containing dialysate and azlocillin
at 37°C. >10% loss of initial concentration occurred within 8h.
Initial concentration of azlocillin maintained for 8h.
47
Netilmicin
No studies have investigated the stability of netilmicin alone in CAPD fluids. One study investigating the efficacy of intraperitoneal netilmicin found that the activity of netilmicin against
P.aemginosa was significantly inhibited in CAPD fluid and peritoneal dialysis effluent. This was demonstrated in peritoneal dialysis fluid and effluent ofrelatively low glucose concentration
(<1.5%), (3).
Netilmicin in combination
Netilmicin and azlocillin were stable for 6h at 37°C when combined in pH adjusted CAPD fluid. Significant decomposition of netilmicin occurred within 8h. Physical compatibility
was not commented on (47).
Drug Mfr Dmg Mfr Solution Mfr Method Results Ref
Netilmicin
sulphate
3mg/L
and
lOmg/L
SC PDF concentrate containing
50% glucose, D
MG B 11-19% loss ofinitial activity m7h and 24-49% loss ofinitial activity in 24h
at roomtemperature. Lossof activity was greater at the lower netilmicin
concentration.
1
Netilmicin
One study has demonstrated that netilmicin was not stable for 7h at room temperature in PDF concentrate containing 50% glucose. The netilmicin concentrations tested were well below
those used in thetreatment ofperitonitis (1).
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OXACILLIN
CAPD fluids
Dmg Mfr Drug Mfr Solution Mfr Method Results Ref
Oxacillin
0.25-16mg/L
BR Mueller-Hinton agar reconstituted
with PD effluent collected after an
overnight dwell of PDF containing
2.5% glucose
(composition not stated)
b TheMICofoxacillin in Mueller-Hinton agar wasnot adversely affected bythe
additionofPD effluent whenmeasuredagainstcoagulase-positive and coagulase-
negative staphylococci. *
49
Oxacillin
Nostudies have investigated the stability ofoxacillin inCAPD fluids. One study investigating the efficacy of intraperitoneal oxacillin found that the activity ofoxacillin against
staphylococci wasnot inhibitedby peritonealdialysiseffluent (49).
* Coagulase-positive staphylococci includes S.aureus. Coagulase-negative staphylococci includes S.epidermidis.
Drag Mfr Drag Mfr Solution Mfr Method Results Ref
Oxacillin
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH adjusted to 6.8
-
B Up to 75% loss of initial activity in 24h in all solutions. This loss was greater
and faster in solutionsof high glucose concentration and highpH.
Temperature not stated.
27
Oxacillin
Only one study has investigated oxacillin stability inPDF concentrates and few details are provided. Oxacillin was not stable for 24h inPDF concentrates containing 30% or50% glucose,
howevertheconcentration testedand the storagetemperature are unknown(27).
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PENICILLIN G
CAPD fluids
Drug Mfr Drag Mfr Solution Mfr Method Results Ref
Penicillin 0
6mg/L
PF PDF containing 1.5% or 4.25%
glucose (Dianeal 137), B
TR B 25% loss of initial activity in 24h in IL plastic bags containing dialysate at
at25°C.
10
Penicillin G
One study has demonstrated thatpenicillinG 6nig/L is not stable for 24h at room temperaturein CAPD fluids of variousglucose concentrations(10).
Peritoneal dialysis fluid concentrates
Dmg Mff Drag Mfr Solution Mfr Method Results Ref
Penicillin G
potassium
500 000
units/L
PD PDF concentrate containing
30% glucose, H
TR B Significant loss of activity occurred within lOmin in PDF concentrate compared
to normal saline (64 fold increase in MIC against S.aureus). No further loss of
activity was evident at 4h.
Temperature not stated.
9
Penicillin G
lOOmg/L
PDF concentrate containing
50% glucose, D
MG B 60% loss of initial activity in 24h.
Temperature not stated.
20
Penicillin G
potassium
500 000
units/L
PD Gentamicin
sulphate
lOOmg/L
SC PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against S.aureus after 4h in PDF
concentrate was the same as its activity after lOmin. The combined activity was
significantly greater than the activity of penicillin G alone.
Temperature not stated.
9
Penicillin G
potassium
500 000
units/L
PD Gentamicin
sulphate
lOOmg/L
Hepaiin
sodium
2500 units.L
sc
RI
PDF concentrate containing
30% glucose, H
TR B
(B)
(-)
The activity of the antibiotic combination against S.aureus was unaffected by the
presence of heparin after lOmin and 4h in PDF concentrate. The combined
activity was significantly greater than the activity of penicillin G alone.
Heparin not studied.
Temperature not stated.
9
Penicillin G
potassium
500 000
units/L
PD Heparin
sodium
2500 units/L
RI PDF concentrate containing
30% glucose, H
TR B
(-)
Penicillin G alone in PDF concentrate compared to normal saline showed
significant loss of activity within lOmin (64 fold increase in MIC against
S.aureus). No further loss of activity was evident at lOmin or 4h when
combined with heparin.
Heparin not studied. Temperature not stated.
9
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Penicillin G
Two studies have investigated penicillin G stability in PDF concentrates. One studydemonstrated that penicillin G lOOmg/L was not stablefor 24h in PDFconcentrate containing 50%
glucose, howeverthe storagetemperature is unknown(20). A second study demonstrated that a significantloss of penicillin G activityoccurs within lOmin in PDF concentratewhen
compared to its activity in normal saline (9).
Penicillin G in combination
Only one studyhas attempted to investigate penicillin G in combination with other drugs in PDF concentrate (9). The initial activityof the penicillin G plus gentamicin combination was
maintained for 4h in PDFconcentrate containing 30%glucose. Synergistic activityagainstS.aureus wasdemonstrated whenpenicillin G was combinedwithgentamicin. This doesnot
imply synergism againstother bacterial species or excludethe possibility of significant inactivation of one or both antibiotics. Physical compatibility was not commented on.
Heparin hadno effecton the activity of penicillin G, or on the combined activity of penicillin G plusgentamicin in PDF concentrate containing 30%glucose. Theeffect of the
combinations on heparin activity is unknown. Physical compatibility was not commented on.
PIPERACILLIN
CAPD fluids
Drug Mfr Drag Mff Solution Mff Method Results Ref
Piperacillin
2(X)mg/L
LE PDF containing 4.25% glucose
(Dianeal 137, PD2), B, C
TR B Initial activity retained for 48h in IL or 2L plastic bags containing dialysate
at25°C.
5
Piperacillin
2()0mg/L
LE PDF containing 1.5% glucose
(Dianeal), A
PDF containing 1.5% glucose
(Dianeal) pH adjusted to 7.4
PD effluent collected after a 6h
i.p. dwell, G
TR
TR
b MBC against P.aeruginosa 4-8 times greater in bufferedPDF than in
Mueller-Hintonbroth. MBCagainst P.aeruginosa more than 16 timesgreater
in PDF and PD effluent than in Mueller-Hinton broth.
Timefor >99.9% Mil (piperacillin lOOmgIL) was 6h in Mueller-Hinton broth
at 37 °C. Bactericidal activitywas rwt demonstrated in 24h in PDF, buffered
PDF orPD effluent.
3
Piperacillin
200mg/L
LE Heparin
500 units/L
PDF containing 4.25% glucose
(Dianeal 137, PD2), B, C
TR B
(-)
Initial activity of piperacillin retainedfor 48h in IL or 2L plasticbagscontaining
dialysate and heparin at 25°C. Heparin not studied.
5
Piperacillin
One study has demonstrated that piperacillin 200mg/L isstable inCAPD fluids containing 4.25% glucose for 48h atroom temperature (5). Another study investigating the efficacy of
intraperitoneal piperacillin found that the activity ofpiperacillin against P.aeruginosa was significantly inhibited inCAPD fluid and peritoneal dialysis effluent (3).
Piperacillin in combination
Piperacillin was stable for 48h atroom temperature when combined with heparin inCAPD fluids containing 4.25% glucose. The effect of the combination on heparin activity isunknown.
Physical compatibility was not commented on (5).
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SISOMICIN
Drug Mfr Drug Mfr Solution Mfr Method Results Ref
Sisomicin
sulphate
3mg/L
and lOmg/L
SC PDF concentrate containing
50% glucose, D
MG B 11-19% loss of initial activity in 7h and 24-49% loss of initial activity in 24h
at room temperature. Loss of activity was greater at the lower sisomicin
concentration.
1
Sisomicin
One study has demonstrated that sisomicin was notstable for7hatroom temi)erature inPDF concentrate containing 50% glucose. The sisomicin concentrations tested were well below
those used in the treatment of peritonitis (1).
CAPD fluids
TEICOPLANIN
Drug Mfr Drug Mfr Solution Mfr Method Results Ref
Teicoplanin
0.09-6mg/L
ML Mueller-Hinton agar reconstituted
with PD effluent collected after an
overnight dwell of PDF containing
2.5% glucose
(composition not stated)
b The MIC of teicoplanin inMueller-Hinton agar was notadversely affected by
theaddition ofPD effluent when measured againstcoagulase-positive
staphylococci and oxacillinresistant coagulase-negative staphylococci.
Theaddition ofPD effluent raised the MIC of teicoplanin against oxacillin
sensitive coagulase-negative staphylococci in 50% ofthe isolates tested (n=10).*
49
Teicoplanin
No studies have investigated the stability ofteicoplanin in CAPD fluids. One study investigating the efficacy ofintraperitoneal teicoplanin found that the activity ofteicoplanin against
staphylococci was generally not adversely affected by peritoneal dialysis effluent. Peritoneal dialysis effluent did inhibit the activity of teicoplanin against some oxacillin sensitive coagulase-
negative staphylococci, however the number ofisolates inthis test group was small and the MIC values obtained were within clinically achievable levels (49).
* Coagulase-positive staphylocojci includes S.aureus. Coagulase-negative staphylococci includes S.epidermidis.
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TICARCILLIN
Drug Mlf Drug Mfr Solution Mfr Method Results Ref
Ticarcillin
200mg/L
BE PDF containing 1.5% or 4.25%
glucose (Dianeal 137), B
TR B At least 95% of initial activity retained for 24h in IL plastic bags containing
dialysate at 25°C.
10
Ticarcillin
One study has demonstrated that ticarcillin 200mg/L is stable inCAPD fluids ofvarious glucose concentrations for 24h atroom temperature (10).
TOBRAMYCIN
CAPD fluids
Dmg Mfr Drug Mfr Solution Mfr Method Results Ref
Tobramycin
sulphate
5mg/L
and
8mg/L
LI PDF containing 2.5% glucose
(Dianeal), E
TR RIA,
EMIT
Stable for 24h at 23 deg C. 4
Tobramycin
lOmg/L
LI PDF containing 4.25% glucose
(Dianeal 137, PD 2), B, C
TR B Initial activity retained for 48h in IL or 2L plastic bags containing dialysate
at25"'C.
5
Tobramycin
65mg/L
LI PDF containing 4.25% glucose
(Dianeal 137), B
TR B 12% loss of initial activity in 24h in IL or 2L plastic bags containing dialysate
at35°C.
5
Tobramycin
8mg/L
LI PDF containing 1.5 % glucose
(Dianeal), A
PDF containing 1.5% glucose
(Dianeal) pH adjusted to 7.4
PD effluent collected after a 6h
i.p. dwell, G
TR
TR
b MBC against P.aeruginosa 8-16 times greater in PDF and PD effluent than in
buffered PDF and Mueller-Hinton broth.
Timefor >99.9% kill (tobramycin SmgIL) was Ih in Mueller-Hinton broth,
2h in PD effluent, 6h in biffered PDF and 24 h in PDF at 37°C.
3
Tobramycin
O.lmg/L
LI PD effluent
(composition not stated)
b Bactericidal activityagainst S.aureus at 37°C was reducedby90% when
PD effluent was used as the growth medium instead ofMueller-Hinton broth.
21
47
Tobramycin
(-)
PDF (composition not stated)
and PD effluent (composition
not stated)
b MIC against P.aeruginosafour times greater in PD effluent than in PDF and
Mueller-Hinton broth.
26
Tobramycin
sulphate
(-)
LI Cefamandole
nafate
125mg/L
LI PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluent at 37 °C more rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
Tobramycin
sulphate
(-)
LI Cefazolin
sodium
125mg/L
LI PD effluent collected after a 6h
i.p. dwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluent at 37°C more rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
Tobramycin
sulphate
(-)
LI Cefoxitin
sodium
125mg/L
MSD PD effluent collected after a 6h
i.p. kwell of PDF containing
1.5% glucose (Dianeal), F
b
(b)
Antibiotic combination in PD effluent at 37°C more rapidly lethal than either
drug alone against E.coli, P.aeruginosa and S.aureus.
6
Tobramycin
65mg/L
LI Cefapirin
500mg/L
BR PDF containing 4.25% glucose
(Dianeal 137), B
TR B
(B)
Initial activity of each antibiotic retained for 24h in IL or 2L plastic bags
containing dialysate at 25°C.
5
Tobramycin
65mg/L
LI Cefapirin
500mg/L
BR PDF containing 4.25% glucose
(Dianeal 137), B
TR B
(B)
Tobramycin lost 12% of initial activity and cefapirin lost 16% of initial activity
within 24h when combined in IL or 2L plastic bags containing dialysate at 35°C.
5
Tobramycin
lOmg/L
LI Heparin
500 units/L
PDF containing 4.25% glucose
(Dianeal 137, PD 2), B, C
TR B
(-)
Initial activity of tobramycin retained for 48h in IL or 2L plastic bags
containing dialysate and heparin at 25°C.
Heparin not studied.
5
Tobramycin
Twostudies have demonstrated thattobramycin 5-lOmg/L is stablein CAPD fluids of various glucose concentrations for 24hat roomtemperature (4,5). At increased temperature,
tobramycin 65mg/L was notstable for24h(5). Three studies have investigated theefficacy of intraperitoneal tobramycin. Peritoneal dialysis effluent significantly inhibited theactivity
of tobramycinagainst P.aeruginosa(3,26), and S.aureus (21).
Tobramycin in combination
Tobramycin andcefapirin were stable for24hat roomtemperature when combined in CAPD fluidcontaining 4.25% glucose. At increased temperature, a significant loss of activity of each
drug occurred within 24h (5).
Synergistic activity against E.coli, P.aeruginosa andS.aureus wasdemonstrated whentobramycin wascombined withcefamandole, cefazolin or cefoxitin in peritoneal dialysis effluent.
Thisdoes not implysynergism against otherbacterial species or exclude the possibility of significant inactivation of one antibiotic by the other(6).
Tobramycin was stable for48hat room temperature when combined withheparin in CAPD fluids containing 4.25% glucose. Theeffect of thecombination on heparin activity is unknown.
Physical compatibility wasnot commentedon (5).
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TOBRAMYCIN (continued)
Drug Mfir Drag Mfr Solution Mfr Method Results Ref
Tobramycin
sulphate
lOOmg/L
LI PDF concentrate containing
30% glucose, H
TR B Significant loss of activity occurred within lOmin in PDF concentrate compared
to normal saline (four-fold increase in MIC against E.coli). No further loss of
activity was evident at 4h.
Temperature not stated.
9
Tobramycin
sulphate
160mg/L
LI PDF concentrate containing
30% glucose, H
TR EMIT Time for 10% decomposition calculated as 2.1 days at23°C. 4
Tobramycin
sulphate
160mg/L
LI PDF concentrate containing
30% glucose, H
TR RIA 10% decomposition in 14.8h at 23°C. 4
Tobramycin
base
3mg/L
and
lOmg/L
LI PDF concentrate containing
50% glucose, D
MG B 34-48% loss of initial activity in 7h and 70-85% loss of initial activity in 24h
at room temperature. Loss of activity was greater at the lower tobramycin
concentration.
1
Tobramycin
sulphate
160mg/L
LI PDF concentrate containing
50% glucose, H
TR EMIT 10% decomposition in 21.Ih at 23°C. 4
Tobramycin
sulphate
160mg/L
LI PDF concentrate containing
50% glucose, H
TR RIA 10% decomposition in 9.4h at 23°C. 4
Tobramycin
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH adjusted to 6.8
-
B 42% loss of initial activity in 24h in all solutions.
Temperature not stated.
27
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Tobramycin
sulphate
lOOmg/L
LI Cephalothin
sodium
2g/L
PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against E.coli after 4h in PDF
concentrate was the same as its activity after lOmin. The combined activity
was significantly greater than the activity of tobramycin alone, but no greater
than the activity of cephalothin alone.
Temperature not stated.
9
Tobramycin LI Cephalothin - PDF concentrate containing TR B The activity of the antibiotic combination against E.coli was unaffectedby the 9
sulphate sodium 30% glucose, H (B) presence of heparin after lOmin and 4h in PDF concentrate. The combined
lOOmg/L 2g/L activity was significantly greater than the activity of tobramycin alone, but no
greater than the activity of cephalothin alone.
Heparin RI (-) Heparin not studied.
sodium Temperature not stated.
2500 units/L
Tobramycin
sulphate
lOOmg/L
LI Heparin
sodium
2500units/L
RI PDF concentrate containing
30% glucose, H
TR B
(-)
Tobramycin alone in PDF concentrate compared to normal saline showed
significant loss of activity within lOmin (four-fold increase in MIC against
E.coli). No further loss of activity was evident at lOmin or 4h when combined
with heparin.
Heparin not studied.
Temperature not stated.
9
Tobramycin
Four studies have investigated tobramycin stability in PDF concentrates. One study, using two direct analytical techniques, produced conflicting results concerning the stability of
tobramycin in PDF concentratecontaining 30% glucose. Tobramycin was found to be stable for 24h using one analytical technique, but not stable using another (4). Overwhelming
evidence suggests that tobramycin is not stable for 24h in PDF concentrates containing either 30% or 50% glucose (1,4, 27). One study demonstrated that a significant loss of tobramycin
activity occurs within lOmin in PDF concentrate when compared to its activity in normal saline (9).
Tobramycin in combination
Only one study has attemptedto investigate tobramycin in combination with other drugs in PDF concentrate (9). The initial activity of the tobramycin plus cephalothin combination was
maintainedfor 4h in PDF concentrate containing30% glucose. Synergisticactivity againstE.coli was not demonstratedwhen tobramycin was combined withcephalothin, howeverthis
combination may be synergistic againstother bacterialspecies or provide broader activity against a variety of bacterialspecies. Physical compatibilitywas not commentedon.
Heparin had no effect on the activityof tobramycin, or on the combined activity of tobramycin plus cephalothin in PDF concentrate containing 30% glucose. The effect of the combinations
on heparin activity is unknown. Physical conq>atibiIity was not commentedon.
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VANCOMYCIN
CAi'u tiums
Drug Mfr Dmg Mfr Solution Mfr Method Results
Kef
Vancomycin
15mg/L
LI PDF containing 1.5% or 4.25%
glucose (Dianeal 137), B
IK B At least95% of initialactivity retained for 24h in IL plastic bags containing
dialysate at 25°C.
10
Vancomycin
20mg/L
LI PDF containing 4.25% glucose
(Dianeal 137, PD 2), B, C
IK B Initial activity retained for 24h in IL or2Lplastic bags containing dialysate
at 25°C. 15% loss of initial activity in 48h at 25°C.
5
Vancomycin
hydrochlcdde
30mg/L
LI PDF containing 1.5% or 4.25%
glucose (Dianeal), A
IK B Initial activity retained for 24h in ILplastic bags containing dialysate at4°C
and23-24°C.
16
Vancomycin
0.09-6mg/L
SI Mueller-Hinton agar reconstituted
with PD effluent collected after an
overnight dwell of PDF containing
2.5% glucose
(composition not stated)
b The MIC ofvancomycin inMueller-Hinton agarwas not adversely affected by
the addition ofPD^uent when measured against coagulase-positive
staphylococci. The addition ofPDeffluent raised the MIC ofvancomycin
against coagulase-negative staphylococci in 77% ofthe isolates tested (n=50). *
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Vancomycin
20mg/L
LI Heparin
500 units/L
PDF containing 4.25% glucose
(Dianeal 137, PD 2), B, C
TK B
(-)
Initial activity of vancomycin retained for24h in IL or2Lplastic bags
containing dialysate and heparin at 25°C. 15% loss of initial activity in48h
at25°C.
Heparinnot studied.
5
Vancomycin
hydrochlOTide
30mg/L
LI Heparin
sodium
500 units/L
CSL PDF containing 1.5% glucose
(Dianeal), A
TK V Solutions storedin glassat4°C and21-22°C demonstrated no visible
precipitation in24h and nochange in pHin 48h.
16
Vancomycin
hydrochlcdde
30mg/L
LI Heparin
sodium
500 units/L
CSL PDF containing 1.5% or 4.25%
glucose (Dianeal), A
TK B
(-)
Initial activity of vancomycin retained for24h in IL plastic bags containing
dialysate andheparin at4°Cand23-24°C.
Heparin not studied.
16
Vancomycin
25mg/L
Moxalactam
disodium
30mg/L
Cefazolin
50mg/L
LI PDF containing 1.5% glucose
(Dianeal), A
IK
(HPLC)
(-)
Moxalactam stable in solutions stored for 6h at 25°C then heated to 37 C for
30min.
Vancomycin andcefazolin not studied.
50
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Vancomycin
Three studies have demonstrated that vancomycin 15-30mg/L is stable in CAPD fluids of various glucose concentrations for 24h at room temperature (5, 10, 16). A significant loss of
activityoccurredwithin48h at room temperature (5). One study investigating the efficacyof intraperitoneal vancomycinfound that the activityof vancomycin againstcoagulase-positive
staphylococci was not inhibitedby peritonealdialysis effluent. Peritoneal dialysis effluentmay inhibit the activityof vancomycinagainst coagulase-negative staphylococci (49).
* Coagulase-positive staphylococciincludes S.aureus. Coagulase-negativestaphylococciincludes S.epidermidis.
Vancomycin in combination
Vancomycin was stable for 24h at room temperature when combined with heparin in CAPD fluids of various glucose concentrations (5,16), but was not stable for 48h (5).
The combination was physicallycompatibleat 4°C and 21-22°C (16). The effect of the combinationon heparin activity is unknown (5,16).
Moxalactamwas stable after storagefor 6h at room temperaturefollowed by heating to 37°C for 3()min whencombinedwith vancomycinplus cefazolinin CAPDfluid containing 1.5%
glucose. The effectof the combination on vancomycinand cefazolin stability is unknown. Physical compatibility was not commented on (50).
Peritoneal dialysis fluid concentrates
Drug Mff Dmg Mff Solution Mff Method Results Ref
Vancomycin
hydrochloride
750mg/L
LI PDF concentrate containing
30% glucose, H
TR B Activity after 4h in PDF concentrate similar to initial activity in normal saline.
Temperature not stated.
9
Vancomycin
hydrochlOTide
lOmg/L
and
50mg/L
LI PDF concentrate containing
50% glucose, D
MG B 93-100% of initial activity was retained for 24h at room temperature.
Stability was greater at the higher vancomycin concentration.
1
Vancomycin
(-)
PDF concentrate containing
30% or 50% glucose
(composition not stated) pH 5.7
PDF concentrate containing
30% or 50% glucose
(composition not stated)
pH adjusted to 6.8
-
B Initial activity retained for 24h in all solutions.
Temperature not stated.
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Vancomycin
hydrochlmde
750mg/L
LI Gentamicin
sulphate
lOOmg/L
SC PDF concentrate containing
30% glucose, H
TR B
(B)
The activity of the antibiotic combination against S.aureus after 4h in PDF
concentrate was the same as its activity after lOmin. The combined activity
was similar to, but no greater than, the activity of vancomycin alone.
Temperature not stated
9
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Peritoneal dialysis fluid concentrates (continued)
Vancomycin
hydrochloiide
750mg/L
LI Gentamicin
sulphate
lOOmg/L
Heparin
sodium
2500 units/L
SC
RI
PDF concentrate containing
30% glucose, H
TR B
(B)
(-)
The activity of the antibiotic combination against S.aureus was unaffected by
the presence of heparin after lOmin and 4h in PDF concentrate. The combined
activity was similar to, but no greater than, the activity of vancomycin alone.
Heparin not studied.
Temperature not stated.
9
Vancomycin LI Heparin RI PDF concentrate containing TR B Activity of vancomycin maintained for 4h in PDF concentrate containing 9
hydrochloride sodium 30% glucose, H (-) heparin.
750mg/L 2500 units/L Heparin not studied.
Temperature not stated.
Vancomycin
Threestudies haveinvestigated vancomycin stabilityin PDF concentrates. Vancomycin lOmg/L and 50mg/L was stablefor 24h at room temperature in PDFconcentrate containing 50%
glucose(1). A secondstudy,in which the test concentrationand storage temperature are not specified, concludedthat vancomycinwas stable for 24h in PDF concentrates containing 30% or
50% glucose (27). A third studydemonstratedthat there was no significantloss of vancomycinactivityafter 4h in PDF concentratewhen compared to its activityin normal saline (9).
Vancomycin in combination
Onlyone study has attempted to investigate vancomycin in combination withotherdrugs in PDFconcentrate (9). The initialactivity of the vancomycin plusgentamicin combination
wasmaintained for4h inPDFconcentrate containing 30%glucose. Synergistic activity against S.aureus was not demonstrated whenvancomycin wascombined withgentamicin, however
thiscombination maybe synergistic against otherbacterial species or provide broader activity against a variety of bacterial species. Physical compatibility wasnotcommented on.
Heparin had no effecton the activity of vancomycin, or on the combinedactivityof vancomycin plus gentamicin in PDF concentrate containing 30% glucose. The effectof the combinations
on heparin activity is unknown. Physical compatibility was not commented on.
APPENDIX 1
The following formulations were obtained from the studies reviewed and do not necessarily represent a comprehensive list of the solutions
available.
A. Dianeal (Travenol Laboratories)
Glucose
Sodium
Chloride
Calcium
Magnesium
Lactate
pH
1.5%, 4.25%
141 mmol/L
101 mmol/L
1.75 mmol/L
0.75 mmol/L
45 mmoI/L
5.4-5.6
B. Dianeal 137 (Travenol Laboratories)
Glucose
Sodium
Chloride
Calcium
M^esium
Lactate
pH
1.5%, 4.25%
132 mmol/L
102 mmol/L
1.75 mmol/L
0.75 mmol/L
35 mmol/L
5.0-5.4
C. PD2 (Travenol Laboratories)
Glucose
Sodium
Chloride
Calcium
Magnesium
Lactate
pH
4.25%
132 mmol/L
96 mmol/L
1.75 mmol/L
0.25 mmol/L
40 mmol/L
5.0-5.4
D. Peritoneal dialysis fluid concentrate (McGaw Laboratories)
Glucose
Sodium
Chloride
Calcium
Magnesium
Acetate
pH
30%, 50%
26(X) mmol/L
20(X) mmol/L
35 mmol/L
10 mmol/L
690 mmol/L
5.4-5.8
E. Peritoneal dialysis fluid concentrate diluted 1 in 20.
Glucose
Sodium
Chloride
Calcium
Magnesium
Acetate
2.5%
130 mmol/L
100 mmol/L
1.75 mmol/L
0.5 mmol/L
34.5 mmol/L
Peritoneal dialysis effluent collected after a 6h i.p. dwell of
Dianeal containing 1.5% glucose
Calcium
Magnesium
Cholesterol
Protein
Osmolarity
pH
sterile
1.12 mmol/L
0.66 mmol/L
10 mg/L
1.46 g/L
266 mOsm/kg
7.2
G. Peritoneal dialysis effluent collected after a 6h i.p. dwell
Glucose
Calcium
Magnesium
Protein
Osmolarity
pH
sterile
0.24-0.33%
1.05-1.55 mmol/L
0.6-0.8 mmol/L
1.56-2.11 g/L
279-298 mOsm/L
7.4-7.54
H. Peiittmeal dialysis fluid concentrate (Travenol Laboratories)
Glucose
Sodium
(Dhloiide
Calcium
Magnesium
Acetate
pH
30%, 50%
2600 mmol/L
20(X) mmol/L
35 mmol/L
10 mmol/L
690 mmol/L
5.4-5.8
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APPENDIX 2
ABBREVIATIONS
B bioassay Manufacturer Abbreviations
b bioactivity (measureof efficacy)
AB AbbottCAPD continuous ambulatory peritoneal dialysis
CCPD continuouscyclic peritoneal dialysis BE Beecham
CT clotting time BR Bristol
EMIT enzyme multiplied immunoassay BS Biosedra Laboratory
FIA fluorescence immunoassay CSL Commonwealth Serum Laboratories
HPLC high performance liquid chromatography GL Glaxo
h hour(s) HO Hoechst-Roussel
i.p. intraperitoneal LE Lederle
IPD intermittentperitoneal dialysis LI Eli Lilly
MBC minimum bactericidal concentration MG American McGaw
mfr manufacturer Ml Miles
MIC minimum inhibitory concentration ML Merrell Dow
min minutes MSD Merck Sharp & Dohme
PD peritonealdialysis PD Parke-Davis
PDF peritonealdialysis fluid PF Pfizer
RIA radioimmunoassay R1 Riker
S spectrophotometry RR Roerig
V visual examination (macroscopic) SC Schering
not stated SI Sigma
TR Travenol
UP Upjohn
WY Wyeth
- Manufacturer not stated
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APPENDIX 2
Miconazole concentrations in PDF admixtures storedin PVC bags and glass ampoules
Bag 1
Initial conc. 20.6 mg/L
% Initial Mic
Sample concentration
time
(hours) Mean Range
Miconazole (Mic) concentrations* inPDF admixtures stored inPVC bags and
glass ampoules
Bag 2
20.0 mg/L
% Initial Mic
concentration
Amp 1
21.6 mg/L
% Initial Mic
concentration
Mean Range Mean Range
Amp 2
22.1 mg/L
% Initial Mic
concentration
Mean Range
0 100.0 5.5 100.0 0.2 100.0 2.0 100.0 2.0
2 93.3 0.6 98.3 0.4 - - - -
4 88.4 1.2 85.0 0.3 - - - -
6 77.4 4.5 79.5 5.1 - - - -
12 68.4 5.3 69.8 1.3 - - - -
24 54.8 2.8 52.7 1.6 95.5 2.2 98.3 7.6
48 40.3 1.0 39.8 3.0 96.2 1.3 97.3 3.2
72 29.2 1.0 33.8 2.8 94.1 1.5 90.4 3.2
120 19.0 0.5 19.1 0.2 - - - -
168 - - - - 85.lt - 87.2 5.1
216 10.8 0.0 10.7 0.1 87.7 2.0 83.3 5.4
Miconazole nitrate concentrations were determined using the calibration curve, and
converted to equivalent concentrations of miconazole by multiplying by the
molecular weight ratio (416.1/479.2)
Single determination only
APPENDIX 3
Sulphamethoxazole and trimethoprim concentrations in PDF admixtures
stored in PVC bags and glass ampoules
Sulphamethoxazole (SMX) concentrations in PDF admixtures stored in PVC bags and glass ampoules
Bag 1 Bag 2 Amp 1 Amp 2 Amp 3 Amp 4
Initial conc. 94.6 mg/L 95.9 mg/L 87.4 mg/L 85.6 mg/L 85.0 mg/L 87.8 mg/L
% Initial SMX % Initial SMX % Initial SMX % Initial SMX % Initial SMX % Initial SMX
Sample concentration concentration concentration concentration concentration concentration
tune
(hours) Mean Range Mean Range Mean Range Mean Range Mean Range Mean Range
0 100.0 0.5 100.0 0.3 100.0 0.6 100.0 0.2 100.0 1.6 100.0 1.0
2 100.2 0.5 97.7 1.0 101.9 1.2 101.6 1.4 - - - -
6 97.3 0.9 95.0 2.8 104.1 3.7 102.7 0.3 - - - -
12 89.1 0.8 92.3 2.4 101.3 1.0 101.9 2.5 - - - -
24 87.5 3.9 90.8 0.2 95.6 2.8 100.6 0.2 97.0 0.1 92.4 0.9
48 85.1 0.4 84.4 1.2 92.1 0.4 92.2 1.5 87.6 0.8 84.8 2.1
72 79.8 0.5 80.5 1.2 83.2 2.3 86.9 1.7 80.7 1.2 79.3 1.3
168 - - - - - - -
- 70.9 2.8 67.5 0.9
216 57.8 0.3 57.0 0.5 - 0.4 - 0.2 64.6 1.7 62.5 2.8
Trimethoprim (TMP) concentrations in PDF admixtures stored in PVCbagsand glassampoules
Bag 1 Bag2 Amp 1 Amp 2 Amp 3 Amp 4
Initial conc. 19.5 mg/L 19.7 mg/L 18.4 mg/L 17.9 mg/L 17.3 mg/L 17.6 mg/L
% Initial TMP % Initial TMP % Initial TMP % Initial TMP % Initial TMP % Initial TMP
Sample concentration concentration concentration concentration concentration concentration
time
(hours) Mean Range Mean Range Mean Range Mean Range Mean Range Mean Range
0 100.0 0.0 100.0 0.4 100.0 1.0 100.0 1.2 100.0 0.4 100.0 0.4
2 99.8 0.6 97.6 0.7 101.4 1.0 100.8 0.8 - - - -
6 97.8 1.1 95.9 2.8 102.9 2.5 102.1 0.6 - - - -
12 94.4 0.0 97.2 3.0 100.4 0.2 101.8 2.8 - - - -
24 92.5 2.4 95.4 0.6 97.2 2.3 102.1 0.6 99.9 1.0 95.1 3.0
48 91.4 1.9 90.5 0.7 96.1 0.6 98.1 1.8 103.9 0.4 102.5 1.4
72 87.6 0.2 88.3 1.1 92.0 1.9 96.6 0.8 102.6 1.4 101.3 1.4
168 - - - - - - - - 102.9 3.3 99.0 1.2
216 85.6 5.1 81.8 2.4 - - - - 100.0 0.4 99.7 3.4
